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Da  Dalton 
DAB   3,3’-diaminobenzidine 
dH2O  Double deionised water 
dNTP  Deoxynucleotide triphosphate 
DMSO  Dimethylsulfoxide 
dsDNA  Double stranded DNA 
DTT   Dithiothreitol 
EC50  Half maximal effective concentration 
E. coli  Escherichia coli 
EDTA   Ethylenediamine tetraacetate 
ELISA   Enzyme-linked immunosorbent assay 
EMCV  Encephalomyocarditis virus 
ER  Endoplasmatic reticulum 
FDA  U.S. Food and Drug Administration 
HCV  Hepatitis C Virus 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus 
H   Hour 
HRP  Horseradish peroxidase 
HZI  Helmholtz Centre for Infection Research, Braunschweig, Germany 
IC50  Half maximal inhibitory concentration 
IFN  Interferon 
IRES  Internal ribosome entry site 
IgG  Immunoglobulin G 
IMAC  Immobilised metal affinity chromatography 
IPTG  Isopropyl-ß-D-thiogalactoside 
LD  Lipid droplet 
LDAO  Lauryldimethyl amine oxide 
 XVI 
Luc  Firefly luciferase gen 
M  Molar = mol/L 
MBP  Maltose binding protein 
MTP  Microtiter plate 
Min  Minute 
NANBH Non-A, non-B hepatitis 
Neo  Neomycin phosphotransferase gen 
NS  Non structural 
NTA   Nitrilotriacetic acid 
PAGE   Polyacrylamide gel-electrophoresis 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline with added Tween 20 
PCR  Polymerase chain reaction 
PDB  Protein Data Bank 
PEG  Polyethylene glycol 
Pfu  Plaque forming unit 
Rpm  Rotations per minute 
SDS   Sodium dodecylsulfate 
STAT-C Specifically targeted antiviral therapy for Hepatitis C 
SVR  Sustained virological response 
TEMED  N,N,N’N’tetramethylethylenediamine 
TLR  Toll-like receptor 
Tris  Tris(hydoxymethyl)aminomethane 
Tween 20  Polyoxyethylenesorbitan monolaurate 
uPA  Urokinase plasminogen activator 
UTR  Untranslated region 
 
Amino acid code 
A Ala Alanin M Met Methionine 
C Cys Cystein N Asn Asparagine 
D Asp Aspartic acid P Pro Proline 
E Glu Glutamic acid Q Gln Glutamine 
F Phe Phenylalanine R Arg Arginine 
G Gly Glycine S Ser Serine 
H His Histidine T Thr Threonine 
I Ile Isoleucine V Val Valine 
K Lys Lysine W Trp Tryptophan 
L Leu Leucine Y Tyr Tyrosine 
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1. Introduction 
1.1 Hepatitis C Virus 
Hepatitis C virus (HCV) infection is the leading cause of chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma (Shepard, 2005). HCV was first termed non-A, non-B hepatitis (NANBH) 
and was discovered in post transfusion patients in 1975 (Feinstone, 1975). The etiological agent of 
HCV was identified over one decade later in 1989 by immunoscreening of serum of a patient with 
NANBH (Choo et al., 1989). It is estimated that worldwide up to 170 million people are chronically 
infected with HCV and a vaccine is not available yet (Yu and Chiang, 2010). The standard of care, 
pegylated interferon-α and ribavirin, achieves a sustained viral response in only about half of the 
treated patients (Manns et al, 2001; Fried et al, 2002) and is associated with considerable severe side 
effects (Fried, 2002). Thus there is a huge unmet need for direct anti-HCV drugs for a more effective 
treatment with fewer side effects. 
 
1.1.1 HCV Epidemiology and Genotypes 
To date about 123 - 170 million people worldwide are persistently infected with HCV (2 – 3% of the 
world population), with 3 to 4 million new infections each year (Shepard, 2005; Bruijne et al., 2009). 
The initial symptoms of the infection are often absent or asymptomatic, as for example abdominal 
pain and influenza-like symptoms. In most cases the infection remains undiagnosed (Hoofnagle et al., 
1997). Of infected individuals 70 to 80% develop a chronic infection (Freeman, 2001; Patel, 2006). 
Approximately 10 – 20% of chronically infected patients develop liver cirrhosis over a period of 10 to 
30 years and 1 – 5% of patients with liver cirrhosis develop a hepatocellular carcinoma (Alberti, 
1999; Lauer, 2001). Liver cirrhosis and hepatocellular carcinoma are conditions requiring surgery and 
the major cause for liver transplantation in Europe and the USA (Perz, 2006). Chronic HCV 
infections are often associated with steatosis, defined as increased fat content of the liver, with 
prevalence of 40 – 80% in patients with chronic HCV (Negro, 2010). Moreover, chronic hepatitis is 
related to insulin resistance and an increased risk of type 2 diabetes mellitus (Mihm, 2010). 
The main route of transmission is direct blood-to-blood contact between humans with high incidence 
among intravenous drug users, recipients of blood products and renal dialysis patients before 
implementation of screening regimens. Other risk factors are tattooing and needle stick injuries. 
Sexual and congenital transmissions appear less frequently (Alter, 1995; Terrault, 2002). Since the 
development of a screening test for HCV in 1990 for blood or blood products the incidence of new 
infections has greatly diminished (Cohen, 1999). However, between 20 – 50% of HCV cases are not 
associated to the classic risk factors (Urbani, 1999). Many patients remain asymptomatic for years 
and are only detected on health screening or at the time of blood transfer (Contreras, 2010). 
There is a large geographic variability in the prevalence of HCV infections. The highest reported 
prevalence rates are in countries located in Africa (5.3%) and Asia (2.15%) compared to lower 
prevalence rates in industrialised countries in North America (1.7%) and Europe (1.03%) (see Figure 
1-1). The prevalence rate varies from 0.6% in Germany and 1.8% in the USA to 22% in Egypt (Sy 
and Jamal, 2006; Shepard et al., 2005). 
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Figure 1-1: Estimated prevalence of HCV infection by WHO region (modified from Shepard, 2005). 
At the time of writing six major HCV genotypes and over 100 subgenotypes have been identified 
(Georgel et al., 2010). The genotypes differ in 31 – 33% of their nucleotide sequence and the 
subgenotypes differ in 20 – 25% of their sequence (Kuiken and Simmonds, 2009). Mutations of the 
viral genome due to a low fidelity of the viral polymerase result in a heterogeneous population of 
virus quasispecies that coexist in an infected patient (Farci et al., 2000; Simmonds et al., 2005). This 
quasispecies model leads to a significant survival advantage for the virus in its battle with the immune 
system, because it allows a rapid increase in genomic variability facilitating the emergence of mutants 
that are better suited to new environmental conditions (Pawlotsky, 2006). This variability also 
hampers the development of a vaccine against the HCV virus. 
The genotypes differ in their geographical prevalence. The genotypes 1, 2 and 3 are distributed 
worldwide. The other genotypes are found in more distinct geographic areas including Egypt 
(genotype 4), South Africa (genotype 5) and Southeast Asia (genotype 6). The most common variants 
in Western Europe and North America are genotype 1a and 1b, followed by the genotypes 2 and 3 
(Bartenschlager et al., 2004; Kuiken and Simmonds, 2009). 
 
1.1.2 HCV life cycle and viral proteins 
HCV belongs to the Hepacivirus genus of the Flaviridae family, which includes human and animal 
pathogens like yellow fever or dengue virus. Viruses within the Flaviviridae family have a related 
genome organisation. They have single stranded RNA genomes, which encode a single polyprotein, 
and conserved nonstructural protein motifs (Lindenbach and Rice, 2003). 
The HCV virion has a size of 55-65 nm in diameter and is enveloped in a lipid bilayer in which two 
envelope proteins (E1 and E2) are anchored and form a heterodimer. The envelope surrounds the 
nucleocapsid which is composed of multiple copies of a small basic core protein and contains the 
RNA genome (see Figure 1-2). The genome is a positive-stranded RNA molecule with a length of 
about 9.6 kb. It represents a single open reading frame (ORF) encoding a polyprotein of about 3000 
amino acids. HCV infects only humans and chimpanzees and targets mainly the hepatocytes 
(Bartenschlager et al., 2004; Nakamura et al., 2008; Moradpour et al., 2007). 
Introduction 
 3 
	  
Figure 1-2: Schematic picture of the Hepatitis C Virus. The envelope with heterodimer of the envelope proteins E1 and 
E2 surrounds the nucleocapsid containing the RNA genome (modified from James A. Perkins, 2001). 
The cell entry of the HCV virion is a complex process that involves several viral and cellular factors. 
In the blood of infected patients, HCV is associated with low density and very low density 
lipoproteins (LDL and VLDL) (Nielsen et al., 2006). The LDL-receptor (LDL-R) has been proposed 
as a potential entry factor (Helle and Dubuisson, 2008). Also glycosaminoglycans (GAGs), such as 
heparin sulfate, and lectins (DC-SIGN and L-SIGN) take part in cell attachment (Barth et al., 2003; 
Cormier et al., 2004). The LDL-R together with the GAGs and lectins may serve for the first contact 
with the hepatocytes and direct the virions to the cell surface molecules tetraspin CD81, SR-BI, and 
the tight junction proteins claudin-1 and occludin for cell entry (Burlone and Budkowska, 2009). 
CD81 and SR-BI are believed to interact with the viral envelope glycoproteins E1 and E2 (Bartosch 
and Cosset, 2006). After binding to the hepatocytes, bound virions are internalised by clathrin 
mediated endocytosis (Meertens et al., 2006). During endocytosis envelope protein E1 and E2 
mediate pH dependent fusion with the membrane of early endosomes and the nucleocapsid is released 
into the cytoplasm (Blanchard et al., 2006; Lavilette et al., 2007). 
	  
	  
Figure 1-3: HCV life cycle. The HCV virions bind to receptors on the cell surface and enter the cytosol via endocytosis. 
After fusion of the envelope membrane with the endosomal membrane the viral genome is released. After translation and 
processing of the polyprotein, the membranous web is formed where the replication of the HCV genome takes place. Virion 
assembly occurs at the ER membranes surrounding lipid droplets and for maturation and release the pathway for producing 
very low density lipoproteins is used (modified from Moradpour et al., 2007). 
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In Figure 1-3 the viral life cycle is shown. Directly after uncoating the translation of the HCV genome 
starts. The single ORF is flanked by a 5`-untranslated region (UTR) and 3`-UTR that are required for 
translation and RNA replication (Friebe et al., 2001). An internal ribosome entry site, located in the 
5`-UTR, mediates the	  expression of the polyprotein precursor (Wang et al., 1993). The polyprotein is 
co- and posttranslationally processed by cellular and viral proteases into 10 mature proteins. The 
HCV genome also encodes an 11th protein, the F-protein (frame-shift protein), through a ribosomal 
frame-shift of the RNA encoding the core protein (Xu et al., 2001). The role of the F-protein in the 
viral life cycle or pathogenesis of HCV is still unclear. The N-terminal located structural proteins 
core, E1 and E2 and the ion channel protein p7 are cleaved by host signal peptidases. The 
nonstructural (NS) proteins are processed by viral proteases. The NS2-3 auto-protease is responsible 
for cis-cleavage of NS3 from NS2. The NS3 protein, with protease and helicase function, needs to 
assemble with its cofactor NS4A to catalyse cis-cleavage at the NS3-NS4A junction and trans-
cleavage at all remaining junctions (Bartenschlager and Lohmann, 2000). All HCV proteins are 
associated with the ER membrane (see Figure 1-4). The viral replication takes place in a special 
membrane compartment, called the membranous web. It is induced by the NS4B Protein (Eggert et 
al., 2005) and contains the replication complex that consists of cellular and viral proteins like the 
phosphoprotein NS5A and the RNA-dependent RNA polymerase NS5B (Moradpour et al., 2007). 
The HCV assembly and release is still not fully understood. It is believed that the assembly of virus 
particles is initiated at lipid droplets and at the surrounding endoplasmatic reticulum (ER) membrane 
of these organelles. For the maturation and release of HCV virions the pathway for producing very-
low density lipoproteins is used (Jones and McLauchan, 2010). 
 
 
Figure 1-4: HCV genome organisation, polyprotein processing, and protein topology. A: The HCV genome is a single-
stranded RNA encoding a single ORF flanked by 5' and 3' UTRs. The translation of the ORF generates a polyprotein. The 
polyprotein undergoes a series of cleavage events, catalysed by host and viral proteases, to produce 10 individual HCV 
proteins. B: The topology of the HCV proteins relative to the ER membrane (modified from Tellinghuisen, 2007). 
Introduction 
 5 
Some 80% of infected individuals develop a chronic persistent HCV infection. Viral clearance by the 
innate and adaptive immune response is required to prevent a chronic infection. The virus has 
developed various strategies to evade the host immune system. The first innate immune response of 
infected hepatocytes is the activation of Toll-like receptors (TLR) and RIG-I-like receptors which 
leads to induction of type I interferon (IFN) production (Rehermann, 2009). The IFN induces an 
antiviral state that also affects neighboring cells. The NS3/4A protease is important for evading the 
innate immune response by cleaving not only the viral precursor polypeptide but also the host TRIF 
and Cardif/MAVS/IPS-1/VISA proteins (Lin et al., 2006). The cleavage of these proteins prevents the 
TLR-3 and RIG-I dependent virus-sensing and type I IFN production (Li et al., 2005; Lemon, 2010). 
Also the NS2 protein seems to interfere with the RIG-I signaling (Kaukinen et al., 2006) and the 
signaling downstream of type I IFN is perturbed by several other HCV proteins (Georgel et al., 2010).  
The adaptive immune system is induced by antigen presenting cells that initiate a virus specific 
humoral and cell-mediated immune response. The humoral immune response leads to the secretion of 
HCV specific antibodies by maturated B-lymphocytes, termed plasma cells. Important for maturation 
of B-lymphocytes is a co-stimulation by activated CD4+ helper T cells. The cell-mediated immune 
response involves the induction of CD8+ cytotoxic T cells. Cytotoxic T cells kill infected hepatocytes 
that present viral antigens on their surface (Schmidt et al., 2011; Walker, 2010). The HCV virus can 
stay a step ahead of the adaptive immune response because of the high viral load and the high error 
rate of the viral RNA polymerase. The high error rate of the polymerase leads to a heterogeneous 
population of virus quasispecies. These quasispecies have mutations in the viral epitopes which 
enables them to evade HCV specific antibodies. HCV also induces continued hypermutation of 
already mature heavy-chain immunoglobin which may lower affinity and specificity of HCV directed 
antibodies (Machida et al., 2008; Georgel et al., 2010). In addition HCV proteins, e.g. NS2, interfere 
with cellular apoptosis mechanism induced by cytotoxic T cells (Machida et al., 2001).  
 
1.1.3 Current treatment of HCV 
In the late 1980s initial studies indicated that recombinant interferon-α (IFN-α), a type I interferon, 
based therapy might have an antiviral effect in non-A, non-B hepatitis infections, but the treatment 
effect was low and severe side effects were reported (Hoofnagle, 1986). Interferons are proteins that 
induce a direct antiviral effect in the cell. In addition interferon-γ, a type II interferon, is a cytokine 
that activates the immune system. The pegylation of the interferon improved the half-life of the drug 
and increased the biological effect. This resulted in longer dosing intervals and higher response rates 
(Bruijne, 2009). Today the most effective treatment of HCV infection is a combination therapy with 
pegylated IFN-α 2a or 2b and ribavirin. Ribavirin is a synthetic nucleoside analog with antiviral 
properties (Reichard, 1991), but the mechanism by which the drug acts is poorly understood. The 
addition of ribavirin to the pegylated IFN-α therapy significantly decreased relapse rates after 
termination of the treatment (Feld, 2005). Treatment length varies between 24 – 72 weeks according 
to the HCV genotype and the viral kinetics of the infected individual (Moradpour, 2009; Lange, 
2010). Genotype 1 shows greater resistance to treatment and a 48 week course of pegylated IFN-α 
and ribavirin is recommended. For patients infected with genotypes 2 or 3, a 24 week course is 
recommended. Treatment is only moderately effective: A sustained viral response (SVR) is achieved 
in 40 - 50% of genotype 1 infected patients compared to 70 - 80% of patients with genotypes 2 and 3 
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(Flamm, 2003). An additional problem is that interferon-ribavirin combination therapy is associated 
with severe side effects such as fatigue, influenza-like symptoms, hematologic abnormalities, and 
neuropsychiatric symptoms (Fried, 2002). The side effects lead many patients to prematurely 
terminate their therapy (Martinot-Peignoux et al., 1998). It is estimated for America that because of a 
combination of a failure in diagnosis, treatment failure, as well as avoidance and discontinuation of 
treatment, approximately only 2% of those with HCV are successfully treated with standard of care 
(Garber, 2007). 
Direct-action antiviral drugs are under development in order to improve the treatment of HCV. Two 
NS3/4A protease inhibitors, telaprevir (Vertex Pharmaceuticals) and boceprevir (Merck) were 
approved by the FDA in 2011 (Klein and Struble, 2011; Poordad, 2011). Both protease inhibitors 
appear to be able to improve sustained response while shortening the length of treatment. However, 
due to a low genetic barrier and high viral mutation rate resistant variants emerge within a few days 
when used in monotherapy. Therefore the inhibitors were combined with pegylated IFN-α and 
ribavirin in clinical trials. For telaprevir 24 – 48 weeks of total therapy including 12 weeks of triple 
therapy improved sustained virologic response rates compared with standard of care. The sustained 
virological response (SVR) rates of HCV genotype 1 patients will be improved by approximately 
30%. Also telaprevir can be used for treatment of prior nonresponders or relapsers infected with HCV 
genotype 1 (Chen and Yu, 2010; Grammatikos and Sarrazin, 2010). The triple therapy with telaprevir 
improves the treatment outcome but has more side effects than the standard of care, including rash, 
gastrointestinal disorders and anemia (Gentile et al., 2010).  
 
1.1.4 HCV Proteases 
Proteases are proteolytic enzymes that catalyse the cleavage of peptides and proteins through the 
hydrolysis of peptide bonds. In many infectious diseases proteases play a crucial role and as such are 
considered as very important drug targets. The classification of proteases is based on the chemical 
residue in the catalytic center which is responsible for nucleophilic attack of the target peptide bond, 
e.g., serine, metallo-, aspartyl or cysteine proteases. The subsites of a protease are the surface pockets 
that bind to a single side chain of a substrate residue and determine the specificity of the protease. 
Subsites are numbered Sn–S1 from the N terminus of the substrate to the scissile bond and S1`–Sn` 
towards the C terminus (non-primed sites and primed sites)	   according to the nomenclature of 
Schechter and Berger. The substrate residues are numbered P1–Pn and P1`–Pn`, respectively (see 
Figure 1-5) (Turk, 2006). 
 
 
Figure 1-5: Schematic picture of a peptide substrate binding to a protease. The subsites of a protease are the surface 
pockets that bind to a single side chain of a substrate residue. Subsites are numbered S1–Sn from the N terminus to the 
scissile bond and S1`–Sn` towards the C terminus (non-primed and primed site). The substrate residues are numbered P1–Pn 
and P1`–Pn`, respectively (from Turk, 2006). 
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The HCV virus encodes two proteases for polyprotein processing. The NS2-3 protease is a cysteine 
protease (Lorenz et al., 2006) and the NS3/4A protease is a serine protease (Lin et al., 1995). 
Serine proteases utilise a catalytic triad, formed by a serine, histidine and aspartic acid residue in the 
active site of the enzyme, for the hydrolysis of a peptide bond. A schematic representation of the 
hydrolytic mechanism of NS3/4A protease is shown in Figure 1-6. 
The aspartic acid positions the histidine residue which acts as a base and abstracts a proton from the 
serine (see Figure 1-6 A). This facilitates the nucleophilic attack of the serine hydroxyl group on the 
carbonyl carbon of the peptide bond to be cleaved. The resulting negatively charged tetrahedral 
intermediate is stabilised through hydrogen bonding of the oxyanion hole. In case of the HCV 
NS3/4A protease the backbone amide NH groups of Ser139 and Gly137 form the oxyanion hole (see 
Figure 1-6 B). The C-terminal fragment of the product is released after proton donation of the 
histidine to the peptide’s amide nitrogen which leads to break down of the tetrahedral intermediate. 
The acyl-enzyme intermediate is attacked by a water molecule forming a second tetrahedral 
intermediate (see Figure 1-6 C). The histidine is accepting the proton of the attacking water molecule 
and donating it to the serine residue resulting in a break down of the tetrahedral intermediate. The N-
terminal fragment is released with regeneration of the free enzyme (Fersht, 1999; Garrett and 
Grisham, 2010). 
 
 
Figure 1-6: Schematic representation of the hydrolytic mechanism of NS3/4A protease (modified from Barbato et al., 
2000). 
Cysteine proteases contain a catalytic dyad formed by a cysteine and histidine residue in the active 
site of the enzyme. Additionally a glutamic acid residue is important for orientation of the side chain 
of the histidine. The thiol group of the cysteine is deprotonated by the histidine and the resulting 
nucleophilic thiolate anion attacks the carbonyl carbon of the peptide bond to be cleaved. A 
tetrahedral intermediate is formed and the oxyanion is stabilised by an oxyanion hole similar to serine 
proteases. The amine of the leaving C-terminal fragment of the cleaved product is protonated by the 
histidine residue of the protease restoring the deprotonated form. The acyl-enzyme intermediate is 
hydrolysed and the N-terminal fragment is released with regeneration of the free enzyme (Otto and 
Schirmeister, 1997; Polaina and MacCabe, 2007). 
 
1.1.4.1 NS2-3 Protease 
The NS2-3 protease is responsible for the intramolecular cleavage between the non structural proteins 
NS2 and NS3 and is one of the two HCV proteases for polyprotein processing (Grakoui, 1993). NS2-
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3 is a cysteine autoprotease with the active site residues entirely located in the NS2 protein. NS2 
consists of a hydrophobic N-terminal region comprising several transmembrane segments and the C-
terminal catalytic domain. Two NS2 monomers form a dimeric cysteine autoprotease with two 
composite active sites (see Figure 1-7). The active site catalytic triad consists of His143 and Glu163 
from one monomer and Cys184 from the second monomer. After intramolecular cleavage between 
NS2 and NS3 the C-terminal Leu-217 of the NS2 protein remains coordinated in the active site and 
inactivates the protease. Deletion or mutation of the C-terminal leucine impairs infectious virus 
production, but not due to inhibition of the protease function. It is suggested that altering the C-
terminus could lead to a conformational change of the NS2 protein thus disrupting protein-protein 
interactions important for viral assembly (Lorenz et al., 2006; Dentzer et al., 2009). For the full 
activity of NS2-3 protease not only the C-terminal part of NS2 but also the N-terminal part of the NS3 
protein that compasses the NS3 serine protease domain with the Zn2+ binding site is necessary 
(Thibeault et al., 2001; Pallaoro et al., 2001). An NS2 protein with two N-terminal NS3 aa has only 
basal proteolytic activity. NS3 acts as a regulatory cofactor of the NS2 protease and is not involved 
directly in the catalysis of the cleavage reaction. The NS3 protein promotes the formation of the 
proteolytic active conformation of the NS2-3 dimer by correct positioning of the cleavage sites 
(Schregel et al., 2009). For in vitro cleavage of NS2-3 the presence of non ionic detergents is 
necessary, suggesting that a hydrophobic environment is needed for correct folding. However, no 
cellular cofactors are needed for in vitro cleavage of purified NS2-3 protease (Thibeault et al., 2001; 
Pallaoro et al., 2001). 
 
 
 
Figure 1-7: NS2 dimer and active site. A: Ribbon diagram showing the NS2 dimer with one catalytic monomer (consisting 
of aa 94-217 of NS2) in blue, the other in red. The two active sites marked with boxes. B: Active site indicated by solid lined 
box. Residues His 143, Glu 163, Pro 164, Cys 184 and Leu 217 are shown. The active site is composed of His 143 and Glu 
163 from one monomer (chain A, drawn in blue), and Cys 184 from the other molecule (chain B, drawn in red). The Leu 217 
is the C-terminal residue at the scissile bond (from Lorenz et al., 2006). 
The cleavage of the NS2-3 protease is essential for infectious virus production in vitro and in vivo. 
The inhibition of the NS2-3 cleavage has a devastating effect on virus production, but it is suggested 
that it is not due to the interruption of the polyprotein processing. The NS3 serine protease domain is 
active in the uncleaved NS2-3 and can process the polyprotein, but uncleaved NS2-3 is rapidly 
degraded. This leads to a decrease in NS3 protein which is also essential for RNA replication 
(Welbourn et al., 2005). Besides the protease function, the NS2 protein is a key organiser for viral 
assembly (Jirasko et al., 2010), is important for evasion of the immune system (Kaukinen et al., 2006) 
and inhibition of apoptosis (Machida et al., 2001). Because of its essential role in the viral life cycle 
the NS2-3 protease is an interesting target for new specific HCV drugs. Although there are few NS2-3 
A	   B	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protease inhibitors the only ones known act indirectly by disrupting the conformation of the 
uncleaved NS2-3 protease. NS4A cofactor derived peptides change the conformation of the NS3 
domain upon binding and inhibit the protease. Also chelating agents that remove the Zn2+ from the 
NS3 zinc binding site lead to a miss folding of the NS3 domain and inhibition of protease activity 
(Thibeault et al., 2001). Cyclosporine A (CsA) is known to act indirect on the NS2 protein. CsA 
interacts with cyclophilins (CyP), which are essential cellular cofactors for HCV. CyP catalyse the 
isomerisation of peptide bonds from the trans form to the cis form and is it suggested that inhibition 
of these enzymes leads to missfolding of the NS2 protein due to a cis-proline (see Figure 1-7 b), 
essential for correct folding, in close proximity to the protease active site (Ciesek et al., 2009). 
 
1.1.4.2 NS3 Protease 
The HCV NS3 protein is a bifunctional enzyme that consists of two domains, an N-terminal serine 
protease domain and a C-terminal helicase/ATPase domain. The enzymatic domains are separated and 
connected by a linker (Yao et al., 1999). The NS3 protease is essential for polyprotein processing and 
the NS3 helicase/ATPase is required for genome replication and virus assembly (Raney et al., 2010). 
The NS3 protease is a chymotrypsin-like serine protease and forms a heterodimeric complex with the 
NS4A protein. NS4A is a 54 aa long cofactor of the NS3 protease domain enhancing the proteolytic 
activity (Lin et al., 1995). NS4A forms an additional ß-strand and stabilises the structure of the NS3 
protease domain (Kim et al., 1996). It also anchors NS3 to the ER membrane (Wolk et al., 2000). For 
the activation of the protease in vitro only residues 21 to 34 of NS4A are required (Tomei et al., 
1996). The crystal structure of NS3/4A revealed the proximity of the C-terminus of NS4A and the N-
terminus of NS3 which led to the design of a single chain protease where the NS4A peptide is linked 
to the NS3 protease domain (Dimasi et al., 1998; Taremi et al., 1998). The NS3 protease domain also 
contains a Zn2+ binding site which is important for stabilisation of the structure (Tedbury and Harris, 
2007). After assembly with its cofactor NS4A, NS3/4A catalyses the cis-cleavage at the NS3-NS4A 
junction and trans-cleavage at all remaining junctions: NS4A-4B, NS4B-5A and NS5A-5B. The 
active site catalytic triad consists of His57, Asp81 and Ser139.  
The NS3/4A protease has the substrate consensus sequence D/EXXXXC-S/A (P6-P1´), with X being 
any amino acid and the scissile bond being located between C and S/A. The intramolecular cleavage 
site between NS3 and NS4A was found to differ from this consensus, having a T in the P1 position 
(Grakoui et al., 1993). The NS3/4A protease has a shallow and solvent exposed substrate binding 
pocket (Kim et al., 1996). Because of the flat substrate binding pocket the substrate-protease 
interactions extend over the whole binding region and explain the inability to cleave small substrates. 
A decapeptide substrate (P6-P4`) was found to be optimal for efficient cleavage by the NS3/4A 
protease. Further truncation resulted in a significantly decrease in proteolytic activity (Landro et al., 
1997). An acidic residue (Asp or Glu) at the P6 position, a cysteine (or threonine) at the P1 position 
and a small side chain residue (Ala or Ser) at the P1` position are important for substrate binding and 
cleavage. The crystal structure of the full length NS3 protein revealed that the active site is located at 
the	   interface between the protease and the helicase domain and it is suggested that the helicase has 
influence on the protease domain. The NS3 C-terminus is bound to the active site of the protease and 
needs to be removed by a conformational change prior to cleavage of a substrate. However, the 
specific activity of full-length NS3/4A and protease domain NS3/4A are similar or is even enhanced 
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for the full-length NS3/4A, implying that relatively little energy is required for the conformational 
change (Yao et al., 1999; Beran and Pyle, 2008). 
 
Figure 1-8: Structure of NS3 protein in complex with NS4A peptide. A) Ribbon structure of the NS3/4A complex; NS3 
protease domain (aa 4-181) in grey, NS4A peptide (aa 31-34) in red and the side chains of active site residues His-57, Asp-
81 and Ser-139 are displayed in stick representation. B) Surface representation of the NS3/4A protease with bound inhibitor 
boceprevir (PDB code 1W3C); protease domain in grey, NS4A peptide in red and inhibitor boceprevir displayed in stick 
representation. The active site Ser-139 is highlighted in blue. C) Ribbon structure of the full-length NS3 protein and the 
protease cofactor NS4A (PDB code 1CU1); the helicase domain is shown in yellow, protease domain in blue and NS4A in 
green. The active site residues are highlighted in red. D) Surface representation of the full-length NS3 protein and the 
protease cofactor NS4A (PDB code 1CU1); same coloring as in C. 
Beside the essential role in polyprotein processing, the NS3/4A protease is involved in evasion of the 
immune response by cleaving proteins of the TLR-3 and RIG-I signaling pathways (Li et al., 2005; 
Lemon, 2010). Inhibition of the NS3/4A protease may not only block viral replication but also 
restores the host immune response which makes the NS3/4A protease one of the most attractive 
targets for novel drug development. The shallow and solvent exposed substrate binding pocket makes 
it relatively difficult to identify specific inhibitors of HCV NS3/4A protease. The finding that the 
protease is inhibited by peptides corresponding to the C-terminus of the cleavage products led to the 
development of first potent competitive protease inhibitors. The hexapeptides (P6-P1) from the C-
terminus of the NS4A and NS5A cleavage sites act as competitive inhibitors of NS3/4A with Ki 
values of 0.6 µM (NS4A: Ac-DEMEEC-OH) and 3.1 µM (NS5A: Ac-EDVVCC-OH). It was shown 
that for optimal binding of the hexapeptide a cysteine residue in position P1 with a free carboxylate is 
required. Also carboxylic acids in position P5 and P6 have dramatic influence on the binding because 
of electrostatic interactions with basic amino acids of the NS3/4A protease (Steinkühler et al., 1998; 
Koch et al., 2001). These interactions are destabilised by increased ionic strength and result in a 
higher Ki value. Using synthetic peptide analogues sequential substitution of the hexapeptides led to 
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the optimised inhibitor Ac-Asp-D-Gla-Leu-Ile-Cha-Cys-OH (D-Gla: γ-carboxyglutamic acid; Cha: ß-
cyclohexyl-L-alanine) with an IC50 value of 40nM (Ingallinella et al., 1998). Further structure-based 
optimisation led to the design of macrocyclic product-based inhibitors, e.g. BILN-2061 which was the 
first compound that showed proof-of-concept in clinical studies. It was withdrawn because of cardiac 
toxicity (Lamarre et al., 2003; Reiser et al., 2005), but other macrocyclic compounds are currently in 
clinical trials, e.g. TMC-435350 and ITMN-191 (Örtqvist et al., 2010). A second group of NS3/4A 
drugs are peptidomimetic inhibitors with an electrophilic α-ketoamide group. The α-ketoamide group 
functions as a trap for the active site serine hydroxyl and forms a covalent bond that is reversible (Lin 
et al., 2006). In 2011, two α-ketoamide inhibitors, telaprevir (Vertex Pharmaceuticals) and boceprevir 
(Merck), were approved by the FDA (Klein and Struble, 2011; Poordad, 2011).  
The product-based drug design was the most successful method for the development of new specific 
NS3/4A protease inhibitors so far. Other approaches, e.g. high-throughput screenings (Sudo et al., 
2005; Gentzsch et al., 2010), antibody fragments (Martin et al., 1997; Kasai et al., 2001), or aptamers 
(Kumar et al., 1997) have been explored, but with limited success. 
 
1.1.5 HCV Model systems 
HCV research has been hampered both by the lack of a robust, efficient cell culture system and by 
lack of a small animal model. Such model systems are very important for the evaluation of potential 
new HCV drugs, e.g., to evaluate cell availability or in vivo stability and pharmacokinetics. 
First studies were done with primary cell cultures, either with HCV infected hepatocytes or primary 
cells isolated from tissues of either infected patients or chimpanzees. However, in these systems viral 
replication and reproducibility were very poor (Iacovacci et al., 1993; Lanford et al., 1994). A 
milestone was the development of the replicon system (Lohmann et al., 1999). The replicon system is 
a cell culture model system where the genes coding for the structural proteins were removed from the 
consensus sequence of a HCV 1b genome (isolate Con1). The HCV non structural proteins are 
produced and the replicon RNA is replicated, but no virus particles are produced. The neomycin 
phosphotransferase gene (neo) was introduced into the truncated viral replicon for its selection in 
transfected cells. The translation of neo is initiated by the HCV 5´ UTR IRES and translation of the 
NS proteins is directed by the IRES of the Encephalomyocarditis virus (EMCV) (see Figure 1-10). 
For a luciferase based HCV replication assay a firefly luciferase gen (luc) was inserted in the replicon 
instead of the neo gen under the control of poliovirus IRES (PI) for higher translation efficiency 
(Lohmann et al., 2003) (see Figure 1-9).  
 
	  
Figure 1-9: Structure of the subgenomic HCV replicon I341 PiLuc/NS3-3´. It is composed of the HCV 5´ UTR, 
poliovirus IRES (PI), the gene encoding the firefly luciferase (luc), the EMCV IRES (EI), the region encoding HCV 1b 
NS3-5B and the 3´ UTR (from Lohmann, 2003). 
The replication of the replicon was poor in the hepatoma cell line Huh7 but was significantly 
increased by cell culture adaptive mutations in all NS proteins (Krieger et al., 2001). The discovery of 
the Huh7.5 subclone that harbors a defect in the RIG-I pathway even enhanced RNA replication 
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(Blight et al., 2002). In addition Huh7-Lunet cells have a gaussia luciferase gen in their genome that 
can be used for a cell viability assay. 
Also HCV full-length genomes and genomic replicons of other genotypes could be established 
(Pietschmann et al., 2002; Ikeda et al., 2002; Blight et al., 2003), but the production of infectious 
virus particles was not possible until the isolation of the HCV genotype 2a strain JFH-1. This HCV 
isolate could replicate in cell culture without adaptive mutations and release viral particles referred to 
as HCVcc (HCV cell culture) (Kato et al., 2003; Wakita et al., 2005). Chimeric constructs with the N-
terminal regions of a different genotype 2a isolate improved the infectivity considerably (see Figure 
1-10) (Lindenbach et al., 2005; Pietschmann et al., 2006). Furthermore the HCVcc are infective in 
animal models (Lindenbach, 2006).  
 
 
Figure 1-10: Comparison of the genomic structure of HCV replicons. Structure of the full length replicon derived from 
the JFH1 consensus genome. In the subgenomic replicon the structural sequences were replaced by a neomycin 
phosphotransferase gene for selection and a EMCV IRES was inserted for translation of the nonstructural proteins. The NS2 
region can also be deleted (red arrow). The infectivity of the full length replicons was significantly increased by creating 
virus chimeras by replacing the core to NS2 region with that of a genotype 2a isolate (from Boonstra et al., 2009). 
The only available immunocompetent animal model for HCV is the chimpanzee, the use of which is 
limited by ethical concerns, limited availability and high costs (Bukh et al., 2004). The most well-
established mouse model at the moment is the xenotransplantation model that is based on liver 
repopulation. In this model immunodeficient uPA/SCID mice are used in which overexpression of a 
urokinase plasminogen activator (uPA) transgene results in severe liver toxicity (Walters et al., 2006). 
Mice, with transgene-induced liver disease, are transplanted with primary human hepatocytes. The 
hepatocytes repopulate the diseased mouse liver and successfully transplanted mice can then be 
infected with HCV (Meuleman and Leroux-Roels, 2008). Recently a mouse model with humanised 
mice with human immune system and liver tissue was developed which allows also the study of the 
specific immune response against HCV (Washburn et al., 2011). These models have several 
shortcomings, e.g. mice are only available in small numbers and of high variability since the ratio of 
human/mouse hepatocytes is critical and must exceed 10% (Bissig et al., 2010). Therefore it is being 
attempted to create a mouse model that is susceptible to HCV infection. Recently HCV was adapted 
in vitro to the mouse CD81 receptor allowing the adapted virus to infect mouse cells (Bitzegeio et al., 
2010). However, the need of additional host factors limits the replication of HCV in mouse cells and 
additional work is needed to overcome the species barrier. 
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1.1.6 HCV drug discovery and drug resistance 
The current standard of care for patients with HCV infection enhances only the anti viral immune 
response and is associated with severe side effects (Fried, 2002). Therefore a lot of effort is focused 
on developing novel specifically targeted antiviral therapies for HCV (STAT-C) to improve the 
treatment. Due to the growing understanding of the HCV life cycle, many targets for new specific 
drugs have been identified. Besides viral proteins and RNA, several host proteins are being addressed 
as drug targets, e.g. alpha-glucosidase and cyclophilins. At the time of writing about 30 STAT-C 
compounds were in clinical trials (Lange et al., 2010). Among the viral proteins the two viral 
proteases NS2-3 and NS3/4A, which are essential for the viral life cycle, are particularly interesting 
targets for new specific drugs. The NS2-3 protease turned out to be a difficult drug target (see 
1.1.4.1), but for the NS3/4A protease several inhibitors are in clinical trials and two drugs were 
approved by the FDA (see 1.1.4.2). One problem of the new protease inhibitors is the rapid 
emergence of resistant variants. In an infected patient 1010-1012 virions are produced per day and the 
HCV RNA polymerase NS5B has a low fidelity with an error rate of approximately 10-3-10-5 
mutations per nucleotide (Herrmann et al., 2000; Bartenschlager and Lohmann, 2000). Because of 
this low polymerase fidelity and the high viral yield, huge numbers of novel variants termed 
quasispecies are produced constantly (Gaudieri et al., 2009). In infected patients variants with 
resistant mutations often already preexist and can be the dominant quasispecies which will have an 
effect on the treatment outcome (Bartels et al., 2008). Monotherapy with different protease inhibitors 
leads to the rapid selection of resistant variants and as such must be avoided at all cost. Chemically 
related inhibitors share a similar resistance profile with resistance mutations at the same positions (see 
Figure 1-11). For the linear α-ketoamide inhibitors mutations in NS3 at positions V36A/M, T54A, 
R155K and A156S confer to a low to medium level of resistance, whereas A156T/V or the double 
mutants 36/155 or 36/156 all confer high level resistance. A mutation of R155 affects the recognition 
step of the inhibitor and thereby a selection of a second mutation that affects the covalent binding step 
will have a resistance synergy effect, as shown by a mutation at V36. It has been shown that, for the 
macrocyclic inhibitors BILN-2061, ITMN191 and TMC435, mutations at position R155, D168 and 
A156T/V confer to high level resistance (Zhou et al., 2007; Bae et al., 2010; Lenz et al., 2010). 
Primary resistance mutations occur at positions where the inhibitors have part of their structure 
extending outside the consensus volume modelled to be occupied by the normal substrates, the 
'substrate envelope', thus the binding of the inhibitors is weakened without severe influence on 
substrate binding. Notably the residues R155 and A156 interact with the inhibitors where they extend 
most extensively from the 'substrate envelope'. It is suggested that drugs that fit entirely within the 
'substrate envelope' will be less susceptible to resistance as has recently been shown for HIV-1 
protease inhibitors (Romano et al., 2010; Nalam et al., 2010). The resistance mutations at position 
R155 confer resistance to all protease inhibitors which are in clinical trials. Interestingly mutations at 
R155 exhibit similar replication activity to the wild-type and show a selective advantage (Sarrazin 
and Zeuzem, 2010; He et al., 2008). The resistance mutation A156V refers to high level resistance for 
α-ketoamide inhibitors and macrocyclic inhibitors, but was not shown for all inhibitors in vitro and in 
vivo (see Figure 1-11). 
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Figure 1-11: Amino acids changes of the NS3/4A protease that are associated with resistance mutations in vivo and/or 
in vitro for different inhibitors * Mutations associated with resistance in vitro but were not described in patients. ** 
Mutations associated with resistance in vitro. Resistance mutations described for linear α-ketoamide inhibitors are shown in 
blue and resistance mutations for macrocyclic inhibitors are shown in green (modified from Sarrazin and Zeuzem, 2010). 
Because of the heterogeneity between genotypes and subgenotypes in their nucleotide sequence, new 
STAT-C compounds will not have the same activity in all HCV variants. The protease inhibitors 
telaprevir and boceprevir show a varying activity in different genotypes. Both inhibitors were 
designed to inhibit HCV genotype 1 and show reduced efficacy in genotype 2, 3 and 4. Also 
development of resistant variants occurs more frequently in patients infected with genotype 1a than 
1b when treated with telaprevir or boceprevir because of a nucleotide difference in both subtypes that 
changes the possibility of resistance (Sarrazin and Zeuzem, 2010). 
The development of new specific HCV drugs that show a high activity for all HCV variants and a 
higher barrier to resistance could be achieved by more flexible binding of the inhibitor that allows 
binding even if resistance mutations occur. This means that more than one amino acid mutation would 
be needed to prevent proper binding of the inhibitor (McKeage et al., 2009; Ghany et al., 2009). 
 
 
1.2 Peptide phage display 
Phage display is a powerful technology for the discovery of peptides that can be used as drugs or as 
lead compounds for drug design. It was first introduced in 1985 by George P. Smith (Smith, 1985) 
and has become a widely established technique in the last decades (Arap, 2005). The phage display 
method connects phenotype and genotype of a peptide or protein and mimics the evolutionary 
process. From the huge diversity of a peptide library single binders are selected under specific 
selection pressure (Collins, 1997). An advantage of peptide phage display libraries is the enormous 
number of different peptides presented on phages that can be screened simultaneously. Selected 
peptides can provide new information about the ligand-target interaction and may be used for 
development of new drugs or lead compounds. Several phage display systems have been developed 
and the most common are based on filamentous phage, e.g. the bacteriophage M13 (Lowman, 1997; 
Molek et al., 2011). 
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1.2.1 Bacteriophage M13 
Bacteriophages are viruses that exclusively infect bacteria. The filamentous phage M13 belongs to the 
family of Inoviridae and has a circular single stranded DNA genome. The genome encodes eleven 
proteins, five coat proteins, three proteins important for viral assembly and three proteins necessary 
for viral replication. The genome is packaged into a coat that comprises the 5 coat proteins (see 
Figure 1-12). The main coat protein is the pVIII protein. About 2700 copies of pVIII form a tube-like 
capsid which is capped by three to five copies of the proteins pIII and pVI at one end and pVII and 
pIX at the other (Model and Russel, 1988). The pIII protein is vital for the infectivity of the phage and 
consists of three domains which are connected by glycine rich linkers. The phage particle has a length 
of about 700 – 900 nm and a width of about 6.5 nm. The M13 phage infects bacteria after binding to 
the F-pilus and can therefore only infect bacteria that contain an F-factor (Vieira und Messing, 1987). 
During production of new phage particles the bacterial cells are not lysed, but the generation time is 
lengthened. Each generation of bacteria can produce about 100 – 200 phages (Breitling and Dübel, 
1997). 
 
 
Figure 1-12: Schematic picture of a M13 bacteriophage. 
 
1.2.2 Presentation of peptides using phage display 
Phage display is a method for the presentation of recombinant polypeptides on the surface of phage, 
whereby the genotype and phenotype of the displayed polypeptide are connected (see Figure 1-13). 
The polypeptide exhibiting a specific phenotype is presented on the surface of the phage and the 
genetic information, the genotype, is packaged into the phage allowing a direct identification of the 
coding sequence after an affinity selection (Barbas et al., 1991; Breitling et al., 1991). Peptides can be 
fused to all capsid proteins for presentation on the phage surface. The fusion to the pIII coat protein is 
widely used and allows the display of even large proteins (Bratkovic, 2010). The genetic information 
was first integrated directly into the phage genome (McCafferty et al., 1990), but this resulted in a 
selection drawback of the phage because of lower infectivity of the pIII and a selective growth 
advantage of phage with smaller genomes. Therefore display vectors, termed phagemids, have been 
developed (Breitling et al., 1991; Barbas et al., 1991). Phagemid contain components of plasmids, a 
bacterial origin of replication and an antibiotic resistance, and elements of phage genomes, a phage 
origin of replication for packaging of the phagemid DNA into the phage particles. Also phagemid 
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encode the peptide-pIII fusion protein which is secreted to the periplasm for phage assembly (see 
Figure 1-13).  
 
 
Figure 1-13: Schematic picture of bacteriophage M13 (A) presenting a peptide as a pIII fusion protein and a 
schematic picture of the phagemid pCPL19YS-2 (B). PL: Lambda promoter, RBS: ribosomal binding site, ompA: ompA 
periplasm secretion signal peptide, gIII: M13 pIII coat protein gene, bla: ß-lactamase gene, colE1 ori: E. coli origin of 
replication, M13 ori: M13 phage origin of replication. 
The phagemid is present in the cell as a dsDNA replicating plasmid. For production of phage particles 
a subsequent infection with a helper phage is essential. The helper phage provides all additional 
components for phage replication and packaging. The helper phage has a mutated origin of replication 
and the genome of the helper-phage will be packaged less efficiently into new phage particles (Vieira 
& Messing, 1987) compared to the phagemid. The phagemid will be packed into the phage particle 
and the peptide-pIII fusion protein will be integrated in the phage coat along with wild type pIII 
protein. The use of a tightly controlled promoter for weak expression of the pIII-fusion protein, e.g. 
the lambda PL promoter under control of the lambda repressor, allows essentially monovalent display. 
The frequency of multivalent particles can be calculated assuming that there are 5 copies of the 
pIII/pIII-hybrid protein per particle distributed approximating to a Poisson distribution. The ratio of 
pIII-hybrid/pIII has been measured by Western-blot analysis (Pollmann, 2010) to be 1:50. According 
to this estimate about 10% of the phage particle will incorporate one fusion protein and only a very 
low percent two or more copies of the fusion protein. The majority of the phage display no fusion 
protein. The monovalent display allows higher differential selection of high affinity binders because 
of the avoidance of avidity effects that could result in a higher apparent affinity of low affinity ligands 
(Russel et al., 2004; Röttgen and Collins, 1995). 
 
1.2.3 Panning: Affinity selection of peptide phage 
The connection of genotype and phenotype during phage display selection allows the simultaneous 
screening of an enormous number of different peptides using their affinity to a target protein. Peptide 
phage display libraries with up to 109 different variants have been constructed and displayed peptides 
with the highest affinity can be enriched from these libraries. Monovalent display allows selection of 
ligands with affinities ranging from 500 nM to low picomolar binding affinities (Lowmann, 1997). 
The selection of specific binders from the phage library is called panning (Parmley and Smith, 1988). 
For an affinity selection the target molecule can be immobilised on a surface or the panning can be 
done in solution with subsequent capture of the target molecule. For direct immobilisation e.g. plastic 
A	   B	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surfaces, coated microtiterplates, resins or beads are used (Russel et al., 2004). The phage displaying 
the peptides are incubated with the target molecule and unbound particles are removed by several 
washing steps (see Figure 1-14).  
 
 
Figure 1-14: Schematic description of an affinity selection procedure with a phage display library. 
Bound phage can be eluted through unspecific elution, e.g. lowering the pH, or denaturing the target 
molecule with DTT or a chaotrope, or through specific elution with a competitive molecule which 
binds at the desired binding site of the target. The eluted phages are amplified and used for further 
selection rounds. Usually 3 – 5 panning rounds are enough for enrichment of specific binders which 
can be identified by sequencing and ELISA tests. This requires enrichment of several hundred- to 
several thousand-fold per panning round. The outcome of an affinity selection depends on a number 
of experimental parameters during panning e.g. target immobilisation, buffer conditions, number and 
duration of washing steps and elution method are very important and have to be adapted for each 
target. 
 
1.2.4 Library diversity and cosmix-plexing  
The library diversity is an important parameter for the selection of peptides with high affinity. 
Roughly speaking a high library complexity increases the chance of enrichment of variants with high 
affinity. The practical limitation of the size of a phage display peptide library is about 1011 variants, 
but the complexity of a library normally does not exceed 109 variants (Lowman, 1997). The number 
of clones required within a library that contains all possible sequences increases exponentially with 
length of the library peptide. The theoretical complexity of a 20mer peptide library is already about 1 
x 1026 variants. Therefore only a minute fraction of all possible variants can be covered in peptide 
libraries. To further extend variability recombination techniques can be used to increase the 
complexity of a library. This is a central concept of cosmix-plexing libraries. Cosmix-plexing is a 
technique to increase diversity through DNA recombination and can be used to further increase the 
diversity of a library before selection and/or to increase the affinity of selected ligands after initial 
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selection rounds. Restriction enzyme sites located at defined positions allow shuffling of DNA 
cassettes. The phagemids are cleaved at type IIs restriction enzyme sites inside the library sequence 
and ligated at high DNA concentration resulting in the formation of long concatemers. After cleavage 
of these concatemers at a restriction site located outside of the library sequence, the DNA is ligated at 
low concentration to yield circular phagemid with recombined library sequence. The orientation and 
order of the fragments is maintained by having non-palindromic sequences where the restiction 
endonucleases produce cohesive ends (see Figure 1-15). After additional selection rounds the 
recombination can be repeated with different restriction sites to further increase the affinity of the 
peptides. The selective enrichment of motifs after recombination and new rounds of selection allows 
the rapid localisation of important binding motives within the long variable region of the selected 
peptides (Collins et al., 2001). 
 
	  
Figure 1-15: Cosmix-plexing procedure. Recombination is achieved by enzyme cleavage and ligation. The circles 
represent phagemid DNA. The left and right fragments of the phagemids are recombined yielding N2 variants from an initial 
selected population of N clones. The orientation of the fragments is maintained by using non-palindromic cohesive ends 
which are generated by cleavage at the recombination and resolution site (from Bratkovic, 2009). 
 
1.2.5 Affinity 
The binding strength of a ligand binding to a protein is called affinity. Non-covalent ligand-protein 
interactions, such as ionic or hydrophobic interactions and hydrogen bonds determine the binding 
affinity. The formation of the ligand-protein complex can be described by the law of mass action (Eq. 
1). 
 
  A + [B] ⇔ [AB]   Eq. 1 
 
[A]: protein concentration, [B]: ligand concentration, [AB]: complex concentration, ka: association rate, kd: 
dissociation rate 
 
In an equilibrium state the concentration of the ligand at which half of the protein has a bound ligand 
is termed equilibrium dissociation constant Kd. The dissociation constant is a dimension for the 
affinity of the ligand and has molar units. The smaller the dissociation constant Kd the higher the 
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affinity of the ligand for the protein. Kd is defined by Eq. 2 and can be measured e.g. by isothermal 
titration calorimetry (Freire, 2004). 
 
  K! = ! !!" = !!!!   Eq. 2 
Kd: dissociation constant, [A]: protein concentration, [B]: ligand concentration, [AB]: complex concentration, 
kd: dissociation rate, ka: association rate  
 
In the case of enzyme inhibitors the dissociation constant of the inhibitor is called Ki. Analogue to the 
Kd the Ki is the concentration of the inhibitor at which half of the enzyme has a bound inhibitor at the 
binding site at equilibrium. The binding affinity of the inhibitor Ki is related to the IC50 value for 
competitive compounds and can be described through Eq. 3 (Cheng and Prusoff, 1973). 
 𝐊𝐢 = 𝐈𝐂𝟓𝟎𝟏! 𝐒𝐊𝐦    Eq. 3 
Ki: binding affinity of the inhibitor, IC50: half maximal inhibitory concentration, [S]: substrate/ligand 
concentration, Km: Michaelis-Menten constant of the substrate/ligand 
 
The IC50 value describes the effectiveness of a drug. For an enzyme inhibitor the commonly used 
relative IC50 is the concentration where the compound has the half maximal inhibitory effect. The IC50 
value of a drug can be determined with a dose-response curve using different concentrations of an 
inhibitor. The IC50 value is dependent on the measurement condition, e.g. substrate affinity and 
enzyme concentration. 
 
1.2.6 Peptide library CPL19YS-2 
The peptide phage display library CPL19YS-2 was constructed by Dr. Erik Pollmann (Pollmannn, 
2010). The library peptide coding region is fused via a short linker in the same open reading-frame to 
the pIII coat protein of the M13 phage. Expression of the fusion protein is under control of the lambda 
PL promoter regulated by the CI lambda repressor. This promoter was previously shown to have an 
appropriate level of expression for monovalent display of the peptide in a host cell with sufficient 
lambda repressor (Röttgen and Collins, 1995). The library peptide consists of 33 aa from which 26 aa 
are variable. At degenerate codons not every amino acid is available at each position (see Figure 
1-16). The amino acids Glu, Lys, Gln and Trp are absent. To reduce the theoretical complexity only 
one negatively and positively charged aa is available in the library. The aa Gln is absent to avoid the 
HPQ motive which binds to streptavidin with high affinity (Devlin et al., 1990). Trp is very 
hydrophobic, and being a very large amino-acid not easily sequestered within a relatively short 
peptide. This may make most peptides containing it very hydrophobic and may lead to unspecific 
interactions especially with plastic sufaces (Adey et al., 1995). Therefore it is not present in the 
library. The repertoire at some positions is also further limited in order to accommodate restriction 
sites and avoid stop codons. A fixed cysteine in the middle of the library can form disulfide bridges 
with further cysteines which may be occur with intermediate frequency at positions convenient for 
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forming loops. It was considered that fascillitating the formation of such secondary structures would 
stabilise the peptide structure increasing the likelihood of forming stronger ligands. 
Three type IIs restriction sites are integrated in the library peptide sequence: This results in a structure 
having four cassettes, allowing recombination of the peptide coding region with the cosmix-plexing 
method (see 1.2.4). The theoretical complexity of the whole library is 1.6 x 1025 variants but the 
highest complexity within a single cassette is 5.5 x 107 variants having a 3-fold coverage in the actual 
library which comprises approximately 1.8 x 108 independent clones (Pollmann, 2010). 
	  
	  
Figure 1-16: CPL19YS-2 library sequence and amino acid availability.The four cassettes of the library are indicated by 
coloured boxes. ´+´ and ´.´ indicate availability or absence of an amino acid at that position. Glutamic acid, lysine, glutamine 
and tryptophan are absent in the library (from Pollmann, 2010). 
 
1.3 Peptides as therapeutics 
Short chains of amino acids are called peptides, but the transition from peptides to small proteins is 
fluent and in general polypeptide chains of less than 50 aa are termed peptides. Despite their short 
length peptides are able to form stable structures, e.g. cyclic, ß-sheet or α-helical structures. (Lien and 
Lowman, 2003; Sato et al., 2006). Various short peptides have been shown to be structured in 
solution, e.g. the 18 aa long RTD-1 defensin peptide (Trabi et al., 2001) or the 20 aa long IgE 
receptor antagonist peptides (Nakamura et al., 2002). 
Peptide and protein interactions are essential for biochemical functions of life. They play an important 
role in modulating all biological processes and are therefore of great interest for the development of 
new therapeutic products. Over the last decades peptide drugs have become an important field for 
drug development with about 131 peptides in clinical development and 54 therapeutic peptides on the 
market (Reichert et al., 2010). Biologics accounted for 25% of FDA approved drugs in 2010 
reflecting the increasing importance of this drug class (Mullard, 2011). One prominent peptide drug 
that showed the potential of therapeutic peptides is enfuvirtide (Roche). The peptide is a 36mer 
consisting of natural amino acids with an acetylated N-terminus. Enfuvirtide blocks HIV cell entry, 
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has a high efficacy and a relative long serum half-life (Kazmierski et al., 2006). The development of 
this drug was a breakthrough for peptides as important pharmaceuticals and was accompanied by 
enormous efforts to dramatically reduce the cost of peptide synthesis and purification (Buchholz and 
Collins, 2011). Main sources for peptide leads are natural bioactive peptides and combinatorial 
peptide libraries, e.g. chemical libraries and phage display libraries (Lien and Lowman, 2003; Kay et 
al., 1998). 
The majority of drug targets for small molecules are enzymes, receptors and ion channels that offer 
substrate binding pockets able to interact with small compounds. The “druggable genome study", was 
an attempt to indentify all proteins belonging to families whereof one member was already targeted 
by a drug, assuming that all members of a family are good drug targets. The study revealed for the 
human genome a much smaller number of possible targets than originally thought (Hopkins and 
Groom, 2002). Many proteins involved in disease processes are not 'druggable' because of the lack of 
suitable ('addressable') binding pockets. Peptides in contrast can have a larger surface area that is 
involved in binding and a synergistic binding effect of many interactions at various sites on the target 
protein. Therefore peptides and protein therapeutics have the potential to extend the number of 
‘druggable’ targets (Groner, 2009). Peptides have other advantages over small molecules, e.g. high 
activity, target specificity, low side-effects and lower potential toxicity since their natural degradation 
in the body produces no toxic substances. However, peptides can also have some important 
drawbacks such as degradation in the stomach preventing oral delivery without extensive 
confectioning, low in vivo stability, short serum half-life, risk of immunogenic effects and inefficient 
cellular uptake (Sato et al., 2006). These drawbacks hamper the development of peptide therapeutics 
and have been addressed in the past years. Alternatively if these issues cannot be resolved the 
peptides can still serve as lead structures for the development of peptide mimetics (Sillerud and 
Larson, 2005). 
 
1.3.1 Application and stability of peptide therapeutics 
Peptides have a low oral bioavailability because they are degraded by proteolytic enzymes and they 
cannot cross the membrane of the intestinal tract. Peptide therapeutics are mostly administered by 
injection or infusion which has a low patient compliance. Therefore non invasive application methods 
are needed. Novel application methods that are in development are intranasal delivery, pulmonary 
delivery, buccal administration, transdermal delivery and even enhanced oral delivery. The most 
promising alternatives are the intranasal and pulmonary delivery with a bioavailability of up to 80%, 
although it should be noted that the variability in uptake from one patient to another has been a major 
barrier in quantifying delivery and a barrier in getting clinical approval. To increase the 
bioavailability several formulation approaches, like absorption enhancer, nanoparticles or liposomes 
have been studied to improve the absorption (Mao et al., 2009). Although non invasive delivery 
methods are promising, injection devices have become more user-friendly improving the compliance 
of patients (Nielsen and Jorgensen, 2009).  
For all delivery methods the in vivo stability of peptides should be improved to reduce the number of 
medications necessary. Peptides have normally a short serum half-life time of minutes to hours. To 
avoid fast clearance modifications, including conjugation with polymers, N- and C-terminal 
modifications and incorporation of unnatural aminoacids, can be used. For protein stabilisation by the 
addition of hydrophilic polymers conjugation with polyethylene glycol (PEG) has been used 
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preferentially, even though hydroxyethyl starch (HESylation) has a long history of acceptance in the 
clinic and is presently a major development program at Fresenius Kabi (Buchholz and Collins, 2011). 
PEG residues are attached to the peptides at the ends or within the peptide. The PEG-conjugates have 
a higher molecular weight, better water solubility and are partially protected from degradation by 
proteases. However, the modification of the peptide can lead to a loss of function. Acetylation and 
glycosylation of the N-terminus and amidation of the C-terminus prevents degradation of the peptides 
by proteases and improves the serum half-life time. The incorporation of D-amino acids or other 
unnatural amino acids can also prevent proteolytic degradation of the peptides. The decrease of 
degradation of the peptides can reduce the possible immunogenicity of the peptides by limited MHC 
presentation of the epitopes (Lien and Lowman, 2003; Sato et al., 2006). A recent approach to 
increase the bioavailability of peptides is the stabilisation of the peptide structure. Bird and co-
workers showed that a hydrocarbon crosslink within an α-helical peptide stabilised the structure and 
led to protease resistance and increased cellular uptake of the peptide (Bird et al., 2010). 
 
1.3.2 Intracellular delivery of peptides 
Peptide drugs that target intracellular proteins have to cross the plasma membrane. Because of the 
highly selective permeability of cell membranes to macromolecules, methods for cell delivery of 
peptides and proteins have been developed. 
Cell penetrating peptides (CPP) are short peptides that can cross cellular membranes and thereby 
deliver a cargo into cells (Schwarze et al., 2000). CPPs can be classified as cationic or amphipathic 
peptides. Cationic CPPs, for example the HIV-Tat peptide (Green and Loewenstein, 1988) and the 
Antennapedia peptide (Joliot et al., 1991), contain segments of positive charged amino acids, whereas 
amphipathic CPPs contain a balanced number of hydrophilic and hydrophobic amino acids and form 
an α-helical structure. Although many CPPs are derived from transduction domains of natural 
proteins artificial CPPs have also been developed (Pooga et al, 1998; Morris et al, 2001) so that the 
number of different cell penetrating peptides is constantly increasing. They have been used for the 
delivery of various cargoes into cells in vitro and in vivo: peptides, proteins, small molecules and 
nucleic acids (Heitz et al, 2009). For cytoplasmic delivery the first step of CPP internalisation 
involves interaction with the extracellular matrix. Most CPPs interact with proteoglycans which act as 
receptors for the initial contact (Pujals et al., 2006). For internalisation direct translocation across the 
plasma membrane, clathrin and caveolin mediated endocytosis and macropinocytosis have been 
proposed. It has been suggested that endocytosis and macropinocytosis are the most important 
pathways for internalisation, but different uptake mechanisms may be exploited in parallel. 
Internalisation and cellular localisation of CPPs also depends strongly on the delivered cargo, the 
concentration of the CPP and the used cell type (Richard et al., 2005; Duchardt et al., 2007; Patel et 
al., 2007; Van den Berg and Dowdy, 2011). Intracellular uptake by endocytosis and macropinocytosis 
requires escape from the endosomal vesicles into the cytoplasm. The mechanism of endosomal escape 
of CPPs is still not clear, but acidification of early endosomes and retrograde transport is thought to 
be critical (Fischer et al., 2003; Potocky et al., 2003). The endosomal escape is the rate limiting step 
of intracellular delivery because only a fraction of the CPP is able to escape from the endosmal 
vesicles and the remaining peptide will be degraded in the lysosomes (Heitz et al., 2009; Patel et al., 
2007).  
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An alternative method for intracellular delivery of biopharmaceuticals is the use of nanoparticles. 
Nanoparticles are vesicles with a membrane like structure in which the cargo is encapsulated. 
Different nanoparticle vectors are in development, for example liposomes, artificial phospholipid 
vesicles, and polymer nanovesicles. The encapsulation into nanovesicles prevents degradation of the 
cargo and immune response against the cargo (Torchilin and Lukyanov, 2003). Cellular uptake of 
nanoparticles is mediated via endocytosis and can be enhanced by modification of the surface, as has 
been shown for attachment of CPPs to the particle surface (Torchilin, 2008). A limiting factor for the 
cytosolic delivery can be the low endosomal escape of nanovesicles and CPPs and a resulting 
degradation of the cargo in the lysosomes (Duchardt et al., 2007). To overcome the endosomal 
entrapment various techniques are in development. One interesting method is the use of pH sensitive 
polymersomes. Polymersomes are nanoparticles that consist of a pH-sensitive copolymer which self 
assembles and forms vesicles in nanometer size at a pH higher than 6.5. They have been used to 
deliver nucleic acids and antibodies and are internalised by cells via endocytosis. Acidification of the 
early endosomes leads to disaggregation of the polymersomes. Because of the abrupt local change in 
osmotic pressure caused by this, pores are formed in the endosomal membrane and the cargo is 
released into the cytosol (Massignani et al., 2009; Massignani et al., 2010). 
The lack of tissue specificity reduces the efficacy of intracellular delivery methods or applied 
biopharmaceuticals in general (Torchilin and Lukyanov, 2003). Cell type specific delivery can be 
achieved by the use of coupled targeting ligands. As targeting ligands peptides, antibodies or small 
molecules can be used, which bind to receptors or surface structures that are specific for cell types or 
tissues (Vasievich and Huang, 2009). For the targeting of hepatocytes coupling of galactosamine or 
coupling with hepatocyte specific peptides to delivery vectors has been described (Seymour et al., 
2002; Gripon et al., 2004; Wakefield, 2005). 
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1.4 Aim of the project 
The aim of this work was the development of inhibitory peptides against the NS2-3 and NS3/4A 
proteases of the Hepatitis C Virus as leads for drugs for HCV treatment. These proteases are essential 
for the viral life cycle and therefore the NS2-3 and NS3/4A proteases are interesting targets for the 
development of new specific antiviral drugs against HCV. Nonetheless, the proteases are difficult 
drug targets, e.g. the NS3/4A protease has a shallow and solvent exposed binding pocket which 
makes it difficult to develop small molecule drugs (Kim et al., 1996). A combinatorial phage display 
peptide library displaying large peptides should be used for iterative affinity enrichment on 
immobilised HCV protease. Larger peptides have the potential for additive binding interactions at 
different sites of the protease. The inhibitory effect of the enriched peptides should be characterised 
and optimised and various methods for cell delivery should be tested. 
 
Specific aims of this work were: 
 
• Production and purification of recombinant proteases NS2-3 and NS3/4A in an active form 
 
• Affinity selection on immobilised HCV proteases with the combinatorial phage display 
peptide library CPL19YS-2 
 
• Characterisation of enriched peptides and backcrossing recombination of inhibitory peptides 
to yield variants with increased affinity 
 
• Cell delivery of inhibitory peptides for inhibition of viral replication in a cell culture model 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Unless stated otherwise, all used chemicals were commercially available and of analytical grade.  
 
2.1.2 Buffers and solutions 
All aqueous solutions were prepared with double deionised water (Millipore, Milli Q ultra-pure). If 
needed the solutions were sterilised by autoclaving or filtration. 
 
2.1.2.1 Buffers 
name	   formulation	  
Buffer	  A	   50	  mM	  TrisHCl	  (pH	  8),	  300	  mM	  NaCl,	  10	  %	  (v/v)	  glycerol,	  0.05	  %	  
Tween	  20,	  5	  mM	  ß-­‐mercaptoethanol	  
Buffer	  D	   50	  mM	  TrisHCl	  (pH	  7.5),	  300	  mM	  NaCl,	  20	  %	  (v/v)	  glycerol,	  0.05	  %	  
Tween	  20,	  5mM	  DTT	  
Buffer	  H	   50	  mM	  HEPES	  (pH7.5)	  
Buffer	  M2235	   50	  mM	  HEPES	  (pH	  7.8),	  100	  mM	  NaCl,	  20%	  glycerol,	  5	  mM	  DTT,	  	  	  	  	  
0.6	  mM	  LDAO	  
Buffer	  (P)	   50	  mM	  TrisHCl	  (pH	  7.5),	  150	  mM	  NaCl,	  10	  %	  (v/v)	  glycerol,	  	  	  	  	  	  	  	  	  	  	  	  
0.05	  %	  Tween	  20	  
Buffer	  P	   Buffer	  (P)	  with	  5mM	  DTT	  
Cleavage	  buffer	  1	  (NS2-­‐3)	  	   50	  mM	  TrisHCl	  (pH	  7.5),	  50%	  glycerol,	  1%	  tritonX,	  250	  mM	  NaCl,	  	  	  	  	  
50	  µM	  ZnCl2,	  3	  mM	  DTT,	  3mM	  cysteine	  
Cleavage	  buffer	  2	  (NS2-­‐3)	   50	  mM	  TrisHCl	  (pH	  7.5),	  50%	  glycerol,	  1%	  CHAPS,	  250	  mM	  NaCl,	  	  	  	  	  
50	  µM	  ZnCl2,	  3	  mM	  DTT,	  3mM	  cysteine	  
Cleavage	  buffer	  3	  (NS2-­‐3)	   50	  mM	  TrisHCl	  (pH	  7.5),	  30%	  glycerol,	  0.2%	  CHAPS,	  50	  µM	  ZnCl2,	  	  	  	  	  	  
3	  mM	  DTT	  
Elution	  buffer;	  pH	  2.2	   0.1	  M	  glycin	  in	  dH2O	  
Laemmli	  sample	  buffer	  (6x)	   10	  %	  (w/v)	  SDS;	  50	  %	  (v/v)	  glycerol;	  0.02	  %	  (w/v)	  bromphenolblue;	  
15	  %	  (v/v)	  ß-­‐mercaptoethanol	  in	  dH2O	  
SDS	  running	  buffer(10x);	  pH	  8.3	   0.25	  M	  Tris;	  2	  M	  glycin;	  1	  %	  (w/v)	  SDS	  in	  dH2O	  
Lysis	  buffer	  lysozym	   50	  mM	  TrisHCl	  (pH	  8),	  0.1%	  Triton	  X100;	  50	  µg/ml	  DNAseI;	  1	  mg/ml	  
lysozyme;	  500	  mM	  NaCl;	  5	  mM	  ß-­‐mercaptoethanol;	  5	  mM	  
imidazole;	  10%	  glycerol	  
Lysis	  buffer	  homogeniser	   50	  mM	  TrisHCl	  (pH	  8),	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  5	  mM	  ß-­‐
mercaptoethanol,	  0.2%	  LDAO,	  10%	  glycerol;	  25µg/ml	  DNAseI	  
Lysis	  buffer	  Inclusion	  Bodies	   25	  mM	  Tris-­‐HCl	  (pH	  8.0),	  6	  M	  guanidine	  hydrochloride,	  500	  mM	  NaCl	  
Dialysis	  Buffer	  NS2-­‐3	   50	  mM	  Tris	  (pH	  7.5),	  50	  µM	  ZnCl2,	  3	  mM	  DTT,	  750	  mM	  guanidine	  
hydrochloride	  
MPBST	   	   0.05	  %	  (v/v)	  Tween	  20,	  2	  %	  milkpowder	  in	  PBS	  
Na-­‐Phosphat	  buffer	  (pH	  8.1)	   0.5	  M:	  21.15	  %	  (v/v)	  NaH2PO4-­‐solution	  (1M	  in	  water);	  28.85	  %	  (v/v)	  
Na2HPO4-­‐solution	  (1M	  in	  water)	  
Neutralisation	  buffer	   	   2.0	  M	  Tris	  in	  dH2O	  
PBS	  (10x)	   	   2.0	  g/L	  KCl;	  2.0	  g/L	  KH2PO4;	  80.0	  g/L	  NaCl;	  11.50	  g/L	  Na2HPO4	  in	  
dH2O	  
PBST	  	   	   0.05	  %	  (v/v)	  Tween	  20	  in	  PBS	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name	   formulation	  
Profinia	  native	  IMAC	  Buffers	   50	  mM	  TrisHCl	  (pH	  8.0),	  500	  mM	  NaCl,	  5	  mM	  Imidazol,	  5	  mM	  ß-­‐
mercaptoethanol,	  0.1	  %	  LDAO,	  10%	  glycerol	  
Wash	  buffer	  1:	  5	  mM	  imidazole	  
Wash	  buffer	  2:	  10	  mM	  imidazole	  
Elution	  buffer:	  250	  mM	  imidazole	  
Profinia	  Desalting	  Buffer	  1	   50	  mM	  TrisHCl	  (pH	  8.0),	  500	  mM	  NaCl,	  5	  mM	  imidazol,	  5	  mM	  ß-­‐
mercaptoethanol,	  0.1	  %	  LDAO,	  10%	  glycerol	  
Profinia	  Desalting	  Buffer	  2	   50	  mM	  Na-­‐acetate	  (pH6.3),	  500	  mM	  NaCl,	  5	  mM	  DTT,	  0.6mM	  LDAO,	  
10%	  glycerol	  
TAE	  (50x);	  pH	  8.5	  	   2	  M	  Tris;	  1	  M	  acetic	  acid;	  50	  mM	  Na2EDTA	  
Tricine	  page	  sample	  buffer	  (4x)	   6%	  (w/v)	  SDS,	  30	  %	  (v/v)	  glycerol;	  0.05	  %	  (w/v)	  coomassie	  blue	  G-­‐
250;	  6	  %	  (v/v)	  ß-­‐mercaptoethanol,	  150	  mM	  Tris	  HCl	  (pH	  7.0)	  
Tricine	  page	  anode	  buffer	  (10x)	   1	  M	  TrisHCl	  (pH	  8.9)	  
Tricine	  page	  cathode	  buffer	  (10x)	   1	  M	  Tris	  pH	  (8.25),	  1	  M	  tricine,	  1%	  (w/v)	  SDS	  
Tricine	  page	  fixing	  solution	   50%	  methanol,	  10%	  acetic	  acid,	  100	  mM	  ammonium	  acetate	  
Tricine	  page	  gel	  buffer	  (3x)	   3	  M	  Tris	  pH	  (8.45),	  0.3%	  (w/v)	  SDS	  
Blotting	  buffer	   6	  g/L	  Tris,	  2.9	  g/L	  glycine,	  0.037	  %	  (v/v)	  SDS,	  20%	  methanol	  
 
2.1.2.2 Solutions 
name	   formulation	  
Acrylamidmix	  29:1	  (Roth)	   30%	  (w/v)	  acrylamide,	  0,8%	  (w/v)	  bisacrylamide	  
APS	   10%	  (w/v)	  ammonium	  persulfate	  in	  dH2O	  
ABTS	  substrate	  solution	   4.62	  mg	  ABTS;	  21	  ml	  0.05	  M	  citric	  acid	  pH	  4.0;	  36	  µl	  30	  %	  H2O2	  	  
Coomassie	  discolouration	  solution	   20	  %	  ethanol;	  10	  %	  acetic	  acid	  
Coomassie	  staining	  solution	   1	  tablet	  PhastGel	  BlueR	  (Pharmacia)	  in	  80	  ml	  dH2O;	  120	  ml	  
methanol;	  before	  use	  add	  200	  ml	  acetic	  acid	  (20	  %)	  
DAB	  substrate	  solution	   1	  mg/ml	  DAB	  (3,3'-­‐Diaminobenzidine),	  0.07%	  imidazole,	  0.02%	  
CoCl2,	  0.01%	  H2O2,	  0.1M	  phosphate	  buffer	  (pH	  7.3)	  
Ethidium	  bromide	   	   50	  mg	  ethidium	  bromide	  in	  10	  ml	  dH2O	  
Loading	  Dye	   (6x)	   4	  g	  sucrose;	  25	  mg	  bromphenolblue;	  add	  10	  ml	  dH2O	  
PEG/NaCl	   2.5	  M	  NaCl;	  20	  %	  PEG	  6000	  in	  dH2O	  
 
2.1.3 Kits 
name	   commercially	  available	  
NucleoSpin	  Extract	  II	  (NS	  II)	   Macherey-­‐Nagel,	  Düren	  
PureYield	  Plasmid	  Miniprep	  System	   Promega,	  Madison,	  USA	  
Qiagen	  Plasmid	  Maxi	  Kit	   Quiagen,	  Venlo,	  Netherlands	  
QIAprep	  Spin	  Miniprep	  Kit	   Quiagen,	  Venlo,	  Netherlands	  
Roti-­‐Black	  P	  silver	  staining	  kit	   Carl	  Roth,	  Karlsruhe	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2.1.4 Media and supplements 
Media	   	  
2	  x	  YT	  medium	   16	  g/L	  tryptone,	  10	  g/L	  yeast	  extract,	  5	  g/L	  NaCl	  optional:	  2	  %	  (w/v)	  agar	  
TB	  medium	   12g/L	  tryptone,	  24g/L	  yeast	  extract,	  0.4%	  (v/v)	  glycerol,	  17	  mM	  KH2PO4,	  	  
72	  mM	  K2HPO4	  
SOC	  medium	   20	  g/L	  tryptone,	  5	  g/L	  yeast	  extract,	  5	  g/L	  NaCl,	  pH	  7.0,	  20	  mM	  Mg2+	  
solution,	  20	  mM	  glucose	  
M9-­‐medium	   100	  ml/l	  M9-­‐salt	  solution	  (10x),	  12.5	  ml	  glucose	  40	  %	  (w/v),	  100	  µl	  CaCl	  (1	  
M),	  1	  ml/l	  MgSO4,	  100	  µl/l	  thiamine,	  100	  µg/ml	  leucine,	  isoleucine,	  valine	  
M9-­‐salt	  solution	  (10x)	   74.1	  g/L	  Na2HPO4	  *	  H2O,	  30	  g/L	  KH2PO4,	  5	  g/L	  NaCl,	  10	  g/L	  NH4Cl	  
	  
 
 
 
 
 
 
 
 
2.1.5 Bacterial strains and bacteriophage 
strain	   genotype	   commercially	  available	  
E.	  coli	  TOP	  10	  F`	   F´[lacIq	  Tn10	  (TetR)]	  mcrA	  ∆(mrr-­‐hsdRMS-­‐mcrBC)	  
φ80	  lacZ∆M15	  ∆lacX74	  recA1	  deoR	  araD139	  ∆(ara-­‐
leu)7697	  galU	  galK	  rpsL	  (StrR)	  end	  A1	  nupG	  
Invitrogen,	  Carlsbad,	  
USA	  
E.	  coli	  TOP	  10	  F`	  λ+	   λ 	  lysogen	  Top10F’	  strain	   Prof.	  John	  Collins,	  
Technical	  University	  
Braunschweig,	  Germany	  
E.	  coli	  XL1-­‐blue	  MRF`	   F´	  [lacIqZ∆M15	  Tn10	  (TetR)	  proAB]	  ∆	  (mcrA)183	  ∆(mrr-­‐
hsdRMS-­‐mcrBC)173	  endA1	  supE44	  thi-­‐1	  recA1	  
gyrA96	  relA1	  lac	  
Stratagene	  Santa	  Clara,	  
USA	  
Rosetta	  2	  (DE3)	   F-­‐	  ompT	  hsdSB(rB
-­‐	  mB
-­‐)	  gal	  dcm	  (DE3)	  pRARE2	  (CamR)	   Merck,	  Darmstadt	  
M13K07	  Helperphage	   mutation	  Met40Ile	  in	  gII;	  origin	  of	  replication	  from	  
P15A;	  Kmr	  from	  Tn903	  
NEB,	  Ipswich,	  USA	  
 
2.1.6 Plasmids 
name	   description	  /	  availability	  
pEPO8-­‐CPL19YS-­‐2	  library	  phagemid	  vector	   constructed	  by	  Dr.	  Erik	  Pollmann,	  kindly	  provided	  by	  HZI,	  
Braunschweig,	  Germany	  
pMALc4E	  plasmid	   NEB,	  Ipswich,	  USA	  
pET28c	   Novagen	  (Merck,	  Darmstadt)	  
HCV	  replicon	  I389/NS2-­‐3'UTR	  (AJ242653)	   kindly	  provided	  by	  Ralf	  Bartenschlager,	  University	  
Heidelberg,	  Germany	  
HCV	  replicon	  I389/NS3-­‐3'UTR	  (AJ242654)	   kindly	  provided	  by	  Ralf	  Bartenschlager,	  University	  
Heidelberg,	  Germany	  
HCV	  replicon	  I341	  PiLuc/3-­‐3'/ET	  
(Lohmann	  et	  al.,	  2003)	  
kindly	  provided	  by	  Ralf	  Bartenschlager,	  University	  
Heidelberg,	  Germany	  
Antibiotics	   	  
Ampicillin	   Stock-­‐solution:	  50	  mg/ml	  in	  dH2O	  
Final	  concentration:	  100	  µg/ml	  
Kanamycin	   Stock-­‐solution:	  50	  mg/ml	  in	  dH2O	  
Final	  concentration:	  30	  µg/ml	  
Tetracyclin	   Stock-­‐solution:	  6	  mg/ml	  in	  70%	  Ethanol	  
Final	  concentration:	  6	  µg/ml	  
Chloramphenicol	   Stock-­‐solution:	  34	  mg/ml	  in	  100%	  Ethanol	  
Final	  concentration:	  34	  µg/ml	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2.1.7 Antibodies, proteins and enzymes 
name	   description	   commercially	  available	  
Anti-­‐g3p	  (pIII)	  antibody	   monoclonal	  murine	  IgG;	  clone	  10C3	   MoBiTec,	  Göttingen	  
Anti-­‐mouse	  IgG,	  HRP	  linked	   horse	  anti-­‐mouse	  IgG	  antibody	   Cell	  Signaling,	  Boston,	  USA	  
Anti-­‐MBP	  antibody	   monoclonal	  murine	  IgG,	  isotype	  IgG2a	   NEB,	  Ipswich,	  USA	  
Anti-­‐poly	  Histidine	  antibody,	  
HRP	  linked	  
monoclonal	  murine	  IgG;	  clone	  His-­‐1	   Sigma-­‐Aldrich,	  St.	  Louis,	  USA	  
Anti-­‐M13	  IgG,	  HRP	  linked	   monoclonal	  murine	  anti-­‐M13	  (pVIII)	  IgG	   GE	  Healthcare,	  UK	  
MBP4*	   Maltose	  binding	  protein	  with	  the	  
polylinker	  encoded	  by	  the	  pMAL-­‐c4E	  
vector	  
NEB,	  Ipswich,	  USA	  
T4	  DNA	  ligase	   	   NEB,	  Ipswich,	  USA	  
T4	  polynucleotide	  kinase	   	   NEB,	  Ipswich,	  USA	  
T4	  DNA	  polymerase	   	   NEB,	  Ipswich,	  USA	  
Antarctic	  phosphatase	   	   NEB,	  Ipswich,	  USA	  
Phusion	  DNA	  Polymerase	   	   Finnzymes,	  Vantaa,	  Finland	  
Restriction	  endonucleases	   	   NEB	  /	  MBI	  Fermentas	  
Neutrophil	  elastase	   	   MD	  Biosciences,	  St.	  Paul,	  USA	  
Trypsin,	  chymotrypsin	   	   Carl	  Roth,	  Karlsruhe	  
DNAseI	   	   Sigma-­‐Aldrich,	  St.	  Louis,	  USA	  
 
2.1.8 Oligonucleotides 
name	   sequence	  (5´	  –	  3´)	  
malE1	   GCCGACATCATAACGGTTCTGGCA	  
malE2	   TGCAAGAACCGTACTTCACCTGGC	  
malE2-­‐rev	   GCCAGGTGAAGTACGGTTCTTGCA	  
malE3	   GGTCGTCAGACTGTCGATGAAGCC	  
malE3-­‐rev	   GGCTTCATCGACAGTCTGACGACC	  
malE4-­‐rev	   CGCCAGGGTTTTCCCAGTCACGAC	  
primNS3-­‐4A	   TTTTGGTACCGGGCTCAGTAGTAATCGTAGGCAGAATCATCCTGTCCGGCAAAGGTGGCCCT
ATTACGGCCTACTCCCAAC	  
primNS3-­‐4A-­‐rev	   GCCGGACTGCAGTTTAGTGATGGTGATGGTGATGGGAGCCCCGCATAGTGGTTTCCATAGA	  
primNS2-­‐3	   GTCGGGTACCGACCAAAGTGCCGTACTTCGTG	  
primNS2-­‐3-­‐rev	   TTTACTGCAGTTTAGTGATGGTGATGGTGATGGGAGCCCCGCATAGTGGTTTCCATAGA	  
primNS3-­‐4A-­‐pET	   GCCGGACTCGAGTTTAGTGATGGTGATGGTGATGGGAGCCCCGCATAGTGGTTTCCATAGA	  
primNS3-­‐4A-­‐pET-­‐rev	   ATTTTCCATGGGTTCTGTTGTAATTGTAGGTAGAATCATTCTGTCCGGTAAAGGTGGCCCTAT
TACGGCCTACTCCCAAC	  
Pep-­‐pMAL	  uni	  5`	   GGCGAGCTCGGA	  
Pep-­‐pMAL	  uni	  3`	   CGTCCTGCAGTTAGTGATGGTGATGGTGATGGGAGCCACCTGGGCTGGAG	  
FSQJCO	   TTCTACAACTTGCTTGGATT	  
RSQJCO	   TCCAGACGTTAGTAAATGAA	  
Ant-­‐pET	  5`	   CATGCGCCAGATTAAAATTTGGTTTCAGAACCGCCGCATGAAATGGAAAAAATC	  
Ant-­‐pET	  3`	   CATGGATTTTTTCCATTTCATGCGGCGGTTCTGAAACCAAATTTTAATCTGGCG	  
Pep-­‐pET	  uni	  5`	   TCTTAACCATGGGCGAGCTCGGA	  
Pep-­‐pET	  uni	  3`	   AGAATTCTCGAGACCTGGGCTGGAG	  
T7	   TAATACGACTCACTATAGGG	  
T7-­‐term	   TATGCTAGTTATTGCTCAG	  
primCP5-­‐46-­‐4D5E	  5`	   GGCGAGCTCGATGAGCTTGTTTATCTTTTGG	  
mutA156V	  5`	   CATCTTTCGGGTTGCCGTGTGC	  
mutA156V	  3`	   GCACACGGCAACCCGAAAGATG	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2.1.9 Peptides 
All peptides were synthesised by Dr. Werner Tegge or Dr. Raimo Franke (Department of Chemical 
Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany). 
	  
name	   sequence	  (N-­‐	  to-­‐	  C-­‐terminus)	  
K5-­‐66-­‐A	   GELGRLVYLLDGPGYDPI-­‐amid	  
K5-­‐66-­‐B	   Ac-­‐HCSLAYGDASTLVVF-­‐amid	  
K6-­‐10-­‐A	   GELGRPVYVLGDPGYYAT-­‐amid	  
K6-­‐10-­‐B	   Ac-­‐HCIYATTNDALIFSV	  
K5-­‐66-­‐R	   GELGRIPSDTYDLAVGALHCPFYLVSGLVYLDG-­‐amid	  
CP5-­‐46-­‐A	   GELGRLVYLLDGPGYDPIHCD-­‐amid	  
CP5-­‐46-­‐P1	   Ac-­‐RLVYLLDGPGYDPI-­‐amid	  
CP5-­‐46-­‐P3	   Ac-­‐DGPGYDPIHCD-­‐amid	  
CP5-­‐46-­‐P4	   Ac-­‐DGPGYDPIHCDVVTRGGS-­‐amid	  
CP5-­‐46-­‐R	   GELGRDIGGPLDLYPVDLHCY-­‐amid	  
CP5-­‐46	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF-­‐amid	  
CP5-­‐46-­‐A-­‐4D4E	   GELDELVYLLDGPGYDPIHS-­‐amid	  
CP5-­‐46-­‐A-­‐6D	   GELGRDVYLLDGPGYDPIHS-­‐amid	  
CP5-­‐46-­‐A-­‐6E	   GELGREVYLLDGPGYDPIHS-­‐amid	  
CP5-­‐46-­‐A-­‐6Q	   GELGRQVYLLDGPGYDPIHS-­‐amid	  
CP5-­‐46-­‐A-­‐10Q	   GELGRLVYLQDGPGYDPIHS-­‐amid	  
CP5-­‐46-­‐A-­‐10E	   GELGRLVYLEDGPGYDPIHS-­‐amid	  
Ant-­‐K5-­‐66-­‐A	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPI	  
Tat-­‐K5-­‐66-­‐A	   GRKKRRQRRRPPQGELGRLVYLLDGPGYDPI	  
Nona-­‐arg-­‐K5-­‐66-­‐A	   RRRRRRRRRGELGRLVYLLDGPGYDPI	  
PTD-­‐5-­‐K5-­‐66-­‐A	   RRQRRTSKLMKRGELGRLVYLLDGPGYDPI	  
Ant-­‐CP5-­‐46	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF	  
Ant-­‐CP6-­‐4	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPIHCFPIYSRGSYASYV	  
CPP-­‐Control	  1	   RLIFAGKQLEDGRGELGRVYLLDGPGYDPI	  
CPP-­‐Control	  2	   RQIKIWFQNRRMKWKKYVGIPRDLGLDGYEPLG	  
	  
	  
2.1.10 DNA and protein ladders 
name	   company	  
GeneRulerTM	  1kb	  Plus	  DNA	  Ladder	   MBI	  Fermentas,	  St.	  Leon-­‐Rot	  
GeneRulerTM	  1kb	  DNA	  Ladder	   MBI	  Fermentas,	  St.	  Leon-­‐Rot	  
GeneRulerTM	  100bp	  Plus	  DNA	  Ladder	   MBI	  Fermentas,	  St.	  Leon-­‐Rot	  
PageRulerTM	  Plus	  Prestained	  Protein	  Ladder	   MBI	  Fermentas,	  St.	  Leon-­‐Rot	  
PageRulerTM	  Low	  Range	  Protein	  Ladder	   MBI	  Fermentas,	  St.	  Leon-­‐Rot	  
	  
	  
2.1.11 Computer software 
program	   description	  
ImageJ	  1.37	   Densitometric	  analysis	  
http://rsb.info.nih.gov/ij	  
VectorNTI	  11	   DNA	  analysis,	  primer	  design	  
Invitrogen,	  Carlsbad,	  USA	  
BioEdit	  7.0.9.0	   Sequence	  alignment	  and	  editing	  
Ibis	  Therapeutics,	  USA	  
Photoshop	  CS5	   Densitometric	  analysis	  and	  image	  editing	  
Adobe	  Systems,	  San	  Jose,	  USA	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program	   description	  
PyMol	  1.3	   Structure	  visualisation	  and	  rendering	  
(DeLano,	  2002)	  
Coot	   Building,	  refining	  and	  analysing	  of	  structure	  models	  
(Emsley	  and	  Cowtan,	  2004)	  
Gimp	  2	   Image	  editing	  
http://www.gimp.org/	  
Graph	  Pad	  Prism	   Graphing,	  nonlinear	  regression	  and	  statistics	  
GraphPad	  Software,	  San	  Diego,	  USA	  
 
2.1.12 Equipment 
type	   apparatus	   manufacturer	  
Microplate	  Reader	   Tecan	  Sunrise	   Tecan,	  Crailsheim	  
	   Synergy	  2	  Multi-­‐Mode	   Biotek,	  Vermont,	  USA	  
Spectrophotometer	   Genesys	  10	  uv	  scanner	   Thermo	  ElectronCorporation,	  
Langenselbold	  
	   ND1000	  NanoDrop	   Peqlab,	  Erlangen	  
Centrifuges	   Sorvall	  RC-­‐5B	  	   Thermo	  Scientific,	  Waltham,	  USA	  
	   Mikro	  200	  	   Hettich	  Zentrifugen,	  Tuttlingen	  
	   Biofuge	  primo	  R	   Heraeus,	  Hanau	  
Gel	  documentation	   Gel	  Jet	  Imager	   Intas,	  Göttingen	  
Overhead	  shaker	   Rotator	  SB2	  	   Stuart,	  Stone,	  UK	  
Platform	  shaker	   Duomax	  1030	   Heidolph,	  Schwabach	  
Thermocycler	   Primus	  Evolution	  96	  	   Clemens	  GmbH,	  Waldbüttelbrunn	  
Balances	   Precisa	  120A	   PAG	  Oerlikon	  AG,	  Zurich,	  Switzerland	  	  
	   Kern	  440-­‐43N	  	   Kern	  &	  Sohn	  GmbH,	  Balingen	  
Concentrator	   miVac	  DUO	  concentrator	   Genevac,	  Ipswich,	  England.	  
Laminar	  flow	  hood	   Lamin	  Air	  HBB	  2472S	   Heraeus,	  Hanau	  
Water	  purification	  unit	   Milli-­‐Quf	  Plus	   Millipore,	  Schwalbach	  
Thermal	  shakers	   Thermomixer	  comfort	  5355	   Eppendorf,	  Hamburg	  
Electrophoresis	  apparatus	   Horizon	  58	   Whatman,	  Dassel	  
	   Miniprotean	  3	  cell	   Bio-­‐Rad,	  Munich	  
Pipettes	   Research	  10	  µL	  	   Eppendorf,	  Hamburg	  
	   Research	  100	  µL	   Eppendorf,	  Hamburg	  
	   Research	  1000	  µL	   Eppendorf,	  Hamburg	  
	   Research	  pro	  8x	  5-­‐100	  µL	   Eppendorf,	  Hamburg	  
	   Finnpipette	  8x	  50-­‐300	  µl	   Thermo	  Scientific,	  Waltham,	  USA	  
Electrophoretic	  transfer	  cell	   TransBlot	  semi-­‐dry	   Bio-­‐Rad,	  Munich	  
Power	  supply	   E835	  Power	  Supply	   Consort,	  Turnhout,	  Belgium	  
Incubator	  	   BE-­‐400	   Memmert,	  Schwabach	  
	   Innova	  4400	  /	  4430	  Incubator	   New	  Brunswick	  Scientific,	  Edison,	  USA	  
	   Shaker	  Type	  AG	  15	   Infors	  AG,	  Bottmingen,	  Switzerland	  
pH-­‐meter	   S20	  SevenEasy	   Mettler-­‐Toledo	  GmbH,	  Giessen	  
Magnetic	  stirrer	   RH	  digital	  KT/C	  IKAMAG	   IKAWerke	  GmbH	  &	  Co.	  KG,	  Stauffen	  
Magnetic	  particle	  concentrator	   Dynal	  MBC-­‐5	   Invitrogen,	  Karlsruhe	  
Electroporator	   EasyjecT	  prima	   EquiBio,	  Milford,	  USA	  
Protein	  Purification	  Instrument	   Profinia	   Bio-­‐Rad,	  Munich	  
Automated	  dispenser	   HoneyBee	  961	   Zinsser	  Analytic,	  Frankfurt	  
Homogeniser	   TS	  Series	  Benchtop	  	   Constant	  Systems	  Ltd,	  Daventry,	  UK	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2.1.13 Disposals 
type	   manufacturer	  
Adhesive	  PCR	  film	   Thermo	  Scientific,	  Waltham,	  USA	  
Amicon	  Ultra	  0.5	  ml	  Centrifugal	  Filters	  (3	  kDa)	   Millipore,	  Schwalbach	  
Amicon	  Ultra	  4	  ml	  Centrifugal	  Filters	  (3	  kDa)	   Millipore,	  Schwalbach	  
Amicon	  Ultra	  4	  ml	  Centrifugal	  Filters	  (10	  kDa)	   Millipore,	  Schwalbach	  
Amicon	  Ultra	  15	  ml	  Centrifugal	  Filters	  (10	  kDa)	   Millipore,	  Schwalbach	  
Amicon	  Ultrafree	  MC	  0.5	  ml	  filter	   Millipore,	  Schwalbach	  
Amylose	  Beads	   NEB,	  Ipswich,	  USA	  
Anti-­‐MBP	  Beads	   NEB,	  Ipswich,	  USA	  
Bio-­‐Scale	  Mini	  Profinity	  IMAC	  Cartridge	  (1	  ml	  /	  5	  ml)	   Bio-­‐Rad,	  Munich	  
Bio-­‐Scale	  Mini	  Bio-­‐Gel	  P-­‐6	  Desalting	  Cartridge	  (10	  ml	  /	  50	  ml)	   Bio-­‐Rad,	  Munich	  
Blot	  paper	  Protean	  XL	   Bio-­‐Rad,	  Munich	  
Cellulose	  acetat	  syringe	  filter	  (0.22	  µm	  and	  0.45	  µm)	   GE	  Healthcare,	  Munich	  
Dialysis	  membrane	  VISKING,	  type	  27/32	  14	  kDa	   Carl	  Roth,	  Karlsruhe	  
EasyXtal	  15-­‐Well	  DG-­‐Tool	  X-­‐Seal	  plate	   Quiagen,	  Venlo,	  Netherlands	  
Electroporation	  cuvette	  (2	  mm)	   Eurogentec,	  Belgium	  
High	  Performance	  Crystal	  Clear	  tape	   Manco	  Inc,	  Avon,	  USA	  
His	  Select	  nickel	  affinity	  gel	   Sigma-­‐Aldrich,	  St.	  Louis,	  USA	  
Intelli-­‐Plate	  96-­‐3	  Crystallisation	  Plate	   Art	  Robbinsons	  Instruments,	  USA	  
Maxisorp	  microtiter	  plates	   Nunc,	  Rochester,	  USA	  
Microtiter	  plate,	  96	  well,	  polystyrene,	  flat	  bottom	   Sarstedt,	  Nümbrecht	  
NeXtal	  24-­‐6	  Well	  Crystallisation	  Plate	  (hanging	  drop)	   Quiagen,	  Venlo,	  Netherlands	  
Nitrocellulose	  membrane	   Carl	  Roth,	  Karlsruhe	  
Parafilm	  ‘M’	   Carl	  Roth,	  Karlsruhe	  
PCR	  plate	  96-­‐well	  (semi-­‐skirted)	   Thermo	  Scientific,	  Waltham,	  USA	  
PCR-­‐sealing	  mat	   Thermo	  Scientific,	  Waltham,	  USA	  
PCR	  reaction	  vial	  (Mµlti	  Ultra	  0.2	  ml)	   Carl	  Roth,	  Karlsruhe	  
Petri	  dishes	  (145/20	  and	  120/17)	   Greiner	  bio-­‐one,	  Frickenhausen	  
Pipettor	  tips	  	   Sarstedt,	  Nümbrecht	  
Profinia	  Native	  IMAC	  Buffer	  Kit	   Bio-­‐Rad,	  Munich	  
Reaction	  vials	  (1.5	  ml	  and	  2	  ml)	   Sarstedt,	  Nümbrecht	  
Reaction	  vials	  (15	  ml	  and	  50	  ml)	   Sarstedt,	  Nümbrecht	  
Screw	  Cap	  tubes	   Sarstedt,	  Nümbrecht	  
µclear	  non-­‐binding	  MTP	  96	  well	  (black)	   Greiner	  bio-­‐one,	  Frickenhausen	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2.2 Methods 
2.2.1 Microbiological methods 
2.2.1.1 Cultivation of bacteria 
E. coli cells were cultivated with either liquid 2xYT media with appropriate antibiotics or on 2xYT 
agar plates containing antibiotics. Incubation was done at 37°C, in case of liquid culture under 
shaking with 180 rpm. 
 
2.2.1.2 Storage of bacteria 
For long term storage of bacteria cultures, 0.8 ml of bacterial cells were mixed with 0.2 ml of sterile 
87% glycerol, frozen in liquid nitrogen and stored at -80°C. For short term storage bacteria were 
stored on agar plates sealed with parafilm at 4°C for up to two weeks. 
 
2.2.1.3 Preparation of electrocompetent cells 
Desired cells were separated by plating on M9 media agar plates supplemented with needed 
antibiotics. A single colony was picked for inoculation of an overnight culture with 2xYT medium 
with appropriate antibiotics. 10 ml overnight culture was used for inoculation of 1 L 2xYT medium 
with antibiotics and cells were grown until OD600 0.9. The culture was cooled for 15 min on ice and 
centrifuged for 15 min at 4°C and 4000 g. The supernatant was removed and the cell pellet was 
resuspended in 1 L precooled dH2O and centrifuged for 15 min at 4°C and 4000 g. The cell pellet was 
washed again with 500 ml precooled dH2O. After centrifugation the pellet was resuspended in 20 ml 
precooled 10% glycerol. After a last centrifugation step of 15 min, 4°C, 4000g cell the pellet was 
resuspended in 2 ml precooled 10% glycerol. 50 µl aliquots were frozen in liquid nitrogen and stored 
at -80°C.  
 
2.2.1.4 Transformation of E. coli cells 
The transformation of E. coli cells was done by electroporation. 50 µl electrocompetent cells were 
mixed with 1–5 µl of DNA in dH2O and incubated for 1 min on ice. The suspension was pipetted into 
an ice-cooled 2 mm electroporation cuvette. Electroporation was done with an electric pulse of 2500 
V for about 5 ms. After electroporation 1 ml of to 37°C prewarmed SOC medium was added to the 
cells immediately and transferred into a sterile 15 ml tube. Cells were incubated at 37°C and 160 rpm 
for 60 min. To determine the number of transformants dilutions were made and plated onto agar 
plates with appropriate antibiotics. For library preparation the cell suspension was plated onto large 
selective antibiotic agar plates. 
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2.2.1.5 Protein production in E. coli 
2.2.1.5.1 Protein production with the pMAL expression system 
For expression of MBP fusion proteins the pMAL expression system was used. The pMALc4E 
expression vector containing the protein insert was transformed into E. coli TOP 10F`cells. For a 
starter culture 2xYT medium containing ampicillin, tetracycline and 2 g/L glucose was inoculated 
from a glycerol stock and incubated over night at 37°C and 180 rpm. For later expression in minimal 
medium the M9 medium was used for the starter culture. The culture was used to inoculate 200 ml of 
the appropriate medium to an OD600 < 0.1 and incubated at 37°C and 180 rpm. For a soluble protein 
expression in 2xYT medium 0.4 mM IPTG were added at an OD600 of about 0.5 and the protein was 
expressed for 3 h at 30°C. For a protein production in ‘inclusion bodies’ 1 mM IPTG were added at 
an OD600 of about 1 and the protein was expressed for 5 h at 37°C . The cells were collected by 
centrifugation at 6000 rpm and 4°C for 20 min and the cell pellets were stored at -20°C for up to four 
weeks. 
 
2.2.1.5.2 Protein production with the pET expression system 
For expression of Antp-fusion proteins and high expression of NS3/4A protease the pET expression 
system was used. The pET28c expression vector containing the protein insert was transformed into E. 
coli Rosetta2 (DE3) cells. For a starter culture LB medium containing kanamycin, chloramphenicol 
and 2 g/L glucose was inoculated from a glycerol stock and incubated over night at 37°C and 180 
rpm. For production of Antp-fusion peptides the starter culture was used to inoculate 200 ml of 2xYT 
medium to an OD600 < 0.1 and incubated at 37°C and 180 rpm. For Expression 1 mM IPTG were 
added at an OD600 of about 0.5 and the protein was expressed for 3 h at 37°C. For high expression of 
NS3/4A protease the starter culture was used to inoculate 4x 500 ml of TB medium in Fernbach flasks 
to an OD600 0.1 and incubated at 37°C and 130 rpm for 3.5 h and at 18°C and 130 rpm for 2 h. After 
5.5 h the OD600 was 5 – 8. The expression was induced by addition of 0.4 mM IPTG and the culture 
was incubated at 18°C for 22 h. The cells were collected by centrifugation at 6000 rpm and 4°C for 20 
min and the cell pellets were stored at -20°C for up to four weeks. 
 
2.2.2 Molecular biological methods 
2.2.2.1 Isolation of plasmid DNA 
For the isolation of plasmid DNA commercial kits were used. For small scale preparation (1 - 5 µg 
plasmid DNA) ‘QIAprep Spin Miniprep’ kit from Qiagen was used. For large scale preparations (> 50 
µg plasmid DNA) the ‘NucleoBond PC 500’ kit from Macherey-Nagel was used. Isolation was 
performed according to manufacturer’s instruction. 
 
2.2.2.2 Determination of DNA concentration 
DNA concentration was determent through separation on 1.0 % agarose gel and comparison with a 
DNA ladder. Several dilution steps of the sample were separated and stained with ethidium bromide 
along with a DNA ladder with predefined DNA amounts. The intensity of the sample band was 
compared to the intensity of the ladder band. 
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2.2.2.3 DNA agarose gel electrophoresis 
DNA agarose gel electrophoresis was used for size dependent separation of DNA samples. The DNA 
was supplemented with loading dye (6x) to reach a final 1x concentration of dye. The DNA sample 
was applied to an agarose gel (1.0 % agarose dissolved in 1xTAE) and separated in an electric field 
(120 V, 20 - 40 min.). The gel was stained in ethidium bromide bath (10 mg/L; 15 min.). For removal 
of unbound ethidium bromide the gel was washed for 10 min in water. DNA bands were detected 
with a gel documentation system. 
 
2.2.2.4 Restriction of DNA 
DNA was cleaved with the aid of restriction enzymes. The enzymes recognise specific sequences and 
produce sticky or blunt ends. The following conditions were used for 50 µl samples: 
 
Component Volume Final concentration 
DNA sample X µl 1 - 5 µg 
Reaction buffer (10 x) 5 µl 1x 
BSA (100x), if 
required 
0.5 µl 1x 
Restriction enzyme  Y µl (up to 5 µl) 10 - 20 U 
dH2O 44.5 µl - X µl - Y µl  
 
The sample was incubated (1.5 – 3 h) at the optimum temperature of the used enzyme and inactivated 
at 65 – 85°C for 20 min if possible. The DNA was purified using the ‘NucleoSpin Extract II’ kit.  
 
2.2.2.5 Amplification of DNA 
For amplification of DNA fragments the polymerase chain reaction (PCR) was used. DNA is 
denatured at high temperature and oligonucleotides, the primers, which are flanking the region that 
should be amplified, are binding to the template DNA. A DNA polymerase elongates the primers 
producing the amplified DNA. A qualitative PCR was used for the amplification of DNA regions for 
cloning. The colony –PCR was used for rapid identification of correct clones after cloning. The 
following conditions and temperature programs were used: 
 
1. Qualitative PCR (50 µl) 
Component Volume Final concentration 
DNA template X µl 20 – 100 ng 
Phusion HF Buffer (10x) 5 µl 1x 
Phusion DNA polymerase 0.5 µl 1 U 
dNTP mix (each 10 mM)  1 µl 0.2 mM each 
Primer 1 and 2 (10 µM) 2.5 µl 500 nM 
dH2O 33.5 µl - X µl  
 
Temperature program:   1. 98°C: 30 s 
2. 98°C: 10 s, 3. X °C: 20 s, 4. 72°C: 10 s/kb (2. – 4. 25x) 
5. 72°C: 5 min 
(3. Annealing temperature X is primer dependent) 
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2. Colony-PCR (25 µl) 
Component Volume Final concentration 
Colony in 150µl water  19.5 µl  
Phusion HF Buffer (10x) 2.5 µl 1x 
Phusion DNA polymerase 0.25 µl 1 U 
dNTP mix (each 10 mM)  0.5 µl 0.2 mM each 
Primer 1 and 2 (10 µM) 0.5 µl 200 nM each 
DMSO 1.25 µl 5% 
 
Temperature program:   1. 98°C: 2 min 
2. 98°C: 10 s, 3. X °C: 20 s, 4. 72°C: 10 s/kb (2. – 4. 25x) 
5. 72°C: 5 min 
(3. Annealing temperature X is primer dependent) 
 
2.2.2.6 Cosmix-plexing 
Cosmix-plexing is a technique to increase diversity through DNA recombination and can be used to 
further increase the diversity of a peptide library. Restriction enzyme sites located at defined positions 
allow shuffling of DNA cassettes. Cosmix-plexing was used for recombination of the peptide library 
CPL19YS-2. In the first restriction reaction 5 µg of the library phagemid DNA is cleaved at a type IIs 
restriction enzyme site located inside the library peptide. The restriction sites of the enzymes BceAI, 
BsrDI and BpmI can be used. After the first cleavage the DNA is ligated with the Quick Ligation Kit 
at a concentration of about 2 µg/µl to form concatemers. The ligase is inactivated for 20 min at 65°C 
and the DNA is diluted 1:8 with water and the concatemers are cleaved with the restriction enzyme 
BglI at a site located outside of the library sequence. After the second restriction the phagemid DNA 
is ligated at a concentration < 20 ng/µl to favor intramolecular ligation. The ligated DNA can be used 
for transformation. 
 
2.2.2.7 Site directed mutagenesis 
For the integration of point mutations into plasmids site directed mutagenesis was used. Two 
complementary oligonucleotides that contain the point mutation in the middle of the DNA sequence 
were used for the linear amplification of the plasmid and thereby integrating the mutation in the 
amplified linear vector. The following conditions were used for 50 µl samples: 
 
Component Volume Final 
concentration 
DNA vector template X µl ~25 ng 
Phusion HF Buffer (10x) 5 µl 1x 
Phusion DNA polymerase 0.5 µl 1 U 
dNTP mix (each 10 mM)  1 µl 0.2 mM each 
Primer 1 and 2 (10 µM) 2.5 µl 500 nM each 
dH2O 41 µl - X µl  
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Temperature program:   1. 98°C: 30 s 
2. 98°C: 10 s, 3. 60°C: 30 s, 4. 72°C: 3 min and 40 s (2. – 4. 18x) 
5. 72°C: 5 min 
 
The methylated template vector was digested by DpnI, a restriction enzyme that recognises a 
methylated recognition sequence. 20 U DpnI were directly added to the amplified DNA and incubated 
for 2 h at 37°C. The restriction enzyme was inactivated at 80°C for 20 min and the DNA was purified 
using the ‘NucleoSpin Extract II’ kit.  
 
2.2.2.8 Creating blunt ends 
For the removal of 3´ overhanging DNA the T4 DNA polymerase was used to form blunt ends. The 3´ 
overhang is removed by the 3´→ 5´ exonuclease activity of the polymerase. The following conditions 
were used for 50 µl samples: 
 
Component Volume Final concentration 
DNA sample X µl 1 - 2 µg 
NEBuffer 1 (10 x) 5 µl 1x 
T4 DNA Polymerase 0.5 µl 10 U 
dH2O 44.5 µl - X µl  
 
The sample was incubated for 15 min at 12°C and the polymerase was inactivated at 75°C for 20 min. 
The DNA was purified using the ‘NucleoSpin Extract II’ kit. 
 
2.2.2.9 Dephosporylation of DNA 
To avoid religation of DNA fragments the 5´ phosphate groups from DNA was removed with the help 
of the Antarctic phosphatase (AP). The DNA was incubated with 5 U of AP for 1 hr at 37°C in 1x AP 
reaction buffer. The phosphatase was inactivated at 65°C for 20 min and the sample was purified 
using the ‘NucleoSpin Extract II’ kit. 
 
2.2.2.10 Phosporylation of DNA 
For the ligation of DNA fragments 5´ phosphate groups are necessary. The transfer of a phosphate 
from ATP to the 5' end of DNA is catalysed by the polynucleotide kinase (PNK). For the 
phosphorylation up to 10 µM DNA in a 50 µl reaction containing 1x T4 DNA ligase buffer and 10 
units of T4 polynucleotide kinase were mixed and the sample was incubated at 37°C for 60 min. The 
enzyme was inactivated at 65°C for 20 min. 
 
2.2.2.11 Hybridisation of oligonucleotides 
For the hybridisation of complementary DNA the single stranded oligonucleotides were mixed at a 
concentration of 2 µM. The sample was heated for 10 min to 98°C and cooled down to room 
temperature. 
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2.2.2.12 DNA ligation 
The ligation of linear DNA fragments was done with the T4 DNA ligase or with the help of the Quick 
Ligation Kit. The T4 ligase was used for liagtion of an insert into a vector. A vector DNA and insert 
DNA molar ratio of 1:3 was usually used. The Quick Ligation Kit was used for the ligation reactions 
during cosmix-plexing. The ligation time and temperature varied between 2 h at 16°C for the T4 DNA 
ligase and 16 h at 4°C for the Quick Ligation Kit. The following conditions were used for 20 µl 
samples: 
 
1. T4 DNA Ligase 
Component Volume Final 
concentration 
Vector X µl 50 -100 ng 
Insert Y µl  
T4 ligase buffer (10x) 2 µl 1x 
T4 DNA ligase 1 µl 400 U 
dH2O 17 µl - X µl – Y µl  
 
2. Quick ligase 
Component Volume Final 
concentration 
DNA sample X µl < 400 ng 
Quick Ligase Buffer 
(2x) 
10 µl 1x 
Quick Ligase 1 µl  
dH2O 9 µl - X µl  
 
 
2.2.3 Phage-Display methods 
2.2.3.1 Packaging of peptide phage display library 
The peptide phage display library CPL19YS-2 was existent in E. coli Top 10 F` λ+ cells. For 
packaging into phagemid particles an infection with M13K07 helper phage was necessary. 200 ml 
2xYT medium containing tetracycline and ampicillin were inoculated from a glycerol stock to an 
OD600 of about 0.1. The culture was grown at 37°C and 180 rpm to an OD600 of 0.5 and the cells were 
infected with 2.5 x 1011 cfu of M13K07. The culture was incubated at 37°C for 30 min without 
agitation and was then grown over night at 37°C and 180 rpm. The culture was cooled on ice and 
centrifuged for 20 min at 8000 rpm and 4°C. The supernatant was decanted mixed with 0.2 volume of 
PEG/NaCl and incubated on ice for at least 2 h. The phage were precipitated by centrifugation for 60 
min at 8000 rpm and 4°C. The supernatant was carefully decanted and remaining liquid removed. The 
pellet was resuspended in 1 ml of appropriate buffer and cleared by 10 min centrifugation at 13000 
rpm at room temperature. NaN3 was added to the phage solution to a final concentration of 0.02%. 
The phage titer was determined (see section 2.2.3.2). 
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2.2.3.2 Determination of phage titer  
The phage titer was determined by infection of E. coli cells and subsequent cultivation on selective 
agar plates. For titer measurement 20 ml 2xYT medium containing tetracycline were inoculated from 
a E. coli Top 10 F` λ+ overnight culture to an OD600 < 0.1 and incubated at 37°C and 180 rpm to an 
OD600 of about 0.5. The phage solution was used for a dilution series in PBS (106 – 1012). 10 µl of 
each dilution were mixed with 50 µl E. coli culture and incubated at 37°C for 1 h. The infected 
culture was plated or spotted on an agar plate with appropriate antibiotic and incubated at 37°C over 
night. To calculate the phage titer the grown colonies (cfu) were counted and multiplied with the 
respective dilution factors. 
 
2.2.3.3 Affinity selection of peptide phage particles against MBP-fusion proteins 
2.2.3.3.1 Panning with magnetic beads 
For an affinity selection using magnetic beads 300 – 500 µg of amylose-magnetic beads or anti-MBP 
magnetic beads that can bind 1.5 – 2-5 µg of MBP-fusion protein were washed twice with the 
appropriate buffer. To block unspecific binding sites the beads were incubated for 1 h with 500 µl 2% 
milk powder in panning buffer with 0.05% Tween 20. The wells were washed twice with 250 µl of 
appropriate buffer and an excess of fusion protein was immobilised for 30 min at 4°C in an overhead 
shaker Prior to selection 200 µl peptide phagemid particles in panning buffer with 2% milk powder 
and 0.05% Tween 20 were incubated with immobilised MBP to reduce unspecific binding and 
specific binding to either the MBP or the magnetic beads. The beads with the immobilised fusion 
protein were washed three times with panning buffer and pre-incubated peptide phage particles were 
added to the beads. The affinity selection was done for 2.5 h at room temperature in an overhead 
shaker. The supernatant containing the unbound phage was removed and the beads were washed 10 
times with 500 µl panning buffer containing 0.05% Tween 20. Bound phage were eluted with acidic 
elution or competitive elution. For acidic elution 200 µl of elution buffer were added to the beads and 
incubated for 10 min in the overhead shaker. The elution buffer containing eluted phage particles was 
removed and immediately mixed with 45 µl neutralisation buffer. For competitive elution 200 µl 
competitor were added to the beads and incubated for 15 min in the overhead shaker. The eluted 
phage solution was used for titer determination and reinfection of E. coli cells (see section 2.2.3.4). 
2.2.3.3.2 Panning in MTPs 
For an affinity selection in microtiter plates (Nunc, Maxisorp) 200 ng of anti-MBP IgG in PBS was 
immobilised for 1 h at room temperature. The wells were washed twice with 250 µl PBS with 0.05% 
Tween 20 (PBST) and unspecific binding sites were blocked by incubation with 350 µl 2% milk 
powder in panning buffer with 0.05% Tween 20 for 1 h at room temperature. The wells were washed 
twice with 250 µl PBST and an excess of fusion protein (1 µg) was immobilised for 1.5 h at 4°C. 
Prior to selection 200 µl peptide phagemid particles in panning buffer with 2% milk powder and 
0.05% Tween 20 were incubated with immobilised MBP to reduce unspecific binding and specific 
binding to either the MBP or the anti-MBP IgG. The wells with the immobilised fusion protein were 
washed three times with panning buffer and pre-incubated peptide phage particles were added. The 
affinity selection was done for 2.5 h at room temperature on a shaker. The supernatant containing the 
unbound phage was removed and the wells were washed 10 – 20 times with 250 µl panning buffer 
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containing 0.05 % Tween 20. Bound phage were eluted with acidic elution or competitive elution. For 
acidic elution 200 µl of elution buffer were added into the wells and incubated for 10 min on a shaker. 
The elution buffer containing eluted phage particles was removed and immediately mixed with 45 µl 
neutralisation buffer. For competitive elution 200 µl competitor were added and incubated for 15 min 
on a shaker. The eluted phage solution was used for titer determination and reinfection of E. coli cells 
(see section 2.2.3.4). 
 
2.2.3.4 Reinfection of E. coli cells with eluted phage 
To determine the titer of eluted phage 10 µl of eluted phage solution were used (see section 2.2.3.2). 
The remaining amount was used for infection of 20 ml of a freshly grown E. coli Top 10 F` λ+ culture 
with an OD600 of 0.5. The culture was incubated at 37°C for 30 min without and for 30 min with 
agitation at 180 rpm. After incubation the cells were pelleted by centrifugation for 10 min at 4000 
rpm and resuspended in 300 µl 2xYT medium containing ampicillin and tetracycline. The cell 
suspension was plated onto a 140/20 mm 2xYT agar plate containing ampicillin and tetracycline and 
incubated overnight at 37°C. The grown cells were washed from the plate with 5ml 2xYT medium 
containing antibiotics and used for packaging into phagemid particles (see section 2.2.3.1). From the 
rest of the cell suspension glycerol stocks were prepared. 
 
2.2.3.5 Characterisation of single clones after reinfection 
Single colonies of clones from the titer determination were picked and resuspended in 150 µl dH2O. 
The suspension was used for colony-PCR. The PCR sample was afterwards 1:20 diluted with dH2O 
and used for sequence analysis with the sequencing primers FSQJCO or RSQJCO. 
 
2.2.3.6 Packaging of single clones 
For packaging of single clones into phagemid particles an infection with M13K07 helper phage was 
necessary. 50 ml 2xYT medium containing tetracycline and ampicillin were inoculated from an 
overnight culture of the single clone to an OD600 of about 0.1. The culture was grown at 37°C and 180 
rpm to an OD600 of 0.5 and the cells were infected with 0.5 x 1010 pfu of M13K07. The culture was 
incubated at 37°C for 30 min without agitation and was then grown over night at 37°C and 180 rpm. 
The culture was cooled on ice and centrifuged for 20 min at 4000 rpm and 4°C. The supernatant was 
decanted mixed with 0.2 volume of PEG/NaCl and incubated on ice for at least 2 h. The phage were 
precipitated by centrifugation for 60 min at 4000 rpm and 4°C. The supernatant was carefully 
decanted and remaining liquid removed. The pellet was resuspended in 0.5 ml of appropriate buffer 
and cleared by 10 min centrifugation at 13000 rpm at room temperature. NaN3 was added to the phage 
solution to a final concentration of 0.02%. The phage titer was determined (see section 2.2.3.2). 
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2.2.4 Proteinbiochemical methods 
2.2.4.1 Phage ELISA with MBP-fusion protein 
For binding of the MBP-fusion protein 200 ng/well of anti-MBP IgG were immobilised in a microtiter 
plate (Nunc, Maxisorp) for 1 h at room temperature. The wells were washed 3 times with PBST and 
unspecific binding sites were blocked by incubation with 350 µl 2% milk powder in PBST for 1 h at 
room temperature. The wells were washed twice with 250 µl of appropriate buffer and an excess of 
fusion protein (1 µg) was immobilised for 1.5 h. The wells were washed three times with 250 µl of 
appropriate buffer and 200 µl peptide phagemid particles in buffer with 2% milk powder and 0.05 % 
Tween 20 were added and incubated for 1.5 h at room temperature. For a competitive phage ELISA 
the competitor was added during binding of phage particles. Unbound phage were removed by 
washing 3 – 10 times with 250 µl buffer with 0.05 % Tween 20. Bound phage were detected with 100 
µl anti-M13 IgG (1:5000 in appropriate buffer with 2% milk powder and 0.05 % Tween 20) for 1.5 h 
at room temperature. For detection 200 µl ABTS substrate solution was added and the absorption at 
410 nm was measured every minute for half an hour in an MTP-reader (Tecan Sunrise).  
 
2.2.4.2 Cell disruption 
2.2.4.2.1 BugBuster 
E. coli pellets were thawed on ice and resuspended in 50 µl / OD600 unit BugBuster solution 
(Novagen). The cells were lysed for 20 min at 20°C under agitation. The insoluble protein fraction 
was pelleted at 15,000 rpm and 4°C for 20 min. The supernatant containing the soluble cytosolic 
proteins was stored and the pellet was resuspended in 50 µl / OD600 unit PBS. The soluble and 
insoluble protein fractions were used for analysis of the protein production. 
2.2.4.2.2 Lysozym lysis buffer 
The E. coli cell pellet from the protein production was thawed on ice and resuspended in ‘lysozym 
lysis buffer’. For resuspension the tenth part of the volume of the production culture was used. The 
cells were lysed for 30 min at 4°C under agitation in an overhead shaker. Insoluble material was 
removed by centrifugation at 14,000 rpm and 4°C for 20 min. The supernatant containing the soluble 
cytosolic proteins was used for protein purification. 
2.2.4.2.3 Homogeniser 
The E. coli cell pellet from the protein production was thawed on ice and resuspended in 
‘homogeniser lysis buffer’. For resuspension the tenth part of the volume of the production culture 
was used. The homogeniser was cooled to 4°C and equilibrated with 40 ml lysis buffer at 10 kpsi. The 
cells were lysed twice at 20 kpsi and insoluble material was removed twice by centrifugation at 
16,000 rpm and 4°C for 20 min. The supernatant containing the soluble cytosolic proteins was used 
for protein purification. 
2.2.4.2.4 ‘Inclusion bodies’ solubilisation 
The E. coli cell pellet from the protein production was thawed on ice and resuspended in ‘inclusion 
bodies lysis buffer’. For resuspension the tenth part of the volume of the production culture was used. 
The cells were lysed for 60 min at room temperature under agitation in an overhead shaker. Insoluble 
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material was removed by centrifugation at 14,000 rpm and 4°C for 20 min. The supernatant 
containing the solubilised ‘inclusion bodies’ was used for protein purification. 
 
2.2.4.3 IMAC protein purification 
For IMAC purification His Select nickel affinity gel was washed with 10 volumes buffer (MBP-
NS3/4A or MBP-peptides: buffer A; MBP-NS2-3: inclusion bodies lysis buffer) and centrifuged for 5 
min at 5000 g and 4°C. 10 ml cell extract was added to 200 µl HIS Select gel and incubated for 30 
min at 4°C in an overhead shaker. The gel was separated by centrifugation for 5 min at 5000 g and 
4°C. The HIS Select gel was washed 3 times with 10 volumes wash buffer (buffer + 10 mM 
imidazole) and bound protein was eluted with two volumes of elution buffer (buffer + 300 mM 
imidazole) for 15 min at 4°C in an overhead shaker. The gel was removed by centrifugation and the 
elution fraction was used for dialysis or buffer exchange with centrifugal filter units and stored at -
80°C afterwards. 
 
2.2.4.4 Protein purification using the Profinia system 
For IMAC purification with the Profinia protein purification instrument (BioRad) the ‘Native IMAC 
purification and desalting’ program for 1 ml IMAC cartridge and 10 ml desalting cartridge or 5 ml 
IMAC cartridge and 50 ml desalting cartridge was used, respectively. The cell extract was loaded 
onto the equilibrated IMAC cartridge which was than washed with the ‘Profinia native IMAC wash 
buffer’ 1 and 2. The bound protein was eluted with the elution buffer. The buffer was exchanged with 
the help of the desalting cartridge. After a first purification with the 5 ml IMAC cartridge and 50 ml 
desalting cartridge the protein was eluted in the ‘Profinia desalting buffer 1’. Imidazole was added to 
the elution fraction to a concentration of 5 mM and used for second purification with the 1 ml IMAC 
cartridge and 10 ml desalting cartridge. The protein was eluted in the ‘Profinia desalting buffer 2’ and 
stored at -80°C. 
 
2.2.4.5 Precipitation of protein samples 
Ethanol precipitation was used to concentrate protein solutions or for removal of buffer components. 
The sample was cooled on ice and cold ethanol was added to a final concentration of 90%. The 
sample was mixed thoroughly and incubated for at least 30 min at -20°C. The protein was collected 
by centrifugation at 15,000 rpm and 4°C for 20 min. The pellet was air dried and resuspended in an 
appropriate amount of buffer.  
 
2.2.4.6 SDS Page 
For separation of protein samples with a size range of 20 – 100 kDa the discontinued Glycine-SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was used. It consists of a stacking and separation 
gel. The separation gel was casted between two glass slides (Bio-Rad Mini-Protean) and polymerised 
with a layer of water on top. The water was removed; the stacking gel casted on top and a comp was 
inserted. After polymerisation the gel was put into the gel chamber which was filled with SDS 
running buffer. The comb was removed and the samples and a protein ladder were loaded onto the 
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gel. Samples were mixed with an appropriate amount of 6x Laemmli-buffer and incubated at 95°C for 
5 – 10 min. The samples were separated at 20 mA for about 45 min. The following formulations were 
used for stacking and separation gels: 
 
Component 
Volume 
                Separating gel 
  10%             12%            15% 
Stacking gel 
  4.5% 
40% acrylamide mix 2.5 ml 3 ml 3.75 ml 0.55 ml 
1 M TrisHCl pH 6.8 - - - 0.625 ml 
1 M TrisHCl pH 8.8 2.5 ml 2.5 ml 2.5 ml - 
10% SDS 100 µl 100 µl 100 µl 50 µl 
APS 80 µl 80 µl 80 µl 40 µl 
TEMED 8 µl 8 µl 8 µl 4 µl 
dH2O 4.8 4.3 ml 3.55 ml 3.75 
 
2.2.4.7 Tricine Page 
For separation of protein samples with a size range of 5 – 100 kDa the discontinued Tricine-SDS-
polyacrylamide gel electrophoresis (Tricine-PAGE) was used. It consists of a stacking and separation 
gel. The separation gel was casted between two glass slides (Bio-Rad Mini-Protean) and a stacking 
gel was casted on top and a comp was inserted. After polymerisation the gel was put into the gel 
chamber which was filled with Tricine-PAGE anode and cathode buffer. The comb was removed and 
the samples and a protein ladder were loaded onto the gel. Samples were mixed with an appropriate 
amount of 4x Tricine-PAGE sample buffer and incubated at 95°C for 5 min. Electrophoresis was 
started with an initial voltage of 30 V and maintained at this voltage until the sample has completely 
entered the stacking gel. Samples were separated at 80 V for about 90 min. The following 
formulations were used for stacking and separation gels: 
 
Component Volume Separating gel 10% Stacking gel 4% 
40% acrylamide mix (19:1) 2.5 ml 0.6 ml 
Gel buffer (3x) 3.333 ml 1.5 
Glycerol (87%) 1.16 ml - 
APS 50 µl 45 µl 
TEMED 5 µl 4.5 µl 
dH2O 2.95 ml 3.85 ml 
 
2.2.4.8 Staining methods 
2.2.4.8.1 Coomassie staining 
Polyacrylamide gels were stained for at least 1 h in coomassie staining solution on a shaker. The gels 
were washed with water and transferred into discoloration solution until destaining was complete. The 
gels were stored in water. 
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2.2.4.8.2 Silver staining 
For silver staining of proteins in polyacrylamide gels the ‘Roti-Black P’ silver staining kit was used. 
The staining was done according to manufacturer’s instruction. 
 
2.2.4.9 Concentration determination of protein solutions 
2.2.4.9.1 Bradford assay 
One method for protein concentration measurement is the Bradford assay. This assay is based on 
complexing of proteins with Brilliant Blue G. Various BSA concentrations were used to create a 
standard curve. Standard and samples were diluted in a 96 well plate. The protein samples were 
mixed with Bradford reagent (Sigma-Aldrich) according to manufacturer’s instruction, incubated at 
room temperature for 30 min and the absorption was measured at 595 nm.  
2.2.4.9.2 Densitometric measurement 
For protein concentration determination the intensity of protein bands was measured. The protein 
samples and various concentrations of a standard protein (MBP4 or BSA) in the same buffer were 
separated on an acrylamid gel and coomassie stained. The stained gel was scanned and the intensity of 
the protein bands was determined using the software Image J. The standard protein was used to create 
a standard curve which was used for calculation of the unknown protein concentration. 
2.2.4.9.3 UV spectroscopy 
The protein concentration was measured at 280 nm with the NanoDrop spectrophotometer. The 
photometer was calibrated to zero absorbance with buffer solution and the absorbance of the protein 
solution was measured. To calculate the molar concentration the absorbance coefficient was used. 
 
2.2.4.10 Dialysis of protein solutions 
For dialysis of protein solutions a dialysis membrane with a 14 kDa molecular weight cut off was 
used. The membrane was cleaned according to manufacturer’s instruction prior to use. The protein 
solution was filled into the membrane which was sealed with dialysis membrane clamps. The dialysis 
was done for 4 h at 4°C under agitation in dialysis buffer. The volume of the lysis buffer was at least 
100-fold the volume of the protein solution. After dialysis the protein solution was stored at -80°C.  
 
2.2.4.11 Western blot 
2.2.4.11.1 Transfer to membrane 
By SDS-PAGE separated proteins were transferred to a nitrocellulose membrane using a semi-dry 
blotter (BioRad). The acrylamide gel was equilibrated in blotting buffer for 20 min. The membrane 
and blot paper ‘Protean XL’ in the size of the gel was wetted in blotting buffer. A filter was put on the 
anode of the semi-dry blotter and the membrane was put on top. The equilibrated gel and another 
filter paper were added on the membrane and air bubbles were rolled out with a spatula. The blotter 
was closed and the proteins were transferred at 15 V for 30 min.  
Materials and Methods 
 
44 
2.2.4.11.2 Immunostaining 
The proteins transferred to a nitrocellulose membrane were detected using antibodies specific to the 
target protein. The membrane was blocked with 2% milk powder in PBS for 1 h at room temperature 
to saturate all free binding sites. The membrane was washed shortly and for 5 min with PBST. A 
protein specific antibody conjugated with HRP was diluted in PBS with 2% milk powder and added 
for 1.5 h to the membrane. Unbound antibody was removed by washing shortly and for 5 min with 
PBST. The immune staining was started by adding the DAB substrate solution and stopped by 
washing of the membrane with water.  
 
2.2.4.12 NS2-3 protease activity assay 
The NS2-3 protease was diluted in ‘cleavage buffer’ for activation. Refolded protease was diluted 1:5 
in cleavage buffer and denatured protease was diluted 1:50 in cleavage buffer. The diluted protease 
was incubated for 5 min on ice and then incubated at 23°C. The protein was precipitated using 
ethanol, dissolved in laemmli buffer and loaded onto a Glycine- or Tricine-SDS PAGE gel. After 
electrophoresis and staining of the gel the amount of cleaved protease was determined by 
densitometric measurement of the protein bands.  
 
2.2.4.13 NS3/4A protease activity assay 
The activity of the NS3/4A protease was tested with a fluorescence resonance energy transfer (FRET) 
assay (Taliani et al., 1996). The substrate M-2235 (Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-y-
[COO]Ala-Ser-Lys(DABCYL)-NH2, Bachem) is derived from the HCV 4A/4B cleavage site. An 
ester bond is incorporated between residues P1 and P1´. The donor chromophore DABCYL and the 
acceptor chromophore EDANS are incorporated into the substrate. The absorbance maximum and 
emission maximum are ~355 nm and ~500 nm, respectively. In the uncut substrate the donor and 
acceptor are in proximity and the emission wavelength of the donor overlaps with the absorbance 
wavelength of the acceptor. For a NS3/4A activity assay in MTPs (µclear non-binding, Greiner bio-
one) normally 0.5 – 1 nM protease were diluted in buffer M2235 (Misialek et al., 2009) and 5 µM 
substrate were added. Substances that have been tested for an inhibitory effect on the NS3/4A 
protease were incubated with the protease 10 – 15 min at room temperature before adding of the 
substrate. The final volume was 200 µl. Fluorescence increase was measured every minute for 30 – 60 
min at 30°C in a MTP reader (Excitation filter: 360/40 nm, emission filter: 460/40 nm, Biotek 
Synergy 2). Velocity of fluorescence increase over one hour was compared to that of a control peptide 
and percent inhibition at each inhibitor concentration was calculated. 
Curve fitting was done with GraphPad Prism using a nonlinear regression model with variable slope 
and normalised response: Y=100/(1+10^((LogIC50-X)*slope)) or using a nonlinear regression model 
with variable slope : Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-X)*slope)). Obtained IC50 values in 
these experiments were converted to apparent Ki values using the equation Ki = IC50/(1 + [S]/Km) for 
competitive inhibitors (Cheng and Prusoff, 1973). 
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2.2.4.14 Encapsulation of peptides into polymersomes 
The encapsulation of peptides into polymersomes was done at the laboratory of Dr Giuseppe Battaglia 
(Department of Biomedical Science, University Sheffield, UK). 10 mg of PMPC25-PDPA70 
copolymer were dissolved in a glass vial in 1 ml PBS pH 2. The pH was gradually increased to pH 6 
and 1 mg peptide was added to the solution and dissolved. The suspension was sonicated for 20 min 
(Sonicor Instruments Corporation) and sterilised using a 0.22 µm filter. The pH of the solution was 
raised to 7.3 and again sonicated for 15 – 30 min. The polymersomes solution was then purified by 
gel permeation chromatography using a sepharose 4B size exclusion column to extract the fraction 
containing polymersomes. In all cases the polymersomes size distribution was determined by dynamic 
light scattering (DLS) and the concentration of the polymer and peptide was measured by HPLC. 
Polymersomes were stored at 4°C until use. 
 
2.2.5 Crystallisation methods 
2.2.5.1 Preparation of protease-peptide complex 
To 40 – 90 µM purified NS3/4A protease at least two fold molar excess of peptide was added in 
‘Profinia Desalting buffer 2’ and incubated on ice for at least 2 h. The solution was centrifuged at 
15,000 rpm and 4°C for 20 min and concentrated to about 220 µM (~5 mg/ml) using an Amicon Ultra 
4 ml centrifugal filter (10 kDa). The peptide (dissolved in 100 % (v/v) DMSO) was added to a final 
concentration of 500 µM resulting in a final DMSO concentration of 5% (v/v). The solution was 
centrifuged at 15,000 rpm and 4°C for 20 min and used for crystal screens. Unused complex was 
stored at -80°C. 
 
2.2.5.2 Initial crystallisation screen 
Initial screening was performed at 19°C with commercial screening suites from QIAGEN (Anions, 
Cations, pHClear II, AmSO4 and JCSG+) using sitting drop, vapor-diffusion technique.  
The reservoir solution and the drops of crystallisation experiments were set up on a Cartesian 
Honeybee crystallisation robot (Zinsser Analytic) in 96-3 well Intelli plates (Hampton Research). The 
reservoir was filled with 65 µl and equal amounts (200 nl) of two different NS3/4A protease 
complexes (~5 mg/ml) and precipitant were dispensed in two of the three sitting wells. In the 
remaining well a control with buffer lacking protein was used to identify likely salt crystals. The 
plates were sealed with tape and incubated at 19°C. Initial crystal formation was observed after 
several days. A total of 480 crystallisation conditions were tested. 
 
2.2.5.3 Optimisation of crystallisation conditions 
Conditions which yielded initial crystals had to be optimised to obtain a suitable size for x-ray 
diffraction measurements. For optimisation of NS3/4A protease and inhibitory peptide co-complex 
crystals hanging drop, vapor-diffusion technique in 24-6 well or 15-6 well plates (EasyXtal from 
QIAGEN) at 19°C was used. The primary method of optimisation was to screen around the initial hit, 
varying the precipitant concentration, the pH or the salt concentration. Grid screens were designed 
with the web-based application ‘MakeTray’ (Hampton Research, Aliso Viejo, USA). The reservoir 
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volume was 500 µl and 1 µl of protein complex with 1 µl reservoir solution were mixed. For each 
condition 100 – 230 µM (2 – 5 mg/ml) of protein complex was used for crystallisation. In the last 
optimisation step dilutions of 100 µM (2 mg/ml) and 120 µM (2.5 mg/ml) NS3/4A protease with 0.1 
M buffer of the crystallisation condition (e.g. 0.1 M MES pH 6.0 or 0.1 M Na-citrate pH 5.1) were 
used. The plates were incubated for up to four weeks and crystal formation was checked as in the 
screening process. 
 
2.2.5.4 X-ray diffraction measurement 
X-ray diffraction measurements and model building was done by Dr. Stefan Schmelz (Department 
Molecular Structural Biology, HZI). Crystals in buffer with 30% glycerol were flash-frozen in liquid 
nitrogen and mounted in a 100K cryostream. X-ray diffraction data were collected at the European 
Synchrotron Radiation Facility (ESRF, Grenoble, ID-29) and at Berliner Elektronenspeicherring-
Gesellschaft für Synchrotronstrahlung (BESSY, MX-15.1). Diffraction intensities of the complexes 
were indexed, integrated and scaled in HKL2000 (Otwinowski and Minor, 1997) or XDS and 
XSCALE (Kabsch, 2010).  
The structure was solved by molecular replacement with Phaser (McCoy et al., 2007), using NS3/4A 
coordinates (Protein Databank code 1DXP) as search a model. The resulting model was refined with 
Phenix.refine (Adams et al., 2004) or Refmac5 (Murshudov et al., 1997) and manually checked with 
COOT (Emsley and Cowtan, 2004). The inhibitory peptides were manually built with COOT (Emsley 
and Cowtan, 2004). Figures and structure alignments were prepared using PyMOL (DeLano, 2002). 
 
2.2.6 Intracellular delivery of inhibitory peptides 
2.2.6.1 Cell culture replicon assay 
The cell culture replicon assay was done by Juliane Gentzsch (Department of Experimental Virology, 
Twincore, Hannover). The replicon assay was used for analysis of intracellular inhibition of viral 
replication. For the assay 4 x 106 cells (Lunet N#3 hCD81_G-Luc_BLR) were transfected by 
electroporation (270 V, 975 µF, 4 mm cuvette) with 5 µg in vitro-transcribed replicon RNA. The cells 
were seeded on a 96 well plate (20000 cells/well in 200 µl medium) and incubated at 37°C for 4 – 5 h. 
After incubation the inhibitory peptides were added in different concentrations (or dilutions for 
polymersomes). Before addition the cells of a few wells were lysed for normalisation to transfection 
efficiency and stored at -20°C. Addition of water or buffer was used as a negative control and 1 ng/ml 
IFN was used as positive control. The medium of the cells was changed to the medium containing the 
inhibitors in different concentrations (duplicates) or the controls. The cells were incubated for 48 h 
with the inhibitors and then used for a luciferase assay. The cells were washed once with PBS and 
lysed. After substrate addition the firefly luciferase activity was detected with a plate luminometer. 
Luciferase levels are tightly correlated to the replication of the replicon. For analysis of cell viability 
the gaussia luciferase activity was measured. 
Curve fitting was done with GraphPad Prism using a nonlinear regression model with variable slope 
and normalised response: Y=100/(1+10^((LogEC50-X)*slope)) or using a nonlinear regression model 
with variable slope: Y=Bottom+(Top-Bottom)/ (1+10^((LogEC50-X)*slope)).  
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3. Results 
3.1 NS2-3 protease 
3.1.1 Production, refolding and activity of recombinant NS2-3 protease 
The HCV NS2-3 protease was produced with the pMAL expression system (New England BioLabs). 
The DNA encoding the NS2-3 protease was inserted into the pMAL-c4E vector down-stream from 
the malE gene, which encodes the maltose-binding protein (MBP). This results in the expression of a 
MBP-NS2-3 fusion protein with a 23 aa linker between MBP and protease (see Figure 3-1). A 
truncated form of the NS2-3 protease that is still capable of autoprocessing was produced according to 
Pallaoro and co-workers. It consists of the residues 907 – 1206 of the HCV polyprotein, 
encompassing the cytoplasmic catalytic domain of NS2 and the NS3 serine protease domain with the 
Zn2+ binding site (Thibeault et al., 2001; Pallaoro et al., 2001). For PCR amplification the HCV 
replicon ‘I389/NS2-3'UTR’ which was constructed from the consensus sequence of genotype 1b 
isolate cDNA served as a template (Lohmann et al., 1999). The primer primNS2-3 and primNS2-3-
rev, which introduced a KpnI and PstI restriction site and a C-terminal His-Tag with a short linker, 
were used. It was intended to use the MBP protein for immobilisation of the protease during affinity 
enrichment and the His-Tag for IMAC purification after production in E. coli. The NS2-3 insert was 
ligated into the dephosphorylated pMAL-c4E vector which was also cut with the restriction enzymes 
KpnI and PstI and transformed into E. coli Top10 F´cells. 
Figure 3-1: Schematic picture of the expression vector pMAL-c4E with NS2-3 insert. The protease insert was ligated 
into the KpnI and PstI cut vector. malE: maltose-binding protein gene, lacZ alpha: ß-galactosidase alpha fragment gene, 
bla: ß-lactamase gene, M13 ori: M13 phage origin of replication, pMB1 ori: E. coli origin of replication from plasmid 
pMB1, lacIq: lac repressor gene. 
Soluble expression of NS2-3 protease results in autocleavage during production. Since the enzyme 
requires zinc for activity the MBP-NS2-3 protease fusion protein was expressed in M9 minimal 
medium without zinc, under which condition most of the material was found as insoluble ‘inclusion 
bodies’. It has previously been reported that the NS3 protease domain requires Zn2+ for correct 
pMAL-cE4 NS2-3 (907-1206)
7552 bp
NS2-3
malE
lacIq
lacZ alpha
bla linker (23 aa)
His Tag
pMB1 ori
M13 ori
rrnB T1T2 transcription terminator
KpnI (2696)
PstI (3631)
NdeI (1527)
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folding and without zinc the misfolded protease accumulates in inclusion bodies (Pallaoro et al., 
2001). The inclusion bodies were solubilised in 6 M guanidine HCl and purified by IMAC. Figure 3-2 
shows the results of the production and purification of the MBP-NS2-3 protein. The protease could be 
produced and purified in suitable amounts and purity. 
	  
	  
Figure 3-2: Production and purification of MBP-NS2-3. 12% SDS-gel, M: molecular weight marker, SB: soluble fraction 
before induction, SI: soluble fraction 5 h after induction, IB: insoluble fraction before induction, II: insoluble fraction 5 h 
after induction, BB: before binding, AB: after binding; W1 and W2: washing fractions, E: elution fraction. 3 µl of each 
fraction were loaded onto the gel. 
The purified MBP-NS2-3 protease solubilised in 6 M guanidine HCl was dialysed against 0.75 M 
guanidine HCl supplemented with Zn2+. Under these conditions the NS2-3 protease refolds but 
undergoes no self-processing (Pallaoro et al., 2001). The dialysed protease was stored at -80°C until 
use. The concentration of purified MBP-NS2-3 was determined by densitometric measurement of the 
coomassie stained protein bands and comparison to a BSA standard. To initiate the auto-cleavage 
reaction the NS2-3 protease was diluted in cleavage buffer and incubated at 23°C. The samples were 
analysed on a SDS-gel and by western blot (see Figure 3-3 A and B). A significant fraction of the 
MBP-NS2-3 protease undergoes self-cleavage. It is assumed that this ensues following correct 
refolding and represents the normal autocatalytic activity of the protein. 
	  
	  
Figure 3-3: Activity assay with refolded MBP-NS2-3 protease. M: molecular weight marker, C: control, CB: cleavage 
buffer. The protease was diluted 1:5 with cleavage buffer 1 (CB) or water (control) and incubated over night at 23°C. 
Samples were separated on 12% SDS gels and silver stained (A) or used for a western blot with detection of the His-Tag 
with a anti-polyHistidine IgG HRP linked (B). 
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To optimise the auto-processing reaction of the NS2-3 protease four different cleavage buffers (see 
Table 3-1), three different protease concentrations and two dilution protocols were analysed. 
Concentrations of 50, 100 and 700 nM NS2-3 protease were tested and the protease was diluted 1:5 or 
1:10 in cleavage buffer. 
 
Table 3-1: Formulation of different cleavage buffers for NS2-3 protease self-processing. 
Cleavage	  Buffer	   Detergent	   Glycerol	  	  	  v/v	  [%]	   NaCl	  [mM]	   Additive	  
1	   1%	  TritonX	   50	   250	   3mM	  cysteine	  
2	   1%	  CHAPS	   50	   250	   3mM	  cysteine	  
3	   0.2%	  CHAPS	   30	   0	   	  
4	   0.05%	  Tween	  20	   10	   150	   	  
Common	  
components	   50	  mM	  TrisHCl	  (pH	  7.5)	   3	  mM	  DTT	   50	  µM	  ZnCl2	  
 
After the auto-cleavage reaction the samples were separated on a SDS-gel and the amount of cleaved 
protease determined by densitometric measurement of the coomassie stained protein bands (see 
Figure 3-4 and Table 3-2). 
	  
 
	  
Figure 3-4: Cleavage of MBP-NS2-3 at different protease concentrations and diluted in various cleavage buffers. 12% 
SDS-gel, M: molecular weight marker, con: NS2-3 diluted in water, CB: cleavage buffer. 
The highest self-processing of the NS2-3 protease could be achieved by dilution in cleavage buffer 2 
(CB2) or CB4 (see Table 3-2). A 1:5 or 1:10 dilution to 100 nM or 50 nM NS2-3 protease resulted in 
about 50% of protease cleavage. Dilution of the protease in cleavage buffer 2 or 4 to 700 nM resulted 
only in cleavage of 25% of the protease. The CB4 was chosen for later experiments because of its 
simpler formulation with less detergent, glycerol and additives that could interfere during the affinity 
selection step of subsequent panning experiments. 
 
Table 3-2: Amount of cleaved NS2-3 protease after dilution in various cleavage buffers and at different 
concentrations. 
	  
50	  nM	  (1:10	  dilution)	   100	  nM	  (1:5	  dilution)	   700	  nM	  (1:5	  dilution)	  
 
NS2-­‐3	  [%] NS2	  [%] NS2-­‐3	  [%] NS2	  [%] NS2-­‐3	  [%] NS2	  [%] 
Cleavage	  buffer	  1 100 0 100 0 92 8 
Cleavage	  buffer	  2 53 47 48 52 75 25 
Cleavage	  buffer	  3 100 0 100 0 100 0 
Cleavage	  buffer	  4 48 52 51 49 75 25 
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  CB1	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  nM	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The correct refolding of the maltose-binding protein was analysed by binding to magnetic beads on 
which amylose is covalently coupled. The MBP needs to be in a functional native conformation to 
bind amylose. As seen in Figure 3-5 the MBP is completely refolded and binds to the amylose beads. 
MBP-NS2-3 protease was detectable neither in the supernatant after binding to the beads nor in the 
washing fraction. 
	  
Figure 3-5: Binding of refolded MBP-NS2-3 to amylose magnetic beads. 12% SDS-gel, M: molecular weight marker, 
BB: before binding, AB: after binding, W: washing fraction, E: eluted protein from amylose beads. 
 
3.1.2 Panning against NS2-3 protease 
For an affinity selection with the peptide phage display library CPL19YS-2 the NS2-3 protease was 
immobilised on anti-MBP magnetic beads. The beads are coupled with monoclonal anti-MBP IgG 
which binds the MBP of the fusion protein. For each panning round 2 µg MBP-NS2-3 protease 
diluted in cleavage buffer 4 were immobilised at 4°C to prevent cleavage (Pallaoro et al., 2001). 
About 1 x 1011 peptide-displaying phagemid particles in PBS were used for selection at RT. To 
reduce unspecific binding and specific binding to either the MBP or the anti-MBP IgG, the peptide 
phagemid were incubated on immobilised MBP prior to selection on the NS2-3 protease. After 
selection on the immobilised protease unbound phagmid were removed by washing 10 times with 
PBS (0.05% Tween 20) and subsequent acidic elution of bound peptide phage. Figure 3-6 shows the 
ratio of eluted and added phage for each panning round. The ratio increases after the second and fifth 
selection round, but is constant after the second and third selection round. 
	  
	  
Figure 3-6: Ratio of eluted/added phage particles. The ratio of five panning rounds on immobilised MBP-NS2-3 with 
phage display peptide library CPL19YS-2 is shown. 
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After the 3rd panning round 24 single clones and after the 4th and 5th panning round 36 single clones 
were selected for sequencing. In Figure 3-7 the sequences of the peptides after the 5th panning round 
are shown.  
 
	  
Figure 3-7: Amino acid sequences of 33 single clones after the 5th panning round on the NS2-3 protease with phage 
display peptide library CPL19YS-2. 
Four peptides showed an enrichment with three or more clones from the sequenced 33 clones (see 
Table 3-3) after the 5th panning round. Three of these peptides (K5-10, K5-11 and K5-17) were also 
seen after the 4th panning round and the clone K5-11 was already present after the 3rd selection round. 
The clone K5-11 showed the highest enrichment of 30% of all sequenced clones after the 5th panning 
round. The peptide sequences do not show a definite homology in their sequence. Only the peptide 
K5-11 and K5-31 have a similar hydrophobic motive in the N-terminal part of the peptide that is 
interrupted by an aspartic acid: L-F-V/L-D-F/L. 
 
Table 3-3: Peptides enriched in panning against MBP-NS2-3 protease. PR: panning round. Constant sequence parts are 
coloured in blue and homologies are coloured in orange. 
Clone	  
name	   Sequence	  
Number	  of	  clones	  
3.	  PR	  	  	  	  	  	  	  	  	  	  4.	  PR	  	  	  	  	  	  	  	  	  	  5.	  PR	  
K5-­‐11	   GELGRLFVDFSSCYYYAAHCNIAPGGPPFVFAV 	  	  	  	  2	  (10	  %)	  	  	  	  	  5	  (16	  %)	  	  	  10	  (30%)	  
K5-­‐17	   GELGRRVFFVGAGDYIDAHCYDFPCGCPVVFLA 	  	  	  	  	  	  -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  (9	  %)	  	  	  	  	  	  	  5	  (15%)	  
K5-­‐31	   GELGRLFLDLGCDAYHSVHCAADPGGRSVDPFF 	  	  	  	  	  	  -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  (9%)	  
K5-­‐10	   GELGRPVSSVYCSHSAVLHCVASYPYASAFPVY 	  	  	  	  	  	  -­‐	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Specific binding of the enriched peptides of the 5th panning round to the NS2-3 protease was analysed 
by phage ELISA. MBP-NS2-3 was immobilised over anti-MBP IgG and incubated with peptide 
presenting phage. Bound phage were detected by an anti-M13 IgG HRP conjugate. Immobilised MBP 
and helper phage M13K07 were used as controls. In Figure 3-8 A and B the results for the peptides 
K11 and K17 are shown. Both peptides show specific binding to the NS2-3 protease in a 
concentration dependent manner and only a low unspecific binding to the MBP control. 
 
	  
Figure 3-8: Phage ELISA with enriched clones K11 and K17. Binding of peptide presenting phage particles to NS2-3 
protease was analysed. 0.6 µg MBP-NS2-3 was immobilised over anti-MBP IgG (100 ng), detection of bound phage by anti-
M13 IgG HRP conjugate, 10 washing steps before and after addition of detection antibody. Con: MBP control, negative 
control with M13K07 helper phage. A: Phage ELISA with clone K11, B: Phage ELISA with clone K17 (see Table 3-3). 
In Figure 3-9 the results for the peptides K10 and K31 are shown. The peptide phage of the clones 
K10 and K31 do not show specific binding to the NS2-3 protease. The binding to the MBP control is 
as high as to the protease or in the case of clone K31 even higher. K10 and K31 are probably specific 
binders of the MBP or the anti-MBP IgG. 
 
	  
Figure 3-9: Phage ELISA with enriched clones K10 and K31 (see Table 3-3). Binding of peptide presenting phage 
particles to NS2-3 protease was analysed. 0.6 µg MBP-NS2-3 was immobilised over anti-MBP IgG (100 ng), detection of 
bound phage by anti-M13 IgG HRP conjugate, 10 washing steps before and after addition of detection antibody. Con: MBP 
control, negative control with M13K07 helper phage. 
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3.1.3 Production of peptides 
To test if the peptides K11 and K17 inhibit the NS2-3 cleavage reaction the peptides should be 
produced without fusion to the M13 phage. Because of the relative long and hydrophobic sequence of 
the peptides a chemical synthesis would have been difficult. Therefore it was proposed to produce the 
peptides in E. coli and purify them by IMAC. The peptides were produced with an N-terminal fusion 
to the Antennapedia peptide (Antp). The Antp should increase the solubility of the peptides and could 
be used for later cellular delivery of the peptides.  
For production of the peptides the pET expression system (Novagen) was used. In pET vectors the 
cloned DNA is under the control of the bacteriophage T7 transcription and translation signals for 
strong expression. The Antp DNA sequence was inserted into the pET28c expression vector at the 
NcoI restriction site with the oligonucleotids ‘Ant-pET 5`’ and ‘Ant-pET 3`’. The Antp 
oligonuleotides were designed to leave only one NcoI restriction site at the 3` end. The 
oligonuleotides were hybridised and ligated into the pET28c vector which was cut with the restriction 
enzyme NcoI. The insertion of the Antp was checked by sequencing. For cloning of the peptide insert 
into the vector the NcoI and XhoI restriction sites should be used. This results in a ‘SM’ linker 
between the Antennapedia peptide and cloned DNA and an N-terminal His-Tag that can be used for 
IMAC purification. The sequences coding the enriched peptides were amplified by PCR with the 
primer ‘Pep-pET uni 5`’ and ‘Pep-pET uni 3`’ introducing an NcoI and XhoI restriction site. The 
corresponding peptide phagemid served as a template. The peptide insert was ligated into the 
dephosphorylated pET28c-Antp vector which was also cut with the restriction enzymes NcoI and 
XhoI and transformed into E. coli Rosetta 2 cells. Rosetta 2 cells supply tRNAs for 7 rare codons in 
E. coli and carry a chromosomal copy of the T7 RNA polymerase gene.  
After expression of the peptides most of the material was found as insoluble ‘inclusion bodies’. The 
inclusion bodies were solubilised in 6 M guanidine HCl and purified by IMAC. Figure 3-10 shows the 
results of the expression and purification of the K11 and K17 Antennapedia fusion peptides (Ant-K11 
and Ant-K17). 
	  
	  
	  
Figure 3-10: Production and purification of Ant-K17 and Ant-K11 peptides. 10% Tricine PAGE gel, M: molecular 
weight marker, BI: before induction, I: 5 h after induction, BB: before binding, AB: after binding; W: washing fractions, E: 
elution fraction. 3 µl of each fraction were loaded onto the gel. A: Ant-K17, B: Ant-K11. 
The peptides could be produced and purified in suitable amounts. The purity of the peptides was 
about 55% for the Ant-K17 peptide and 80% for the Ant-K11 peptide. The concentration of the 
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purified Antennapedia fusion peptides was determined by Bradford protein assay taking the purity of 
the eluted protein into consideration. The concentration of the K11-peptide was about 80 µM and for 
the K17-peptide 18 µM. 
 
3.1.4 Inhibition of NS2-3 protease activity 
The inhibitory effect of the peptides on NS2-3 protease cleavage was tested in an activity assay. 
MBP-NS2-3 protease solubilised in 6 M guanidine HCl was mixed with peptide also solubilised in 6 
M guanidine HCl and diluted 1:50 in cleavage buffer 4 and incubated for 5 minutes on ice for 
refolding of the protease. The cleavage reaction was initiated by increasing the temperature to 23°C 
(Pallaoro et al., 2001). During dialysis refolded NS2-3 protease was not used for the activity assay 
because it is known that the protease has formed dimers after refolding (Pallaoro et al., 2001). 
Therefore inhibition of dimer formation would not be detectable. 
To identify the optimal incubation time the cleavage kinetics of the NS2-3 protease were first 
determined without added peptide. The cleavage kinetics of the NS2-3 protease showed the maximum 
of the cleavage reaction after about 1.5 hours of incubation in cleavage buffer at 23°C (see Figure 
3-11). After 1.5 hours of incubation no significant increase in protease cleavage was measurable. The 
amount of cleaved NS2-3 protease was about 20%. 
 
 
Figure 3-11: Cleavage kinetics of the MBP-NS2-3 protease. NS2-3 protease was diluted 1:50 in cleavage buffer 4 to 50 
nM and incubated at 23°C for different durations. Samples were separeated on a SDS-gel and the amount of cleaved 
protease determined by densitometric measurement of the coomassie stained protein bands. The amount of cleaved protease 
after   1.5 h was set to 100%. 
NS2-3 activity assay samples were incubated for 1.5 hours at 23°C. The sample was concentrated by 
ethanol precipitation and loaded onto a 10% Tricine-page gel. The amount of cleaved protease was 
determined by densitometric measurement of the coomassie stained protein bands (see Figure 3-12). 
To exclude that the added peptides only interfere with the refolding of the MBP-NS2-3 protease the 
peptide Ant-K5-66 was chosen as a control (see appendix  
Figure 7-1). The peptide binds specific to the NS3 protease domain. The peptides were added to the 
protease to a final concentration of 270 nM.  
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Figure 3-12: NS2-3 protease activity assay with peptides Ant-K11 and Ant-K17. NS2-3 protease with or without peptide 
was diluted 1:50 in cleavage buffer 4 to 50 nM protease and 270 nM peptide and incubated at 23°C for 1.5 h. Samples were 
separated on a 10% Tricine-page gel. M: molecular weight marker, NC: negative control (1:50 dilution of NS2-3 protease 
with water), PC: positive control without peptide, 5-66: control with peptide Ant-K5-66, K11: sample with peptide Ant-K11, 
K17: sample with peptide Ant-K17. 
The results of the NS2-3 activity assay with the peptides K11 and K17 are shown in Figure 3-13. The 
control peptide K5-66 reduced the cleavage of the protease to about 75% compared to the control 
without peptide. The peptide K11 showed a reduction of the protease cleavage to about 90%. The 
peptide K17 showed the highest inhibitory effect on NS2-3 cleavage. After incubation with peptide 
K17 only about 55% of NS2-3 were processed. 
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Figure 3-13: Inhibitory effect of peptides on NS2-3 protease cleavage. Con: positive control without peptide, K5-66: 
control with peptide Ant-K5-66, K11: sample with peptide Ant-K11, K17: sample with peptide Ant-K17. Protease 50 nM, 
peptide 270 nM. The amount of cleaved protease of the control without peptide was set to 100%. 
Since the peptide K11 showed no inhibitory effect on protease cleavage compared to the control 
peptide the activity assay was only repeated with peptide K17 to confirm the results. In Figure 3-14 
the combined results of different experiments are shown.  
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Figure 3-14: Inhibitory effect of peptides on NS2-3 protease cleavage. Con: positive control without peptide, K5-66: 
control with peptide Ant-K5-66, K17: sample with peptide Ant-K17. Protease 50nM, peptide 270 nM. A: the amount of 
cleaved protease of the control without peptide was set to 100%, B: the amount of cleaved protease with the control peptide 
K5-66 was set to 100%. P-values were calculated with GraphPad Prism (unpaired t-test with two-tailed p-value and 95% 
confidence interval). 
The control peptide K5-66 reduced the protease cleavage to about 80% compared to the control 
without peptide. This is statistically significant with a p-value below 0.05. The peptide K17 showed 
reduction of protease cleavage to about 60% which is statistically significant (p-value below 0.05) 
also in comparison to the control peptide K5-66. In direct comparison to the peptide K5-66 the 
protease processing is reduced to about 70% for peptide K17 at 270 nM. 
The concentration dependency of the inhibitory effect of peptide K17 was tested at three different 
concentrations. The results are shown in Figure 3-15. 
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Figure 3-15: Concentration dependence of inhibitory effect of peptide Ant-K17 on NS2-3 protease cleavage. Mean 
value of NS2-3 cleavage of control peptide Ant-K5-66 was set to 100% for each concentration. 
The inhibition of protease cleavage is concentration dependent for the peptide K17. At a peptide 
concentration of 90 nM no inhibition was detectable compared to the control peptide K5-66.  
A	   B	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NS2-3 protease dialysed against 0.75 M guanidine HCl supplemented with Zn2+ refolds and forms 
protease dimers but undergoes no self-processing under these conditions (Pallaoro et al., 2001). To 
analyse the effect of the peptide K17 on refolded protease the assay was done with dialysed protease. 
In Figure 3-16 the results of two experiments are shown. 
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Figure 3-16: Inhibitory effect of peptides on NS2-3 cleavage with prior refolded MBP-NS2-3 protease. Con: positive 
control without peptide, K5-66: control with peptide Ant-K5-66, K17: sample with peptide Ant-K17. Protease 50 nM, 
peptide 270 nM. The cleaved protease of the control was set to 100%. P-values were calculated with GraphPad Prism 
(unpaired t-test with two-tailed p-value and 95% confidence interval). 
The inhibitory effect of the peptide K17 is reduced in the activity assay when measured with refolded 
protease. 77% of the NS2-3 protease is cleaved compared to the control without peptide. With the 
control peptide K5-66 the processing of the protease is reduced to about 87%. The inhibitory effect of 
the peptide K17 is statistically significant (p-value below 0.05) when compared to the control without 
peptide but the values show a high fluctuation around the mean value. 
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3.2 NS3/4A protease 
3.2.1 Production and activity of recombinant NS3/4A protease 
The HCV NS3/4A protease was produced with the pMAL expression system (New England BioLabs) 
similar to the NS2-3 protease. The DNA encoding the NS3/4A protease was inserted into the pMAL-
c4E vector down-stream from the malE gene, which encodes the maltose-binding protein (MBP). This 
results in the expression of a MBP-NS3/4A fusion protein with a 23 aa linker between MBP and 
protease. A single chain form of the NS3 protease domain linked to the NS4A cofactor peptide was 
produced according to Dimasi and co-workers. It consists of the residues 21 – 34 of the NS4A peptide 
and the residues 2 – 180 of the NS3 serine protease domain which are connected by a GG linker (see 
Figure 3-17 A and B). For PCR amplification the HCV replicon ‘I389/NS3-3'UTR’ which was 
constructed from the consensus sequence of genotype 1b isolate cDNA served as a template 
(Lohmann et al., 1999). The primer ‘primNS3/4A’ and ‘primNS3/4a-rev’ which introduced a KpnI 
and PstI restriction site, the N-terminal NS4A peptide with the GG-linker and a C-terminal His-Tag 
with a short linker were used. It was intended to use the MBP protein for immobilisation of the 
protease during affinity enrichment and the His-Tag for IMAC purification of the protein after 
production in E. coli. The NS3/4A insert was ligated into the dephosphorylated pMAL-c4E vector 
which was also cut with the restriction enzymes KpnI and PstI and transformed into E. coli Top10 
F´cells. 
	  
Figure 3-17: Single chain NS3/4A. A: Sequence of the single-chain NS3/4A. Residues 21 – 34 of NS4A and residues 2 – 
180 of NS3 were connected by a GG linker. The C-terminal His-Tag with linker is shown. B: Model of single chain 
NS3/4A, NS4A: red, NS3: green, linker with neighboring amino acid of NS3 and NS4A is shown in blue (RGGP) (modified 
from Dimasi et al., 1998). 
The MBP-NS3/4A fusion protein was produced in soluble form at 30°C. The protease was purified by 
IMAC and the elution fraction dialysed against buffer D. The dialysed protease was stored at -80°C 
until usage. In Figure 3-18 A the results of the production and purification of the MBP-NS3/4A 
protein are shown. The protease could be produced and purified in suitable amounts and purity. The 
A	  
B	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full-length of the protease and the purification of the correct protein was confirmed by InVision His-
tag In-gel staining (see Figure 3-18 B). 
 
	  
Figure 3-18: Production and purification of MBP-NS3/4A. 12% SDS-gel, M: molecular weight marker, BI: before 
induction, I: 3 h after induction, BB: before binding, AB: after binding; W1-3: washing fractions, E: elution fraction. 3 µl of 
each fraction were loaded onto the gel, except for the elution fraction: 1 µl. A: Coomassie stained SDS-page, B: ‘InVision 
His-tag In-gel Stain’ stained SDS-gel. 
The concentration of purified MBP-NS3/4A was determined by densitometric measurement of the 
Coomassie stained protein bands and comparison to a MBP standard. Concentrations of up to 7 
mg/ml of MBP-NS3/4A could be obtained. 
The activity of the purified NS3/4A protease was tested with a fluorescence resonance energy transfer 
(FRET) assay (Taliani et al., 1996; Misialek et al., 2009). Figure 3-19 shows the results for various 
protease concentrations. The NS3/4A protease was active and therefore in a native active 
conformation and could be used for an affinity enrichment. The correct folding of the NS3/4A single-
chain construct was later confirmed by structure determination (see 3.2.7.2). 
 
 
Figure 3-19: Activity assay with MBP-NS3/4A protease. Assay was done in buffer M2235 with 5 µM substrate M-2235 
(Bachem) and 0, 1, 2 or 6 nM NS3/4A. Excitation filter: 360/40 nm, emission filter: 460/40 nm, RFU: Relative Fluorescence 
Units. Equation of trend lines are shown. 
 
M	  	  	  	  	  	  Bi	  	  	  	  	  	  	  I	  	  	  	  	  	  BB	  	  	  	  AB	  	  	  	  	  	  E	  	  	  	  	  W1	  	  	  	  W2	  	  	  	  W3	   M	  	  	  	  	  	  	  Bi	  	  	  	  	  	  	  I	  	  	  	  	  	  BB	  	  	  	  AB	  	  	  	  	  E	  	  	  	  	  	  W1	  	  	  	  W2	  	  	  	  W3	  
A	   B	  
ç	  MBP-­‐NS3/4A	  
kDa	  
130	  
70	  
55	  
40	  
35	  
25	  
Results 
 
60 
3.2.2 Panning against NS3/4A protease 
For affinity selection of inhibitory peptides against the NS3/4A protease with the peptide phage 
display library CPL19YS-2 various panning conditions were used (see Table 3-4). The protease was 
immobilised in microtiter plates (MTPs) or on magnetic beads. In MTPs the protease was bound via 
immobilised anti-MBP IgG which binds the MBP of the fusion protein. The magnetic beads have 
covalently bound amylose or anti-MBP IgG on their surface for binding of the MBP. For the affinity 
selections two different panning buffers were used: one buffer with a high salt concentration of about 
140 mM (1xPBS) and one buffer with no salt (buffer H). For the binding of the NS3/4A substrates or 
for the binding of known peptide inhibitors ionic interactions are important (Ingallinella et al., 1998). 
For an initial enrichment a buffer with a low ionic strength was used to strengthen the possible ionic 
interactions of peptides and protease. Bound phage were eluted by acidic and competitive elution. 
Acidic elution is a nonspecific elution which elutes all bound phage by denaturing the target protein 
through change of the pH. For competitive elution a known NS3/4A inhibitor N-1725 (Bachem) was 
used which binds at the subsites S1 – S6 of the protease and has an IC50 value of 40 nM at 150 nM 
NaCl (Ingallinella et al., 1998). 
 
Table 3-4: Panning conditions of affinity selections on NS3/4A protease. MTP: microtiter plate, PR: panning round. 
Immobilisation	  
method	  
Salt	  
[mM]	  
Elution	  
method	  
Enrichment	  
of	  peptides	  
Amylose	  and	  
anti-­‐MBP	  Beads	   140	  
acidic	  
competitive	   no	  
MTP	   140	   acidic	  competitive	   no	  
Anti-­‐MBP	  Beads	   0	   acidic	  competitive	   no	  
MTP	   0	   acidic	  competitive	   yes	  
 
Only the panning in MTPs with a low ionic strength buffer led to the enrichment of peptides with 
acidic and competitive elution. For each panning round 1 µg MBP-NS3/4 protease was immobilised 
on 200 ng anti-MBP IgG and about 1 – 4 x 1011 peptide phages in buffer H were used for selection. 
To reduce unspecific binding and specific binding to either the MBP or the anti-MBP IgG, the peptide 
phagemid were incubated on immobilised MBP prior to selection on the NS3/4A protease. After 
selection unbound phage were removed by 10-fold washing with buffer H (0.05% Tween 20). The 
panning was performed by Juliane Lindner. In Figure 3-20 the sequences of peptides after the 5th 
panning round of acidic elution and after the 6th panning round of competitive elution are shown. 
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Figure 3-20: Amino acid sequences of single clones after the 5th or 6th panning round on NS3/4A protease with phage 
display peptide library CPL19YS-2. A: Sequences of 40 single clones after the 6th panning round with competitive 
elution, B: Sequences of 39 single clones after the 5th panning round with acidic elution. 
Both elution conditions led to the enrichment of one clone. Clone K5-66 for the acidic elution after 
the 5th panning round and clone K6-10 for the competitive elution after the 6th panning round. Also 
two clones, K5-78 and K6-7, were identified which were found in a previous panning round (see 
Table 3-5). The clone K5-66 showed the highest enrichment being present as 70% of all sequenced 
clones after the 6th panning round. The peptide sequences of clones K5-66 and K6-10 show a 
homology in their sequence. They have a similar quite hydrophobic 9 aa long motiv in the N-terminal 
part of the peptide that is interrupted by an aspartic acid: V-Y-L/V-L-D/G-G/D-P-G-Y (see Table 
3-5). 
 
Table 3-5: Peptides enriched in ‘low salt panning’ against MBP-NS3/4A protease in MTP. Results of acidic and 
competitive elution. PR: panning round. Constant sequence parts are coloured in blue and homologies are coloured in 
orange. 
Elution	  
method	  
Clone	  
name	   Sequence	  
Number	  of	  clones	  
	  5.	  PR	  	  	  	  	  	  	  	  	  	  	  	  6.	  PR	  
acidic	   K5-­‐78	   GELGRPDHDVTRPRSISSHCVVASCPAAFFVVV 	  	  	  	  2	  (5%)	  	  	  	  	  	  	  	  	  	  1	  (2.5%)	  
acidic	   K5-­‐66	   GELGRLVYLLDGPGYDPIHCSLAYGDASTLVVF 	  	  	  	  7	  (17%)	  	  	  	  	  29	  (72.5%)	  
competitive	   K6-­‐10	   GELGRPVYVLGDPGYYATHCIYATTNDALIFSV 	  	  	  	  	  	  	  -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  (17.5%)	  
competitive	   K6-­‐7	   GELGRLVLLVPCGGSFDFHCVVLPCTRAVIAIS 	  	  	  	  2	  (5%)	  	  	  	  	  	  	  	  	  	  2	  (5%)	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Specific binding of the enriched peptides to the NS3/4A protease was analysed by phage ELISA. 
MBP-NS3/4A was immobilised over anti-MBP IgG and incubated with peptide-presenting phagemid 
particles. Bound phage were detected by an anti-M13 IgG HRP conjugate. Immobilised MBP, anti-
MBP IgG alone and helper phage M13K07 were used as controls. In Figure 3-21 the results for the 
clones K6-10, K6-7, K5-66 and K5-78 are shown. 
 
	  
Figure 3-21: Phage ELISA with enriched clones K6-10, K6-7, K5-66 and K5-78. Binding of peptide presenting phage 
particles to NS3/4A protease was analysed. 1 µg MBP-NS3/4A was immobilised over anti-MBP IgG (200 ng), 1 x 10^9 
phage/well in buffer H, detection of bound phage by anti-M13 IgG HRP conjugate, 3 washing steps before and after addition 
of detection antibody. Con 1: immobilised MBP control, con 2: immobilised anti-MBP IgG control, negative control with 
M13K07 helper phage. Measurements with NS3/4A protease were done in duplicate. 
The peptides K6-10 and K5-66 show specific binding to the NS3/4A protease but also a high 
background binding to the controls. The peptide phage of the clones K6-7 and K5-78 do not show 
specific binding to the NS3/4A protease. The binding to the MBP control is as high as to the protease. 
The phage ELISA with the peptides K6-10 and K5-66 was optimised by variation of the amount of 
peptide phage and by increasing the washing steps before and after addition of the detection antibody 
to reduce the amount of unspecific bound phage. Also the inhibitor used for competitive elution was 
added to the peptide phage to analyse if the peptides bind at the same epitope as the inhibitor. If the 
peptides bind at the same epitope the ELISA signal would be reduced because the inhibitor would 
block the binding site of the NS3/4A protease. In Figure 3-22 A and B the results of the phage ELISA 
are shown. 
 
Figure 3-22: Phage ELISA with clone K5-66 (A) and K6-10 (B). Binding of peptide presenting phage particles to NS3/4A 
protease was analysed. Buffer: buffer H, 1 µg MBP-NS3/4A was immobilised over anti-MBP IgG (200 ng), detection of 
bound phage by anti-M13 IgG HRP conjugate, 6 washing steps before and after addition of detection antibody. Con: 
immobilised MBP control, + Inh: 1 µM NS3/4A inhibitor N-1725 (Bachem) added as competitor (Ingallinella et al., 1998), 
negative control with M13K07 helper phage incubated on NS3/4A protease. 
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Both peptides show specific binding to the NS3/4A protease in a concentration dependent manner and 
only a low unspecific binding to the MBP control at lower phage concentrations. Also the peptides 
show a reduced ELISA signal when protease inhibitor was added during binding to the protease. This 
implies a competitive binding of the peptides K6-10 and K5-66 with the inhibitor and a binding at the 
same epitope of the NS3/4A protease.  
 
3.2.3 Production of MBP fusion peptides 
To test if the peptides K5-66 and K6-10 inhibit the NS3/4A protease activity the peptides should be 
produced without fusion to the M13 phage. Because of the length and the partly hydrophobic 
sequence of the peptides a chemical synthesis failed. Therefore it was attempted to produce the 
peptides in E. coli and purify them by IMAC. The peptides were produced with a N-terminal fusion to 
the maltose-binding protein to increase the solubility and molecular weight of the peptides. 
The inhibitory peptides were produced with the pMAL expression system (New England BioLabs) 
similar to the NS3/4A protease. The DNA encoding the peptide was inserted into the pMAL-c4E 
vector down-stream from the malE gene, which encodes the maltose-binding protein (MBP). For PCR 
amplification the corresponding peptide phagemid DNA served as a template. The primer ‘pep-pMAL 
uni 5`’ and ‘pep-pMAL uni 3`’ which introduced a 3` PstI restriction site and a C-terminal His-Tag 
with a short linker were used. A 5` KpnI restriction site could not be used because of a KpnI site 
located at the C-terminal constant region of the library peptide (see also Figure 3-26). Therefore the 
pMAL-c4E vector was first cut with KpnI and the overhanging 3`end was removed using the T4 
polymerase exonuclease activity. The blunt ended vector was cut with PstI and dephosphorylated. The 
phosphorylated peptide insert with 5` blunt end was ligated into the pMAL-c4E vector and 
transformed into E. coli Top10 F´cells. The MBP fusion peptides were produced in soluble form at 
30°C. The MBP-peptides were purified by IMAC and the buffer of the elution fraction was 
exchanged with the use of centrifugal filter units with 10 kDa cut off. The peptides in buffer M2235 
were stored at -80°C until usage. In Figure 3-23 the results of the production and purification of one 
peptide is shown as an example (see also appendix 7.2). The peptides could be produced and purified 
in suitable amounts and purity. 
	  
Figure 3-23: Production and purification of MBP-CP5-46-4D5E peptide. 12% SDS-gel, M: molecular weight marker, 
BI: before induction, I: 3 h after induction, BB: before binding, AB: after binding; W1-3: washing fractions, E: elution 
fraction. 3 µl of each fraction were loaded onto the gel, except elution fraction: 1 µl 1:5 dilution. 
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The concentration of purified MBP-peptide was determined by densitometric measurement of the 
coomassie stained protein bands and comparison to a MBP standard. Concentrations of up to 4.4 
mg/ml of MBP-fusion peptides could be obtained. 
 
3.2.4 Inhibition of NS3/4A activity 
The MBP fusion proteins of the peptides K5-66 and K6-10 were tested in the NS3/4A activity assay if 
they have an inhibitory effect on protease activity. Various peptide concentrations were tested and the 
IC50 value was calculated with GraphPad Prism using a nonlinear regression model. In Figure 3-24 
the results for both peptides are shown. 
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Figure 3-24: Determination of the IC50 of peptide K5-66 (A) and K6-10 (B) using the NS3/4A activity assay. Assay was 
done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 1 nM NS3/4A. Peptides produced as MBP fusion proteins 
with His-Tag. Excitation filter: 360/40 nm, emission filter: 460/40 nm. Velocity of fluorescence increase over one hour was 
compared to that of the NS2-K11 control peptide (K5-66) or MBP control (K6-10). Each measurement was done in 
duplicate, IC50 in nM. The curve was fitted with GraphPad Prism using a nonlinear regression model with variable slope 
and normalised response: Y=100/(1+10^((LogIC50-X)*slope)). 
Both peptides have an inhibitory effect on protease activity. Peptide K5-66 has an IC50 value of about 
21 nM and peptide K6-10 of about 26 nM. 
To analyse if the MBP or His-Tag have an inhibitory effect on the protease the peptide NS2-K11 that 
was not enriched in the panning against the NS3/4A protease was used as a control (see Figure 3-25). 
The peptide shows no inhibition of protease activity. 
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Figure 3-25: NS3/4A activity assay with control peptide MBP-NS2-K11. Assay was done in buffer M2235 with 5 µM 
substrate M-2235 (Bachem) and 1 nM NS3/4A. Peptide NS2-K11 produced as MBP fusion protein with His-Tag. Excitation 
filter: 360/40 nm, emission filter: 460/40 nm. Velocity of fluorescence increase over one hour was compared to that of a 
MBP control. Each measurement was done in duplicate 
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Also the N-terminal and C-terminal part of the peptides were tested separately to see which sequence 
is important for NS3/4A protease inhibition. These peptides were synthesised chemically. See Table 
3-6 for results. In both cases the N-terminal part of the peptides, which comprises the homolog 
sequence motive, is important for inhibition of the protease and binds presumably to the active site. 
The inhibitory effect is reduced compared to that of the full length peptide, about 6-fold for peptide 
K5-66 and 9-fold for peptide K6-10. The C-terminal parts have no inhibitory effect at the tested 
concentrations but seem to work synergistically with the N-terminal parts.  
	  
Table 3-6: Inhibitory effect of peptides K5-66, K6-10 and their N- and C-terminal parts on NS3/4A activity. IC50 
values were calculated with GraphPad Prism using a nonlinear regression model with variable slope and normalised 
response: Y=100/(1+10^((LogIC50-X)*slope)). Constant sequence parts are coloured in blue and homologies are coloured in 
orange. 
Peptide	   Sequence	   IC50	  [nM]	   Ki	  [nM]	  
K5-­‐66	   GELGRLVYLLDGPGYDPIHCSLAYGDASTLVVF 20.7	  ±	  3.6	   9.6	  ±	  1.7	  
K5-­‐66-­‐A	   GELGRLVYLLDGPGYDPI 125.4	   58	  
K5-­‐66-­‐B	                      HCSLAYGDASTLVVF >>	  1µM	   -­‐	  
K6-­‐10	   GELGRPVYVLGDPGYYATHCIYATTNDALIFSV 25.6	  ±	  3.5	   11.8	  ±	  1.7	  
K6-­‐10-­‐A	   GELGRPVYVLGDPGYYAT 227.6	   105	  
K6-­‐10-­‐B	                     HCIYATTNDALIFSV >>	  1µM	   -­‐	  
NS2-­‐K11	   GELGRLFVDFSSCYYYAAHCNIAPGGPPFVFAV >>	  1	  µM	   -­‐	  
K5-­‐66-­‐R	   GELGRIPSDTYDLAVGALHCPFYLVSGLVYLDG >>	  1	  µM	   -­‐	  
 
3.2.5 Cosmix-plexing of inhibitory peptides K5-66 and K6-10 
After initial selection rounds with the peptide phage display library CPL19YS-2 which yielded the 
inhibitory peptides K5-66 and K6-10 a recombination was done using the cosmix-plexing technique 
(Collins et al., 2001) to further improve the affinity of the peptides. The pre-selected populations, 
after the 5th panning round with acidic elution, and after the 6th panning round with competitive 
elution were chosen for recombination. Both populations contain about 20% of the clone K5-66 or 
K6-10, respectively. The N-terminal parts of these peptides, which show sequence homology, bind 
presumably to the active site of the protease and seem to work synergistically with the C-terminal 
parts (see Table 3-6). It was intended to recombine the N- and C-terminal parts of the peptides with 
pre-selected peptides showing weak affinity to form novel ligands that exhibit stronger binding to the 
NS3/4A protease. Isolated phagemid DNA was recombined using the BsrDI restriction site. 
Recombination at this site shuffles the cassettes that are separated by the constant ‘HC’ motive in the 
middle of the library peptide (see Figure 3-26).  
	  
Figure 3-26: CPL19YS-2 library sequence. The four coloured boxes indicate the four cassettes of the library, constant aa 
are written beneath the nucleotide sequence. The recognition sequences and restriction sites of restriction enzymes are 
labeled, the three type IIs restriction enzyme sites are marked with a box (modified from Pollmann, 2010). 
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After cosmix-plexing of the pre-selected population after the 5th panning round with acidic elution 
and 6th panning round with competitive elution the number of single clones was 8.9 x 107 and        9.6 
x 107, respectively. The effective recombination at the BsrDI site was confirmed by sequencing. The 
results from both recombinations are shown in Figure 3-27 A and B. 
	  
Figure 3-27: Amino acid sequences of 45 single clones after recombination with the cosmix-plexing method using the 
BsrDI restriction site. The eluted clones of the 5th panning round with acidic elution or 6th panning round with competitive 
elution were recombined. A: Sequences of single clones after the recombination of the 5th panning round with acidic 
elution, B: Sequences of single clones after the 6th panning round with competitive elution. 
After cosmix-plexing several peptides with recognisable recombined sequences were found, e.g. A-
D10, A-C8, A-A3, A-A11, B-F10 and B-G7. There was still a high proportion of ‘original’ or 
‘parental’ peptides, e.g. K5-66 (25%, A-A2) and K6-10 (12%, B-E11). Notably for the peptide K5-66 
most new variants have an ‘original’ C-terminus (A-C8 – A-B1). Also after recombination of the 
clones from the competitive elution 6th PR, an additional peptide (B-F2) was found that appears to 
have already been enriched and which had previously escaped identification. 
The recombined variants of the acidic and competitive elution were packed in phagemid particles and 
submitted to further affinity selection. The panning was performed in a buffer with a salt 
A	   B	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concentration of about 70 nM (0.5xPBS) to increase the stringency through weakening of ionic 
interactions. Bound phagemid particles were eluted by acidic elution. For each panning round 1 µg 
MBP-NS3/4 protease was immobilised on 200 ng anti-MBP IgG in MTPs and about 2 – 5 x 1011 
peptide phage in 0.5xPBS were used for selection. To reduce unspecific binding and specific binding 
to either the MBP or the anti-MBP IgG, the peptide phagemid were incubated on immobilised MBP 
prior to selection on the NS3/4A protease. After selection unbound phage were removed by 16-fold 
washing (1. PR) or 20-fold washing (2. PR) with 0.5xPBS (0.05% Tween 20). In Figure 3-28 the 
sequences of peptides after the 2nd panning round are shown. 
	  
Figure 3-28: Amino acid sequences of single clones after the 2nd panning round after cosmix-plexing. A: Sequences of 
42 single clones from panning with recombined sequences of the 5th panning round with acidic elution, B: Sequences of 40 
single clones from panning with recombined sequences of the 6th panning round with competitive elution. 
After two rounds of affinity selection with the recombined peptides of the 5th panning round with 
acidic elution an enrichment of the ‘original’ clone K5-66 (A-E1, about 55%) was seen. Also the N-
terminal part of the clone K5-66 (A-F2 – A-G7, about 93%) was highly enriched. Some of the 
peptides with a different C-terminal sequence shared sequence homology. Two motives were 
enriched: S/T-R-G-G/(-)-S (clones A-F2 and A-H3) and S-S-C-C (clones A-G4 and A-F4). From the 
clones with a different C-terminal part the clone A-H3 showed the highest enrichment (about 10%). 
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After affinity selection with the recombined peptides of the 6th panning round with competitive 
elution an enrichment of various peptides was seen. The ‘original’ clone K6-10 (B-C12) was not 
enriched during panning (before: 12%, after: 10%), however, the N-terminal part did show an 
enrichment (35%). The enriched peptide that was first identified after recombination (B-A11) was 
also enriched during panning (before: 7.5%, after: 15%). Notably the C-terminal part of this peptide 
showed a strong enrichment (50%). Most interestingly a new variant with the N-terminal part of 
peptide K5-66 and the C-terminal part of clone B-A11 showed a high enrichment (25%) and was also 
found after affinity selection with the recombined peptides of the 5th panning round with acidic 
elution (clone A-F2). The clone K5-66 had not previously been identified in the panning with 
competitive elution.  
Several clones were chosen for a phage ELISA (see Table 3-7). 
 
Table 3-7: Peptides enriched in against MBP-NS3/4A protease after cosmix-plexing. PR: panning round. Constant 
sequence parts are coloured in blue and homologies are coloured in orange or green. 
Peptide	   Sequence	  
K5-­‐66	   GELGRLVYLLDGPGYDPIHCSLAYGDASTLVVF 
CP5-­‐46	  (A-­‐H3)	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 
CP5-­‐11	  (A-­‐G4)	   GELGRLVYLLDGPGYDPIHCPASSCCHAFDVTA 
CP6-­‐4	  (A-­‐F2,	  B-­‐A5)	   GELGRLVYLLDGPGYDPIHCFPIYSRGSYASYV 
CP6-­‐11	  (B-­‐A11)	   GELGRRSFSVCSHPSHDLHCFPIYSRGSYASYV 
 
An increase of the affinity of the enriched peptides to the NS3/4A protease was analysed by phage 
ELISA and comparison to the peptide K5-66. MBP-NS3/4A was immobilised on anti-MBP IgG 
coated MTPs and incubated with peptide presenting phagemid particles. Bound phage were detected 
by an anti-M13 IgG HRP conjugate. Immobilised MBP and helper phage M13K07 were used as 
controls. In Figure 3-29 the results with the clones CP5-46 (A-H3), CP5-11 (A-G4), CP6-4 (B-A5) 
and CP6-11 (B-A11) are shown. 
	  
Figure 3-29: Phage ELISA with enriched clones after cosmix-plexing. Binding of peptide presenting phage particles to 
NS3/4A protease. 1 µg MBP-NS3/4A was immobilised over anti-MBP IgG (200 ng), 5 x 10^8 phages/well in 1xPBS, 
detection of bound phage by anti-M13 IgG HRP conjugate, 10 washing steps with 1xPBS before and after addition of 
detection antibody. con: immobilised MBP control, negative control with M13K07 helper phage. Measurements were done 
in duplicate. 
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The peptides CP5-46 and CP6-4 show an increased ELISA signal than the peptide K5-66 and should 
have a higher affinity to NS3/4A protease. The peptide phage of the clones CP5-11 and CP6-11 do 
not show show an increased ELISA signal compared to the peptide K5-66. 
The peptides CP5-46, CP6-4 and CP6-11 were produced as MBP fusion proteins and tested in the 
NS3/4A activity assay if they have an increased inhibitory effect on protease activity compared to the 
peptide K5-66. Various peptide concentrations were tested and the IC50 value was calculated with 
GraphPad Prism using a nonlinear regression model. In Figure 3-30 the results for the peptides   
CP5-46 and CP6-4 are shown. 
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Figure 3-30: Determination of the IC50 of peptide CP5-46 (A) and CP-6-4 (B) using the NS3/4A activity assay. Assay 
was done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 1 nM NS3/4A. Peptides produced as MBP fusion 
proteins with His-Tag. Excitation filter: 360/40 nm, emission filter: 460/40 nm. Velocity of fluorescence increase over one 
hour was compared to that of the NS2-K11 control peptide. Each measurement was done in duplicate, IC50 in nM. The curve 
was fitted with GraphPad Prism using (A) a nonlinear regression model with variable slope and normalised response: 
Y=100/(1+10^((LogIC50-X)*slope)) or (B) a nonlinear regression model with variable slope : Y=Bottom+(Top-Bottom)/ 
(1+10^((LogIC50-X)*slope)). 
The peptide CP5-46 has an increased inhibitory effect on protease activity with an IC50 value of about 
11.3 nM, i.e. the cosmix-plexing strategy had rapidly yielded two-fold improvement compared to the 
best peptide, K5-66, isolated before the recombination. The peptide CP6-11 (see appendix Figure 7-6 
B) showed only a low inhibitory effect on NS3/4A protease activity with an IC50 value of about 2.4 
µM (see Table 3-8). The peptide CP6-4 with the N-terminal part of K5-66 and the C-terminal part of 
CP6-11 showed an increase in the inhibitory effect with an IC50 value of about 15.8 nM. The 
recombination of pre-selected peptides using the cosmix-plexing technique resulted in novel ligands 
that exhibit stronger inhibition of the NS3/4A protease. 
 
Table 3-8: Inhibitory effect of peptides enriched after cosmix-plexing on NS3/4A activity. IC50 values were calculated 
with GraphPad Prism using a nonlinear regression model with variable slope and normalised response. Constant sequence 
parts are coloured in blue and homologies are coloured in orange or green. 
Peptide	   Sequence	   IC50	  [nM]	   Ki	  [nM]	  
K5-­‐66	   GELGRLVYLLDGPGYDPIHCSLAYGDASTLVVF 20,7	  ±	  3,6	   9.6	  ±	  1.7	  
CP5-­‐46	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 11.3	  ±	  1.6	   5.2	  ±	  0.75	  
CP6-­‐4	   GELGRLVYLLDGPGYDPIHCFPIYSRGSYASYV 15.8	  ±	  2.4	   7.3	  ±	  1.1	  
CP6-­‐11	   GELGRRSFSVCSHPSHDLHCFPIYSRGSYASYV ~2.38	  µM	   ~1.08	  µM	  
 
All peptides that were tested in the NS3/4A activity assay were produced as MBP fusion proteins with 
an N-terminal MBP with a 23 aa linker and a C-terminal His-Tag. To analyse if the extensions have 
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an impact on the inhibitory effect the peptide CP5-46 was produced by chemical synthesis and tested 
in the NS3/4A activity assay. The synthetic peptide without N- or C-terminal fusions shows no 
significant difference in the IC50 value (see Table 3-9 and appendix Figure 7-6 A). 
 
Table 3-9: Comparison of IC50 value of MBP-fusion peptide and synthetic peptide. 
Peptide	   IC50	  [nM]	  
MBP-­‐CP5-­‐46	   11.3	  ±	  1.6	  
CP5-­‐46	   13.3	  ±	  2.7	  
 
To more narrowly identify the most important inhibitory sequence motive of peptide CP5-46 that is 
important for inhibition of the NS3/4A protease, or rather to identify regions which contribute little or 
nothing to the inhibitory effect, several truncated peptides were tested in the activity assay. The 
results are shown in Table 3-10 (see also appendix Figure 7-7). 
 
Table 3-10: Identification of the binding motive necessary for NS3/4A inhibition of peptide CP5-46. IC50 values were 
calculated with GraphPad Prism using a nonlinear regression model with variable slope and normalised response: 
Y=100/(1+10^((LogIC50-X)*slope)). Constant sequence parts are coloured in blue. 
Peptide	  name	   Sequence	   IC50	  [nM]	  
CP5-­‐46	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 13.3	  
CP5-­‐46-­‐A	   GELGRLVYLLDGPGYDPIHCD 124.0	  
K5-­‐66-­‐A	   GELGRLVYLLDGPGYDPI 125.4	  
CP5-­‐46-­‐P1	       RLVYLLDGPGYDPI 157.1	  
CP5-­‐46-­‐P3	             DGPGYDPIHCD >>	  1µM	  
CP5-­‐46-­‐P4	             DGPGYDPIHCDVVTRGGS >>	  1µM	  
CP5-­‐46-­‐R	  (control)	   GELGRDIGGPLDLYPVDLHCY >>	  1µM	  
 
As seen before for inhibition of NS3/4A protease activity the N-terminal part of the peptide is 
important. Especially a part of the N-terminal constant region and the following hydrophobic amino 
acids are necessary for inhibition of the protease. Without the N-terminal hydrophobic amino acids 
(aa 6 – 10) the inhibitory effect is completely abolished (see Table 3-10 peptides CP5-46-P3 and P4). 
A synergy between the N-terminal and the C-proximal region is also implied. 
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3.2.6 Peptide cleavage and specificity 
3.2.6.1 Specificity of the peptide CP5-46 
The specificity of peptide CP5-46 for the NS3/4A protease was tested with three other serine 
proteases: chymotrypsin, trypsin and elastase. The reduction of the protease activity was measured in 
the presence of 50 µM peptide CP5-46. The known serine protease inhibitor aprotinin was used as a 
positive control at the same concentration. The results are shown in Figure 3-31. The peptide CP5-46 
showed no inhibition of the tested serine proteases at a concentration of 50 µM.  
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Figure 3-31: Specificity of the peptide CP5-46 for the NS3/4A protease. The inhibition of the serine proteases trypsin, 
chymotrypsin and elastase was tested. Trypsin: 5 µM protease, 800 µM substrate N-α-benzoyl-DL-Arg-pNA in 100 mM 
TrisHCl pH 8, 20 mM CaCl2. Chymotrypsin: 300 nM protease, 200 µM substrate Succinyl-Ala-Ala-Pro-Phe-pNA in 40 mM 
Hepes pH 7.5, 15 mM CaCl2. Elastase: 20 nM protease, 200 µM substrate Succinyl-Ala-Ala-Ala-pNA in 100 mM TrisHCl 
pH 8, 20 mM CaCl2. Concentration of peptide CP5-46 and positive control aprotinin was 50 µM, control: enzyme without 
inhibitor. Absorbance increase at 405 nm was measured every 30 s for 20 min in a microplate reader. The slope of the 
absorbance increase of the control was set to 100%. Each measurement was done in duplicate. 
 
3.2.6.2 Cleavage of peptide CP5-46 by the NS3/4A protease 
To analyse if the peptide CP5-46 is cleaved by the NS3/4A protease 10 µM peptide was incubated 
with 1 µM protease for 16 hours at 30°C and the samples were analysed by LC/MS. LC/MS analysis 
was done by Dr. Raimo Franke (Department of Chemical Biology, HZI). The results are shown in 
Table 3-11. Almost no reduction of the peptide concentration was measurable after incubation with 
the protease and no cleavage fragments were found in the LC/MS spectra (data not shown). Therefore 
it can be assumed that the peptide is not cleaved by the NS3/4A protease. 
 
Table 3-11: Cleavage of peptide CP5-46 by the NS3/4A protease. 10 µM peptide in buffer M2235 were incubated with      
1 µM NS3/4A for 16 h at 30°C and analysed by LC/MS. Control: peptide without protease, NS3/4A: peptide with protease. 
	  
Area	  CP5-­‐46	  
[mAU	  x	  min]	   %	  
control	   8.187	   100	  
NS3/4A	   7.838	   95.7	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3.2.7 Structure-based optimisation 
To further optimise the inhibitory peptide CP5-46 crystallisation of the NS3/4A protease in complex 
with the peptide was attempted. The structure of the peptide-protease complex which can be obtained 
by X-ray defraction of such crystals should show the exact site and geometry of binding and allow 
identification of the atoms involved in the interaction. Molecular modelling can then be applied to 
identify potential amino acids exchanges that might improve the potency of the peptide as an 
inhibitor. 
 
3.2.7.1 Production of NS3/4A for crystallisation 
For crystallisation experiments the HCV NS3/4A protease was produced as a single chain construct 
similar to the MBP-NS3/4A protease. The NS3/4A protease needed to be produced without MBP 
fusion because the flexible linker region would hamper crystal formation due to the conformational 
heterogeneity (Smyth et al., 2003). 
For production of the protease the pET expression system (Novagen) was used. In pET vectors the 
cloned DNA is under the control of the bacteriophage T7 transcription and translation signals for 
strong expression. For PCR amplification the HCV replicon ‘I389/NS3-3'UTR’ which was 
constructed from the consensus sequence of genotype 1b isolate cDNA served as a template 
(Lohmann et al., 1999). The primer ‘primNS3/4A-pET’ and ‘primNS3/4a-pET-rev’, which 
introduced NcoI and XhoI restriction sites, the N-terminal NS4A peptide with the GG-linker and a C-
terminal His-Tag with a short linker were used. The protease insert was ligated into the 
dephosphorylated pET28c vector, which was had also been cut with the restriction enzymes NcoI and 
XhoI and transformed into E. coli Rosetta 2 cells. The NS3/4A protease was produced in soluble form 
at 18°C. IMAC purification was carried out with the Profinia protein purification system (Bio-Rad). 
For the first purification step a 5 ml IMAC affinity cartridge and a 50 ml desalting cartridge and for 
the second purification step a 1 ml / 10 ml cartridges were used. The protease in ‘Profinia Desalting 
Buffer 2’ was stored at -80 °C until usage. In Figure 3-32 the results of the production and 
purification are shown.  
	  
Figure 3-32: Production and purification of NS3/4A. 12% SDS-gel, M: molecular weight marker, BI: before induction, 
SI: soluble fraction after cell lysis (1:70), FT1: flow through 5 ml IMAC cartridge (1:10), W1-2: washing fractions 5 ml 
IMAC cartridge, E1: elution fraction 50 ml desalting cartridge, FT2: flow through 1 ml IMAC cartridge, W3-4: washing 
fractions 1 ml IMAC cartridge, E-2: elution fraction 10 ml desalting cartridge, 3 µl of each fraction were loaded onto the gel, 
except for the elution fractions: 1 µl. 
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Up to 8 mg NS3/4A protease could be purified from 2 L culture with a purity of > 90% as estimated 
from a SDS gel (see Figure 3-32). The concentration of purified NS3/4A was determined by UV 
spectroscopy at 280 nm and calculated with a theoretical molar absorption coefficient of ε280 = 18,450 
M–1cm–1 (Calculated with ProtParam, Gasteiger et al., 2005). Concentrations of about 90 µM (~2 
mg/ml) of NS3/4A could be obtained. 
The activity of the purified NS3/4A protease was tested with a fluorescence resonance energy transfer 
(FRET) assay (Taliani et al., 1996; Misialek et al., 2009). Figure 3-19 shows the results of both 
elution fractions. The NS3/4A protease of both fractions had the same specific activity as the MBP-
NS3/4A protease produced for affinity enrichment (see Figure 3-19: 1 nM wild type protease 20.6 
RFU/min). It was concluded that the protease is in a native active conformation and thus suitable for 
crystallisation studies. 
 
	  
Figure 3-33: Activity assay with NS3/4A protease. Assay was done in buffer M2235 with 5 µM substrate M-2235 
(Bachem) and 15 or 25 nM NS3/4A. Excitation filter: 360/40 nm, emission filter: 460/40 nm. Elu1ml: Elution fraction after 
IMAC purification with 1 ml affinity cartridge, Elu5ml: Elution fraction after IMAC purification with 5 ml affinity cartridge, 
control: 5 µM substrate M-2235 without NS3/4A protease, RFU: Relative Fluorescence Units. Equation of trend lines of the 
linear parts of the graphs are shown. 
 
3.2.7.2 Co-crystallisation of NS3/4A with CP5-46 and CP5-46-A 
Co-crystallisation experiments were done with the peptide CP5-46 and a truncated form CP5-46-A 
(see Table 3-12). 
 
Table 3-12: Peptides used for co-crystallisation experiments. 
Peptide	  name	   Sequence	   Ki[nM]	  
CP5-­‐46	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 5.2	  
CP5-­‐46-­‐A	   GELGRLVYLLDGPGYDPIHCD 57.3	  
 
The peptides were co-crystallised with NS3-4A in several screening conditions containing high salt 
such as NaCl, KCl or (NH4)2SO4. Crystals were obtained under several conditions although these 
were initially too small for X-ray diffraction measurement (see Figure 3-34 A). The conditions were 
optimised by stochastic optimisation and grid screening to a final condition with 0.1 M MES pH 6.0, 
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2.2 M KCl, 5% isopropanol (~100 µM NS3/4A, diluted with 0.1 M buffer, and ~500 µM peptide with 
a final molar ratio of protease and peptide of 1:5). Crystals for diffraction measurement could only be 
obtained for peptide CP5-46-A (see Figure 3-34 B).  
	  
Figure 3-34: A: initial crystals of CP5-46-A / NS3/4A complex. B: optimised crystal of CP5-46-A / NS3/4A complex. C: 
crystal packing of CP5-46-A / NS3/4A complex. Space group P61. NS3/4A: blue, CP5-46-A: red. 
The crystals diffracted to 2.1 Å and belonged to the hexagonal space group P61 with cell dimensions 
of a = b = 93.2 Å and c = 120 Å (see appendix Figure 7-9). The crystal packing of the complex is 
shown in Figure 3-34 C. X-ray diffraction measurements and model building was done by Dr. Stefan 
Schmelz (Department Molecular Structural Biology, HZI). 
In Figure 3-35 A and B the resolved structure of the NS3/4A single chain construct is shown. 
 
	  
Figure 3-35: Structure of the single chain NS3/4A protease. The NS3 protease domain (blue) is shown with modeled 
surface (A) or as ribbon structure (B). The NS4 peptide is shown as ribbon structure (orange). The red square (B) shows the 
linker region between NS4A and NS3 (Figures A and B made by Dr. Stefan Schmelz). 
Comparing to a previous crystal structure (Protein Databank code 1DXP) it was concluded that the 
NS3/4A protease was correctly folded. The N- and C-terminal sub-domains of NS3 formed two ß-
barrel structures with the NS4 peptide contributing an additional ß-strand to the N-terminal sub-
domain (Lin 2006). No electron density was observed for the flexible ‘GG’ linker between NS4A and 
NS3 (Figure 3-35 B, red square). 
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In Figure 3-36 A – D various views of the resolved structure of the peptide CP5-46-A bound to the 
NS3/4A protease are shown. 
 
 
	  
Figure 3-36: Structure of the bound peptide CP5-46-A (green) to the NS3 protease domain (blue) with NS4A cofactor 
(orange). The peptide is shown as stick structure with modeled surface and the NS3/4A protease is shown as ribbon 
structure with modeled surface. A – D: Views from different angles. (D) blue square: primed-site of the protease (S`), red 
square: active site region of the protease, green square: non-primed-site of the protease (S). 
Electron density for the amino acids 4 – 20 of the peptide could be measured. CP5-46-A binds to 
NS3/4A covering a large part of the protease surface. The active site is covered (see Figure 3-36 D, 
red square) and the peptide is coordinated at several positions on the non-primed and primed site of 
the protease (see Figure 3-36 D, green and blue square). 
In Figure 3-37 A – C the coordination of the peptide at the non-primed and primed site of the protease 
and the blocking of the active site are shown in detail. 
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Figure 3-37: Detailed views on the interactions of peptide CP5-46-A (green) with NS3/4A (blue). A: primed site of the 
protease with bound ‘proline’-finger motive, coordinated water molecules are shown as red dots. B: View on the active site 
of NS3/4A (blue) with bound peptide CP5-46-A (green). The side chains of the amino acids of the catalytic triad: S139, 
H57, D81 are shown as orange sticks. The distance between the S139 of the catalytic triad and the nearest peptide backbone 
(L9-L10) is shown in Å (red dashed line). H-bonds are indicated as grey dashed lines. C: non-primed site of the protease, 
peptide (green) forms ß-strand with backbone of the NS3/4A protease (blue) (Figures A and C made by Dr. Stefan Schmelz). 
 
The substrate binding pockets of proteases are termed subsites. Non-primed subsites are numbered  
Sn – S1 from the N terminus of the substrate to the scissile bond and primed sites S1` – Sn` towards 
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the C terminus. The substrate residues binding to the pockets are numbered P1 – Pn and P1` – Pn`, 
respectively (see section 1.1.4). The C-terminal part of the peptide CP5-46-A, which is located at the 
primed site of the protease, forms a ‘proline’-finger motive that binds to a pocket located next to the 
NS4A peptide (see Figure 3-37 A and Figure 3-39). The finger motive is coordinated by several 
hydrogen bonds and water molecules. His19 forms an intramolecular salt bridge with Asp11 
stabilizing the structure, but removal of Cys20 and His19 from the peptide has no influence on the 
IC50 value (see Table 3-10).  
The bound peptide covers the active site of the protease and the hydroxyl group of the Ser139 of the 
catalytic triad is over 3.3 Å away from the nearest peptide carbonyl carbon of Leu9 or Leu10 and 
therefore too far away for a nucleophilic attack (see Figure 3-37 B). The residues of the catalytic triad, 
namely Ser139, His57 and D81, are not directly affected by the binding of the peptide. The 
positioning of the side chain of His57 by D81 and the abstraction of a proton from Ser139 by His57 
are not disturbed. Protease residues Lys136 and Gly137 are forming two hydrogen bonds with the 
peptide residues Leu9 and Leu10 moving the peptide backbone away from the active site residues. 
Notably the backbone amide of Gly137 is part of the oxyanion hole (Kim et al., 1996). The S1` 
pocket can also bind larger side chains than that of the natural P1` residue Ser (Urbani et al., 1997). 
The larger side chain of peptide P1` residue Leu10 has an auxiliary effect on moving the peptide 
backbone away from the active site residues. 
The N-terminal part of the peptide, which binds to the non-primed site of the protease, forms an anti-
parallel ß-strand with the backbone of the NS3/4A protease (see Figure 3-37 C). Four hydrogen bonds 
are formed between the backbone amide and carbonyl group of protease residues Cys159 and Ala157 
and peptide residues Lys5 and Val7, respectively. Notably the same anti-parallel ß-strand is conserved 
between all protease substrates (Romano et al., 2010). In Figure 3-38 the comparison of binding of 
peptide CP5-46-A and substrate 4B5A is shown. In the region of the anti-parallel ß-strand the binding 
of the peptide and substrate backbone (Gly4 – Leu6) is similar. In the region of the active site the 
peptide backbone is shifted away from the active site residues as described above. 
 
	  
	  
Figure 3-38: Comparison of binding of peptide CP5-46-A (green stick model) and substrate 4B5A (blue stick model). 
NS3 protease domain is shown as blue ribbon structure. The side chains of active site residues: S139, H57, D81 are shown 
as orange sticks. Substrate 4B5A (SECTTPC, PDB ID 3M5N, Romano et al., 2010) was aligned with Pymol. 
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Notably the peptide CP5-46-A binds to regions of the substrate subsites S6 – S4` at the non-prime and 
prime region of the protease (see Figure 3-39). The anti-parallel ß-strand (R5 – V7) binds in the 
region of S5 – S3. In comparison to the natural substrate a negative charged amino acid at position P6 
is missing that could interact with Lys165 or Arg163. Amino acids Tyr7 – Pro13 bind to the regions 
of the subsites S2 – S4`. The ‘proline’-finger motive extends the binding of the peptide at the S` site 
of the protease to a region probably not occupied by the natural substrate. 
 
 
Figure 3-39: Structure of peptide CP5-46-A bound to the NS3/4A protease. The peptide is shown in stick representation 
with modelled surface. H-bond between H19 and D11 is indicated as grey dashed line. Location of the protease subsites are 
labelled with semi circles (positions from Ingallinella et al., 2000 and Ingallinella et al., 2002). 
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In Figure 3-40 the comparison of binding of peptide CP5-46-A and the peptidomimetic small 
molecule inhibitors boceprevir, TMC435 and ITMN-191 are shown.  
	  
	  
	  
	  
Figure 3-40: Comparison of binding of peptide CP5-46-A (blue stick model) and small molecule inhibitors boceprevir 
(yellow stick model, PDB ID 2OC8), TMC435 (brown stick model, PDB ID 3KEE) and ITMN-191 (green stick model, 
PDB ID 3M5L). A: Comparison of binding of TMC435 (brown stick model) and ITMN-191 (green stick model). B: 
Comparison of binding of boceprevir (yellow stick model) and ITMN-191 (green stick model). C: Comparison of binding of 
peptide CP5-46-A (blue stick model) and ITMN-191 (green stick model). D: Comparison of binding of peptide CP5-46-A 
(blue stick model) and boceprevir (yellow stick model). The residues binding to the protease subsites are indicated (P1` - 
P6). Structures were aligned with Pymol. 
The two macrocyclic inhibitors TMC435 and ITMN-191, which are both developed from BILN-2061, 
have a similar structure with an almost identical binding pattern to the NS3/4A protease (Figure 3-40 
A). Both inhibitors are bound at the active site, spanning the S3 – S1` subsites. A P1` cyclopropyl 
group binds to the S1` subsite of the NS3/4A protease. The P1 to P3 side chains are connected to a 
macrocycle. Both inhibitors have a large P2 substituent that binds to an extended S2 subsite. 
Additionally ITMN-191 has a P4 tert-butyl group that fits into the S4 subsite of NS3/4A (Cummings 
et al., 2010; Romano et al., 2010). The linear α-ketoamide inhibitor boceprevir binds to the S4–S1 
subsites of the NS3/4A protease and shows almost the same binding of the backbone compared to the 
macrocyclic inhibitors (Figure 3-40 B). The functional groups are positioned similar and the binding 
to the S1 and S3 subsites is achieved with similar atom types. The P4 tert-butyl group of boceprevir is 
identical to that of ITMN-191 and shows the same binding at the S4 subsite (Romano et al., 2010). 
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The peptide CP5-46-A has a different mode of binding than the small molecule inhibitors (Figure 
3-40 C and D). The peptide backbone has a similar geometric structure but is shifted away from the 
active side residues of the NS3/4A protease compared to the small molecule inhibitors. The side 
chains of the peptide residues P1` – P4 are similar to the functional groups of TMC435, ITMN-191 
and boceprevir. The P1` cyclopropyl group of TMC435 and ITMN-191 (see Figure 3-40 C) and the 
P1 cyclobutyl group of boceprevir (see Figure 3-40 D) are similar to the isopropyl side chains of 
Leu10 and Leu9, respectively. The functional groups are hydrophobic and the positioning in the 
protease subsites is very similar. The P3 functional groups of the small molecule inhibitors overlap 
closely with the P3 residue Tyr8 of the peptide and are also hydrophobic. The P4 tert-butyl group of 
the small molecule inhibitors is similar to the isopropyl side chain of the Leu6 residue of the peptide 
and is positioned similar in the S4 pocket. The same similarity is also seen for the functional group of 
the P3 residues of the peptide and boceprevir but the position of the bound side chains is different. 
 
3.2.7.3 Structure-based optimisation of peptide CP5-46-A 
Examination of the crystal structure of the complex, allowed a prognosis that exchanges at four 
positions for potential amino acid exchanges, might improve binding geometry and charge interaction 
between the peptide and the enzyme. It was envisaged that these could improve the inhibitory effect 
with respect to the peptide CP5-46-A:  
Leu10 binds in the S1` pocket of the NS3/4A protease; modelling of the surface area of the side chain 
showed that the pocket is not completely occupied by the amino acid side chain (see Figure 3-41 A). 
Leu10 was exchanged to Asp, Glu or Gln for potential interaction with the side chains of protease 
residues Gln41, His57 or with the backbone of Gly58. 
The S4 pocket is not fully occupied by the Leu6 residue (see Figure 3-41 B). An exchange of this Leu 
by Glu or Gln was suggested, which should allow a better potential interaction with the residues 
Arg155 or Arg123 of the NS3/4A protease. 
Comparison of the bound peptide to the bound substrate residues P1 – P6 of the cleavage site 4A4B 
(PDB ID 3M5M, Romano et al., 2010) revealed a similar binding of the peptide backbone and the 
substrate backbone of amino acids R5 and G6 of the peptide and P5-Glu and P6-Asp of the substrate 
4A4B (see Figure 3-41 C). Positions P5 and P6 are important for the binding of the substrate 4A4B 
because of electrostatic interactions with basic amino acids especially interaction of P6-Asp with 
Lys165 of the NS3/4A protease (Steinkühler et al., 1998; Koch et al., 2001; Romano et al., 2010). In 
order to imitate this binding it was proposed to exchange Gly4 to Asp4 and Arg5 to Glu5 mimicking 
the substrate 4A4B. 
In order to facilitate the chemical synthesis and later handling of the peptide, Cys20 which is not 
important for binding of the peptide, was changed to a Ser20 (see Figure 3-41 D). 
 
 
 
 
 
 
Results 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 3-41: Potential sites of peptide CP5-46-A (green) for improvement. A: Leu10 binds in the S1` pocket of the 
NS3/4A protease (blue). B: S4 pocket is not fully occupied by the Leu6 residue. C: similar binding of the peptide and the 
substrate 4A4B (red) of amino acids R5 and G6 of the peptide and P5-D and P6-E of the substrate. D: Cys20 is not 
important for binding of the peptide (Figures A, B and D made by Dr. Stefan Schmelz). 
All peptides with suggested amino acid exchanges were produced chemically and tested in the 
NS3/4A activity assay. The results of are summarised in Table 3-13 (see Figure 7-8). 
 
Table 3-13: Comparison of IC50 values of the CP5-46-A variants. 
Peptide	   Sequence	   IC50	  [nM]	  
CP5-­‐46-­‐A	   GELGRLVYLLDGPGYDPIHCD 124.0	  
CP5-­‐46-­‐A-­‐4D5E	   GELDELVYLLDGPGYDPIHS 22.8	  
CP5-­‐46-­‐A-­‐6D	   GELGRDVYLLDGPGYDPIHS 2.7	  µM	  
CP5-­‐46-­‐A-­‐6E	   GELGREVYLLDGPGYDPIHS >>	  1µM	  
CP5-­‐46-­‐A-­‐6Q	   GELGRQVYLLDGPGYDPIHS >>	  1µM	  
CP5-­‐46-­‐A-­‐10Q	   GELGRLVYLQDGPGYDPIHS >>	  1µM	  
CP5-­‐46-­‐A-­‐10E	   GELGRLVYLEDGPGYDPIHS >>	  1µM	  
 
Amino acid exchanges at position 10 totally abrogated the inhibitory effect of the protease. At 
position 6 exchanges to amino acids with longer side chains (Glu and Gln) diminished or abolished 
the inhibitory effect. An exchange to Asp at position 6 decreased the IC50 20-fold. Only the change at 
position 4 and 5 to the negative charged amino acids Asp and Glu increased the potency of the 
peptide about 6-fold to an IC50 of about 23 nM. 
The peptides with the amino acid changes 6E, 10Q and 10E were examined with respect to cleavage 
by the NS3/4A protease. 10 µM peptide was incubated with 1 µM protease for 16 hours and the 
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samples were analysed by LC/MS. LC/MS analysis was done by Dr. Raimo Franke (Department of 
Chemical Biology, HZI). Almost no reduction of peptide concentration was measurable after 
incubation with the protease and no cleavage fragments were found in the LC/MS spectra (data not 
shown). Therefore it can be assumed that the peptides are not cleaved by the NS3/4A protease. 
The optimised peptide CP5-46A-4D5E was co-crystallised with NS3-4A. One important question was 
whether or not the proposed ionic interactions between the peptide residues Glu5 and Asp4, especially 
the interaction between Asp4 and Lys165 of the NS3/4A protease, had in fact contributed to the 
observed increase of the inhibitory effect. The crystallisation conditions were optimised and crystals 
could be obtained with 0.1 M Na-citrate pH 5.1, 2.2M KCl, 5% isopropanol (~100 µM NS3/4A, 
diluted with 0.1 M buffer, and ~500 µM peptide with a final molar ratio of protease and peptide of 
1:5). The crystals diffracted to 2.8 Å and belonged to the space group P61. Diffraction measurements 
and model building was done by Dr. Stefan Schmelz (Department Molecular Structural Biology, 
HZI).  
In Figure 3-42 A and B the alignment of the structures of the peptides CP5-46-A (green) and CP5-
46A-4D5E (blue) bound to the NS3/4A protease are shown. 
	  
	  
Figure 3-42: Comparison of structure of peptide CP5-46-A (green) and CP5-46A-4D5E (blue) bound to the NS3/4A 
protease. A: Alignment of structures of the peptides CP5-46-A (green) and CP5-46A-4D5E (blue) bound to the NS3/4A 
protease; the peptides are shown in stick representation with modelled surface. B: Zoom on the non-prime sites of the 
peptides CP5-46-A (green) and CP5-46A-4D5E (blue) bound to the NS3/4A protease. C: Comparison of binding of N-
terminal part of the peptide CP5-46A-4D5E (blue) and the substrate 4A4B (yellow, PDB ID 3M5M). K165 of the NS3/4A 
protease is shown. 
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The alignment of the structures of peptides CP5-46-A and CP5-46A-4D5E bound to the NS3/4A 
protease shows that the binding of the optimised peptide is not altered by the change of the amino 
acids Gly4 to Asp4 and Arg5 to Glu5. The N-terminal part of the peptide still forms an anti-parallel ß-
strand with the backbone of the NS3/4A protease at the non-primed site of the protease and the C-
terminal part of the peptide forms a ‘proline’-finger motive at the primed site of the protease. 
The suggested ionic interactions between Asp4 of the peptide CP5-46A-4D5E and Lys165 of the 
NS3/4A protease have apparently not formed. The side chain of Asp4 points in the opposite direction 
away from Lys165 of the NS3/4A protease (see Figure 3-42 C). Notably the position of the backbone 
and side chain of Glu5 is similar to the binding of P5-Glu of the substrate 4A4B (PDB ID 3M5M, 
Romano et al., 2010) mimicking the binding of the substrate. 
 
The full-length peptide CP5-46 was produced as an MBP fusion protein with the acidic amino acid 
exchanges at position 4 and 5. The mutations were introduced with the primer ‘primCP5-46-4D5E 5`’ 
and the peptide produced as mentioned in section 3.2.3. The purified peptide was tested in the 
NS3/4A activity assay. The results are shown in Table 3-14 (see also Figure 3-47 A).  
 
Table 3-14: Comparison of IC50 values and Ki values of the peptides CP5-46 and CP5-46-4D5E. 
Peptide	   Sequence	   IC50	  [nM]	   Ki	  [nM]	  
CP5-­‐46	   GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 11.3	  ±	  1.6	   5.2	  ±	  0.75	  
CP5-­‐46-­‐4D5E	   GELDELVYLLDGPGYDPIHCDVVTRGGSHLFNF 1.14	  ±	  0.053	   0.53	  ±	  0.02	  
 
The introduction of the amino acid exchanges Asp4 and Glu5 improved the IC50 value of the full-
length peptide 10-fold to 1.14 nM with a Ki of about 530 pM.  
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3.2.8 NS3/4A protease resistance mutation A156V 
An important problem of new protease inhibitors in development is the rapid emergence of resistant 
variants. Because of the low viral polymerase fidelity and the high viral yield, huge numbers of novel 
variants are produced constantly (Gaudieri et al., 2009). Monotherapy with different protease 
inhibitors leads to the rapid selection of resistant protease variants. Amino acids associated with 
resistance mutations against protease inhibitors are shown in Figure 3-43.  
 
	  
Figure 3-43: Resistant mutations of the NS3/4A protease. The peptide CP5-46-A is shown as stick structure with 
modeled surface (green), the NS3 domain (grey) and NS4A (orange) are shown as ribbon structure. Amino acids of NS3 that 
are known to be involved in resistance mutations against protease inhibitors are shown as purple sticks. For R155 two 
possible rotamers are shown. 
Several amino acids of NS3 that are involved in resistance mutations against protease inhibitors are in 
proximity of the bound peptide CP5-46-A: Q41, F43, A156, V158 and D168 (see Figure 3-44). 
 
 
Figure 3-44: Resistance mutations in proximity to the peptide CP5-46-A (green). Amino acids of NS3 that are known to 
be involved in resistance mutations against protease inhibitors and are in proximity to the peptide CP5-46-A are shown in 
purple. Stick presentation with modeled surface. 
Especially A156 is totally covered by the modelled surface of the peptide and in direct contact. A 
mutation at this position could have the highest impact on the inhibitory potency of the peptide. 
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Chemically related inhibitors share a similar resistance profile with resistance mutations at the same 
positions. The resistance mutation A156V has the greatest impact on the activity of both compound 
groups, the linear α-ketoamide inhibitors and the macrocyclic inhibitors (see Table 3-15, Lenz et al., 
2010). 
 
Table 3-15: Effect of NS3 mutation A156V. Fold change in the EC50 for the mutant replicon compared to that for the 
wild-type replicon (Lenz et al., 2010). 
Inhibitor	   Fold	  change	  
TMC435	   2149	  
BILN-­‐2061	   2085	  
ITMN-­‐191	   63	  
Boceprevir	   75	  
Telaprevir	   112	  
 
It was thus of primary interest to investigate the effect of the peptide CP5-46-4D5E on known 
resistant HCV NS3/4A mutations, in particular A156V. It is noted again here that it had been a 
primary intention in developing longer peptides as inhibitors to have inhibitors which might provide 
an alternative binding mechanism to the small molecular weight inhibitors in development. In Figure 
3-45 the A156V mutation was modelled and the three possible rotamers are shown.  
 
	  
	  
Figure 3-45: Model of the resistance mutation A156V. The peptide is shown as stick structure with modeled surface 
(green) and the protease is shown as ribbon structure (grey). A: the aa A156 in stick presentation with modeled surface is 
shown in purple. B, C and D: modeled mutation of A156 to V, the three possible rotamers are shown. 
The Val occupies much more space then the previous Ala and should interfere with the binding of the 
peptide because of a steric clash between Y8 (of the peptide inhibitor) and V156. 
The point mutation for mutation of Ala156 to Val was inserted by site directed mutagenesis. The 
complementary primer ‘mutA156V’ and ‘mutA156V-rev’ with the point mutation were used for 
A156	  
A156V	   A156V	   A156V	  
A	  
B	   C	   D	  
Y8	  
Y8	  
Y8	  
Y8	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linear amplification of the pMAL-c4E vector with NS3/4A single chain construct (see 3.2.1). After 
amplification the methylated template DNA was digested with DpnI and the amplified vector was 
transformed into E. coli Top10 F´cells.  
A number of isolated clones were sequenced and the presence of NS3/4A genes with the A156V 
confirmed. The MBP-NS3/4A A156V fusion protein was produced in soluble form at 30°C. The 
protease was purified by IMAC and the buffer of the elution fraction was exchanged with the use of 
centrifugal filter units with 10 kDa cut off. The protease was stored at -80°C until usage. The protease 
could be produced and purified in suitable amounts and purity (see appendix Figure 7-10). 
The concentration of purified NS3/4A A156V was determined by densitometric measurement of the 
coomassie stained protein bands and comparison to a MBP standard. A concentration of about 3 
mg/ml of MBP-NS3/4A A156V could be obtained. 
The activity of the purified NS3/4A protease was tested with the NS3/4A activity assay (Taliani et al., 
1996; Misialek et al., 2009). Figure 3-46 shows the results for two protease concentrations. The 
NS3/4A A156V protease had the same specific activity as the wild type protease (see Figure 3-19: 1 
nM wild type protease 20.6 RFU/min). 
 
 
Figure 3-46: Activity assay with mutant MBP-NS3/4A protease A156V. Assay was done in buffer M2235 with 5 µM 
substrate M-2235 (Bachem) and 1 nM or 2 nM NS3/4A A156V. con: control without protease. Excitation filter: 360/40 nm, 
emission filter: 460/40 nm, RFU: Relative Fluorescence Units. Equation of trend lines are shown. 
 
The optimised peptide CP5-46-4D5E was tested with the NS3/4A protease with the resistance 
mutation A156V. The results of the activity assay are shown in Figure 3-47 B. 
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Figure 3-47: Determination of the IC50 of peptide CP5-46-4D5E using the wild type NS3/4A (A) or NS3/4A mutant 
A156V. Activity assay was done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 0.5 nM NS3/4A. Peptide 
CP5-46-4D5E produced as MBP fusion protein with His-Tag. Excitation filter: 360/40 nm, emission filter: 460/40 nm. 
Velocity of fluorescence increase over one hour was compared to that of the NS2-K11 control peptide. Each measurement 
was done in duplicate, IC50 in nM. The curve was fitted with GraphPad Prism using a nonlinear regression model with 
variable slope and normalised response: Y=100/(1+10^((LogIC50-X)*slope)). 
Compared to the wild type protease (Figure 3-47 A) the IC50 value changes from 1.14 nM to about 
1.65 nM. This corresponds to a 1.5-fold increase (see Table 3-16). Compared to the other NS3/4A 
inhibitors (see Table 3-15) the peptide shows negligible susceptibility to the A156V mutation. 
 
Table 3-16: Effect of NS3 mutation A156V on peptide CP5-46-4D5E. Fold change (FC) in the IC50 for the mutant 
NS3/4A protease compared to that for the wild-type (wt) protease. 
Protease	   IC50	  [nM]	   FC	  
NS3/4A	  wt	   1.14	  ±	  0.047	   	  
NS3/4A	  A156V	   1.65	  ±	  0.248	   1.5	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3.3 Intracellular delivery of inhibitory peptides 
The inhibitory peptides against the NS3/4A protease target an intracellular enzyme. Therefore they 
have to cross the plasma membrane to reach their site of action. Because of the highly selective 
permeability of cell membranes to macromolecules, methods designed for membrane permeability 
were assayed for their suitability for cell delivery of the peptide inhibitors described above. The 
intracellular delivery of inhibitory peptides was attempted using fusion of the peptide to cell 
penetrating peptides (CPP) and via encapsulation into polymersomes. 
 
3.3.1 Intracellular delivery of peptides using cell penetrating peptides 
CPPs are short peptides that can traverse the cell membrane and thereby deliver a cargo into 
eukaryotic cells (Schwarze et al., 2000). For peptide delivery several CPPs have been described in the 
literature and were tested for their suitability to transfer the inhibitors described. These include 
cationic CPPs: HIV-Tat peptide (Green and Loewenstein, 1988), the Antennapedia peptide (Joliot et 
al., 1991) and the nona-arg peptide. Also an amphipathic peptide, the PTD-5 peptide, was tested (see 
Table 3-17). 
 
Table 3-17: Peptides (black) fused to cell penetrating peptides (blue) used for cell delivery.
Peptide	  name	   Sequence	  
Ant-­‐K5-­‐66-­‐A	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPI 
Tat-­‐K5-­‐66-­‐A	   GRKKRRQRRRPPQGELGRLVYLLDGPGYDPI 
Nona-­‐arg-­‐K5-­‐66-­‐A	   RRRRRRRRRGELGRLVYLLDGPGYDPI 
PTD-­‐5-­‐K5-­‐66-­‐A	   RRQRRTSKLMKRGELGRLVYLLDGPGYDPI 
Ant-­‐CP5-­‐46	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF 
Ant-­‐CP6-­‐4	   RQIKIWFQNRRMKWKKGELGRLVYLLDGPGYDPIHCFPIYSRGSYASYV 
CPP-­‐Control	  1	   RLIFAGKQLEDGRGELGRVYLLDGPGYDPI 
CPP-­‐Control	  2	   RQIKIWFQNRRMKWKKYVGIPRDLGLDGYEPLG 
 
All CPP-peptide fusions were chemically synthesised and inhibition of viral replication in cell culture 
was tested with the replicon assay using the HCV Con1 replicon ‘i341 PiLuc/3-3´/ET’ (Lohmann et 
al., 2003) which was constructed from the consensus sequence of genotype 1b isolate cDNA. For 
measurement of HCV replication a fire-fly luciferase gene was inserted in the replicon. The luciferase 
activity reflects the HCV RNA level in the cells and is therefore a measure of viral replication. The 
assay was done in Huh7-Lunet cells which have a gaussia luciferase gene in their genome that can be 
used for a cell viability assay. The cell culture replicon assay was performed by Juliane Gentzsch 
(Department of Experimental Virology, Twincore, Hannover) with the synthetic peptides described in 
Table 3-17. The peptide K5-66-A was chosen for initial tests with different CPPs. The results of the 
replicon cell culture assay are shown in Figure 3-48 A – F. 
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Figure 3-48: Inhibition of viral replication in cell culture using various peptides. Replicon pFK i341 PiLuc/3-3´/ET 
(Lohmann et al, 2003). Luciferase assay after 48h, luciferase activity compared to water control. Black triangle: Firefly 
luciferase activity that reflects replication of Con1 replicon, white square: Gaussia luciferase activity that reflects cell 
viability. A: Control 1: peptide K5-66-A with 13 aa N-terminal ubiquitin fusion, B: Control 2: scrambled peptide K5-66-A 
sequence with Antennapedia-peptide fusion. Each measurement was done in duplicate. 
The first control peptide K5-66-A with an N-terminal ubiquitin fusion showed no inhibition of the 
viral replication. Also no decrease in the cell viability was detectable (Figure 3-48 A). Interestingly 
the scrambled control peptide with Antennapedia peptide fusion showed an inhibitory effect at 20 
µM. A peptide concentration of 100 µM started to be toxic for the cells (Figure 3-48 B). A fusion of 
K5-66-A to the Tat peptide or nona-arg peptide showed only a low inhibition of viral replication at 20 
E	   F	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µM and started to be toxic at higher concentration (Figure 3-48 D and E). A PTD-5-K5-66-A fusion 
showed no inhibitory effect or toxicity (Figure 3-48 F). The highest inhibition of replication was 
exhibited by the N-terminal fusion of the Antennapedia peptide. At a concentration of 20 µM an 
almost two log reduction of viral replication was detectable but the peptide fusion started to become 
slightly toxic (70% cell viability compared to control) (Figure 3-48 C). The EC50 value of the Antp-
K5-66-A peptide is about 3.4 µM (see Figure 3-49). Compared to the IC50 value of the NS3/4A in 
vitro assay (125 nM) this corresponds to a 27-fold increase.  
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Figure 3-49: Inhibition of viral replication in cell culture using peptide Antp-K5-66-A. Determination of the IC50 of 
peptide Antp-K5-66-A. Replicon pFK i341 PiLuc/3-3´/ET (Lohmann et al, 2003) luciferase assay after 48 h, luciferase 
activity compared to water control. Each measurement was done in duplicate, EC50 in µM. The curve was fitted with 
GraphPad Prism using a nonlinear regression model with variable slope: Y=Bottom+(Top-Bottom)/ (1+10^((LogEC50-
X)*slope)). *: cell viability decreased to 70%. 
The Antennapedia peptide seems to be the most promising CPP for intracellular delivery. Therefore it 
was fused to the full length peptides CP5-46 and CP6-4 and the fusion peptides were tested in the 
replicon cell culture assay. The results are shown in Figure 3-50 A and B. 
 
Figure 3-50: Inhibition of viral replication in cell culture using peptides Antp-CP5-46 and Antp-CP6-4. Replicon pFK 
i341 PiLuc/3-3´/ET (Lohmann et al, 2003). Luciferase assay after 48 h, luciferase activity compared to water control. Black 
triangle: Firefly luciferase activity that reflects replication of Con1 replicon, white square: Gaussia luciferase activity that 
reflects cell viability. A: Antennapedia-peptide CP5-46-peptide fusion. B: Antennapedia-peptide CP6-4-peptide fusion. 
The Antennapedia peptide CP5-46 and CP6-4 fusions have a lower inhibitory effect than the K5-66-A 
peptide in the replicon cell culture model. At a concentration of 20 µM a reduction of viral replication 
* 
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to about 20 to 30% was detectable compared to a reduction to about 1% of the K5-66-A peptide. At 
100 µM both fusion peptides started to become toxic 
 
3.3.2 Intracellular delivery of peptides using polymersomes 
Polymersomes are nanoparticles that consist of a pH-sensitive copolymer which self assembles and 
forms vesicles in nanometer size at a pH higher than 6.5. They are internalised by cells via 
endocytosis. Acidification of the early endosomes leads to disaggregation of the polymersomes. 
Because of the abrupt local change in osmotic pressure caused by this, pores are formed in the 
endosomal membrane and the cargo is released into the cytosol (Massignani et al., 2009; Massignani 
et al., 2010). 
The peptide CP5-46-A and a scrambled control peptide were packaged into polymersomes for 
intracellular delivery (see Table 3-18).  
 
Table 3-18: Peptides used for packaging into polymersomes. 
Peptide	  name	   Sequence	  
CP5-­‐46-­‐A	   GELGRLVYLLDGPGYDPIHCD 
Control	   GELGRDIGGPLDLYPVDLHCY 
 
The packaging was done at the laboratory of Dr. Giuseppe Battaglia (Department of Biomedical 
Science, University Sheffield, UK) who kindly assented for me to learn this novel technology in his 
lab. Both peptides could be encapsulated into polymersomes with a final concentration of about 6.3 
µM and a polymer concentration of about 2 mg/ml as quantified by HPLC. The polymersome size 
distribution determined by dynamic light scattering ranged from 50 – 600 nm with an average size of 
200 nm (see Figure 3-51 A and B). 
 
 
	  
Figure 3-51: Size distribution of polymersomes determined by dynamic light scattering in nm. A: Size distribution of 
polymersomes with encapsulated peptide CP5-46. B: Size distribution of polymersomes with encapsulated control peptide. 
Inhibition of viral replication in cell culture by the polymersomes was tested with the replicon assay 
assay using the HCV Con1 replicon ‘i341 PiLuc/3-3'/ET’. For quantification of HCV replication a 
firefly luciferase gene was inserted in the replicon. The luciferase activity reflects the HCV RNA 
amount in the cells. The assay was done in Huh7-Lunet cells which have a gaussia luciferase gene in 
A	   B	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their genome for measurement of cell viability. The cell culture replicon assay was done by Juliane 
Gentzsch (Department of Experimental Virology, Twincore, Hannover). The polymersomes were 
added to the cells at three different peptide concentrations: 3, 1.5 and 0.3 µM (1:2, 1:4 and 1:10 
dilution, respectively). In Figure 3-52 the results of the replicon cell culture assay are shown. 
 
Figure 3-52: Inhibition of viral replication in cell culture using polymersomes. Replicon pFK i341 PiLuc/3-3´/ET 
(Lohmann et al, 2003). Luciferase assay after 48 h, luciferase activity compared to water control. Black triangle: Firefly 
luciferase activity that reflects replication of Con1 replicon, white square: Gaussia luciferase activity that reflects cell 
viability. A: control peptide encapsulated in polymersomes. B: peptide CP5-46-A encapsulated in polymersomes. 
No inhibition of the viral replication was measurable for the peptide CP5-46-A and the control 
peptide. Notably an increase of the viral replication was detectable upon addition of polymersomes 
that was concentration dependent. At the highest polymersome concentration and dilution of the cell 
culture medium (2 mg/ml and 1:2 dilution) the polymersomes started to become toxic (Figure 3-52 A 
and B). It is assumed that the intracellular peptide delivery was not very efficient. 
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4. Discussion 
It is estimated that worldwide up to 170 million people are chronically infected with HCV (Yu and 
Chiang, 2010). The standard of care achieves a sustained viral response in only about half of the 
patients treated and is associated with considerable severe side effects (Manns et al, 2001; Fried, 
2002). HCV infection is the leading cause of liver cirrhosis and hepatocellular carcinoma (Shepard, 
2005). Thus there is a huge unmet need for direct anti-HCV drugs for more effective treatments with 
fewer side effects. The viral proteases, the NS2-3 and NS3/4A proteases, essential for the viral life 
cycle, are interesting targets for new specific HCV drugs. A combinatorial phage display peptide 
library displaying large peptides is described in this thesis and how it was used for iterative affinity 
enrichment on these immobilised HCV proteases for development of inhibitory peptides against the 
HCV proteases. In the latter stages of optimisation of the peptides as inhibitors, X-ray crystallography 
and structural modelling were successfully implemented. This endeavour was undertaken with the 
intention that the products developed, or their derivatives can either be confectioned to be of use for 
future treatment of HCV, especially in combatting development of spontaneous viral resistance to 
drugs or at the very least to deliver novel lead structures for further structure-based drug design which 
are not simply based on geometric fit into the active site of the enzymes. 
 
4.1 NS2-3 protease 
The NS2-3 protease is responsible for the intramolecular cleavage between the non structural proteins 
NS2 and NS3. It is a cysteine autoprotease with the active site residues entirely located in the NS2 
protein (Grakoui, 1993; Lorenz et al., 2006). Two NS2 monomers form a dimeric cysteine 
autoprotease with two composite active sites. After intramolecular cleavage between NS2 and NS3 
the protease is inactivated. For the full activity of NS2-3 protease not only the C-terminal part of NS2 
but also the N-terminal part of the NS3 protein that encompasses the NS3 serine protease domain with 
the Zn2+ binding site is necessary (Thibeault et al., 2001; Pallaoro et al., 2001). Although there are 
few NS2-3 protease inhibitors the only ones known act indirectly by disrupting the conformation of 
the uncleaved NS2-3 protease. Because of the essential role of the NS2 protein for the viral life cycle 
peptides that directly inhibit NS2-3 protease cleavage and/or dimer formation would be interesting for 
the development of new specific HCV drugs.  
 
4.1.1 Affinity selection against NS2-3 protease 
The NS2-3 protease was produced by recombinant expression in E. coli to be applied for affinity 
enrichment of ligands, which were then to be screened for their inhibitor activity. It was produced 
with an N-terminal MBP fusion for later immobilisation. The protease could not be produced in a 
native active form because soluble expression of NS2-3 protease results in auto-cleavage during 
production (data not shown and Pallaoro et al., 2001). Therefore, it was necessary to produce the 
NS2-3 protease in an insoluble form and to refold it to a native active state. For refolding known 
buffer conditions were used under which the protease refolds but undergoes no self-processing 
(Pallaoro et al., 2001). After refolding of the protease the intramolecular cleavage was induced by 
dilution into a cleavage buffer. After optimisation of the cleavage buffer processing of about 50% of 
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the NS2-3 protease was detectable. The cleavage buffer could be optimised to a simpler formulation 
with less detergent, glycerol and additives that could interfere during the affinity selection. 
Interestingly cleavage buffer formulations described in the literature all contain detergent 
concentrations above the critical micelle concentration (CMC) for optimal cleavage of NS2-3 
(Thibeault et al., 2001; Pallaoro et al., 2001). The detergent concentration used in the optimised 
cleavage buffer (0.05% Tween 20) is below the CMC (0.1%). It is proposed that the NS2-3 protease 
is associated with cellular membranes (Lorenz et al., 2006) and aggregation of the protease is avoided 
by binding of the detergent to the transmembrane segments. At detergent concentrations below the 
CMC most membrane proteins tend to be insoluble (Le Maire et al., 2000). The maltose binding 
protein is known to increase the solubility of the fusion partner by prevention of aggregation (Kapust 
and Waugh, 1999). Therefore the lower detergent concentration that was necessary for efficient 
cleavage of the NS2-3 protease could be due to additional stabilisation and solubilisation effects of 
the MBP fusion. The less efficient processing of NS2-3 protease at higher protease concentrations is 
correlated with aggregation observed at protein concentrations above 200 nM (Pallaoro et al., 2001). 
About 50% of the NS2-3 protease remained unprocessed after incubation in cleavage buffer. This 
may be a natural phenomenon characteristic of the enzyme, although processing of up to 70% of 
refolded protease is described (Pallaoro et al., 2001). However, it can be assumed that some of the 
protease is not correctly refolded perhaps due to impurities after purification that interfere with the 
refolding process or due to sub-optimal refolding and cleavage conditions. Binding tests of the 
refolded MBP showed that the refolding of the MBP is almost complete. Therefore, if there is also 
incorrectly refolded NS2-3 it will also be immobilised, which could lead to unspecific binding of 
peptides. 
Pallaoro and coworkers showed that after refolding under mildly denaturating conditions the NS2-3 
protease is not active, but can however, already form dimers. It is thus concluded that the refolded 
NS2-3 protease used for the affinity enrichment could also contain refolded NS2-3 dimers. An NS2 
monomer consists of two subdomains connected by an extended linker and has probably a very 
flexible structure, which is stabilised after dimer formation. The active site is formed after dimer 
formation of two NS2 monomers (Lorenz et al., 2006). NS2 monomers are targets for peptides that 
interfere with dimer formation and NS2 dimers are targets for peptides that bind to the composite 
active site and prevent cleavage. Also the NS3 serine protease part, which is important for correct 
folding of the NS2 protein and positioning of the NS2 active site, can be a target for peptides that 
interfere with intramolecular coordination. These various targets are showing the lack of a confined 
dominant binding site. 
During the panning with the peptide phage display library CPL19YS-2 the amount of immobilised 
NS2-3 protease was kept constant and the stringency of the washing conditions was not increased 
over five panning rounds. If peptides are enriched during panning an increased ratio of eluted and 
added phage after each panning round would be expected. For the panning against the NS2-3 protease 
the ratio increased from the first to fifth panning round which is a sign of enrichment of peptides. 
Sequencing of several peptide coding sequences after the 3rd, 4th and 5th panning round confirmed the 
enrichment of peptides. Four peptides showed an enrichment after the 5th panning round, of which 
three were also identified after the 4th panning round and one also after the 3rd panning round. A 
significant enrichment of peptides was first seen after the 4th panning round with six enriched 
peptides. A comparison of their sequences did not reveal any obvious homology or common structural 
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consensus motif. This variety of different peptides indicates the lack of a confined dominant binding 
site. This may be due to the actual nature of the protease which can bind peptides on various parts of 
its surface with similar affinity or it could additionally or solely be due to the heterogeneity of the 
NS2-3 protease species created by partial refolding, misfolding or dimer formation offering many 
different possible binding sites for peptides. After the 5th panning round two peptides were more 
strongly enriched. Also no ‘junk’ clones with deletions or frame shifts within the peptide-coding 
region were observed. Such ‘junk’ clones would be a sign for unspecific enrichment of clones with 
faster propagation which are often observed accumulating in the absence of specific enrichment of 
truly affine specific clones (Collins, 1997).  
Specific binding of the enriched peptides of the 5th panning round to the NS2-3 protease was analysed 
by phage ELISA and showed that only two of the four peptides bind specifically to the NS2-3 
protease. The peptides with the highest enrichment in the 5th panning round both bind specifically to 
the NS2-3 protease but it is unclear whether or not the peptides bind to the NS2-3 monomer or NS2-3 
dimer. The other two peptides bind strongly to the MBP or the anti-MBP IgG thus partly explaining 
the lack of similarity between the enriched sequences.  
The enriched peptides do not show a definite homology in their sequence. Both sequences are 
hydrophobic at the N-terminal and C-terminal ends. Hydrophobic amino acids are over represented in 
these variable regions (Pollmann, 2010). Interestingly both peptides could form potential disulfide 
bridges with a loop length of six amino acids (peptide E11) or four to six amino acids (peptide E17). 
These disulfide bridges could stabilise a secondary structure of the peptides. 
To test if the peptides that bind to the NS2-3 protease also inhibit cleavage of the protease the 
peptides were produced without fusion to the M13 phage. An N-terminal fusion to the Antp peptide 
was used to both increase the solubility of the peptides and could potentially serve for cellular 
delivery of the peptides. An increase in the molecular weight of the peptide can be important for 
protection of the peptides from proteolytic degradation in serum (Li, 2009). Despite the fusion to the 
hydrophilic Antp the peptides aggregated after expression forming insoluble ‘inclusion bodies’. 
Aggregation of the peptides occurred presumably because of the hydrophobicity of the peptides. The 
peptides were purified under denaturing and reducing conditions disrupting the secondary structure 
and possible disulfide bridges of the peptides. The yield of purified peptide fluctuated from one 
preparation to the next. It was observed that an unwanted E. coli protein was co-purified, in the case 
of the Ant-K17 peptide reducing the purity to 55% of total protein. 
 
4.1.2 Inhibition of NS2-3 activity 
The inhibitory effect of the peptides on NS2-3 protease cleavage was tested in a protease activity 
assay. For the activity assay denatured NS2-3 protease was refolded in cleavage buffer in the presence 
of the peptide. Prior refolding of the NS2-3 protease was not used for the activity assay because it is 
known that the protease can form dimers after refolding (Pallaoro et al., 2001). Therefore inhibition 
of dimer formation would not have been detectable. The peptide Ant-K5-66 which is known to bind 
to the NS3/4A protease was used as a control to see if there is an effect on the refolding of the NS2-3 
protease. The control peptide reduced the cleavage of NS2-3 protease to about 80% compared to the 
control without peptide, i.e. a reduction of 20%. This could be due to interference in the refolding 
process, possibly leading to misfolded protease that is not active. The peptide E11 has less of an effect 
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on the protease activity indicating no impact of the peptide on dimer formation or protease cleavage. 
The peptide E17 showed a higher reduction of the protease activity to 60% compared to the control 
without peptide. This could be due to inhibition of the NS2-3 dimer formation or to blocking of the 
active site. In direct comparison to the peptide K5-66 the protease processing is reduced to about 70% 
and the inhibition is concentration dependent with an inhibitory effect at concentrations higher than 
90 nM. The inhibitory effect of the peptide E17 is quite low with an IC50 higher than 300 nM. 
However, the peptide could be a starting point for the development of peptides with a higher 
inhibitory effect, e.g. with the cosmix plexing technology.  
The inhibition of protease cleavage diminishes for the peptide K17 when refolded NS2-3 protease 
was used for the activity assay. These results could indicate that the peptide K17 inhibits the dimer 
formation of the NS2-3 protease. Little is known about the kinetics of dimer formation and cleavage 
velocity of the NS2-3 protease. If the cleavage occurs directly after dimer formation, the addition of 
the peptide after refolding of the protease could be too late for the binding of the peptide to the active 
site and inhibition of cleavage. It should be noticed that the peptide E17 prep contained the highest 
level of contamination by unwanted protein. These impurities could also have an effect on NS2-3 
refolding and could account for some of the inhibitory effect of the peptide. This does not appear to 
be the case since the same impurities do not increase the inhibitory effect of the peptide E11 peptide 
(about twice as much protein contaminants compared to the purified control peptide Antp-K5-66). 
The assay was performed under reducing conditions which prevent formation of disulfide bridges that 
could be important for the peptide structure and possibly compromise the inhibitory effect of the 
peptide. 
Besides the essential role in HCV polyprotein processing, the NS2 protein is a key organiser for viral 
assembly (Jirasko et al., 2010), is important for evasion of the immune system (Kaukinen et al., 2006) 
and inhibition of apoptosis (Machida et al., 2001). This opens the possibility that peptides binding to 
the NS2 protein could interfere with the viral life cycle at one of these other steps without inhibiting 
the protease function. If the cell delivery of the peptides is accomplished they could be tested in the 
cell-based infectious HCV assay which is decisive in evaluating the effect of the peptides E11 and 
E17 on the NS2 protein. This would be a valuable extension to purely in vitro enzyme assays 
performed to date. 
 
4.2 NS3/4A protease 
The HCV NS3 protein is a bifunctional enzyme that consists of two domains, an N-terminal serine 
protease domain and a C-terminal helicase/ATPase domain. The NS3 protease is essential for 
polyprotein processing (Yao et al., 1999). It is a chymotrypsin-like serine protease and forms a 
heterodimeric complex with the NS4A protein which is a cofactor of the NS3 protease domain 
enhancing the proteolytic activity (Lin et al., 1995). The shallow and solvent exposed substrate 
binding pocket made it difficult to identify specific inhibitors of HCV NS3/4A protease (Kim et al., 
1996). The finding that the protease is inhibited by peptides corresponding to the C-terminus of the 
cleavage products led to the development of first protease inhibitors (Ingallinella et al., 1998; 
Lamarre et al., 2003). This product-based drug design was used for the development of the two α-
ketoamide inhibitors, telaprevir (Vertex Pharmaceuticals) and boceprevir (Merck) which were 
approved in 2011 (Poordad, 2011). Most of the new protease inhibitors are bound at the active site of 
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the NS3/4A protease, spanning only the S4–S1` subsites and thus showing a similar binding pattern 
and resistance profile. The newly developed drugs can only be used as supplement to the current 
treatment because of the high mutation rate during HCV replication which leads to rapid development 
of resistance to the drugs. Treated patients will be exposed to the same side effects as before (Gentile 
et al., 2010). Large peptides might provide an alternative binding mechanism to the small molecular 
weight inhibitors in development. These might be a priori binding at alternative sites and/or because 
of their larger interactive surface be less affected by HCV resistance mutations at the substrate 
binding site (see below for indications that this seems to be the case for the NS3/4A peptide protease 
inhibitors developed here). 
 
4.2.1 Affinity selection against NS3/4A protease 
For affinity enrichment the NS3/4A protease was produced by recombinant expression in E. coli. A 
single chain form of the NS3 protease domain linked to the NS4A cofactor peptide was produced 
according to Dimasi and co-workers. The correct folding of the NS3/4A single chain protein was later 
confirmed by solving the crystal structure of the protease. The MBP fusion showed no effect on the 
activity of the protease compared to a NS3/4A construct without fusion. Interestingly the MBP 
protein strongly increased the solubility of the NS3/4A single chain construct. The MBP-NS3/4A 
could be produced at 30°C in high amounts and in soluble form whereas the NS3/4A protease without 
fusion was mostly found in insoluble form even when produced in cells grown at 18°C (data not 
shown). 
For affinity enrichment the peptide phage display library CPL19YS-2 was used. The N-terminal and 
C-terminal parts of the library peptides are separated by the constant ‘HC’ motive in the middle of the 
library peptide. Various immobilisation strategies for the NS3/4A protease and a number of panning 
conditions were used. To avoid enrichment of peptides that bind to the immobilisation matrix it was 
tried in the first panning series to change the immobilisation strategy after each panning round. Anti-
MBP magnetic beads and amylose magnetic beads were used in alteration for immobilisation but due 
to the low binding affinity of the MBP to the amylose in the micromolar range (Miller et al., 1983) 
the fusion protein started to ‘bleed out’ from the amylose beads during the incubation with the peptide 
phage (data not shown). Therefore for later pannings only anti-MBP magnetic beads or 
immobilisation in MTPs over anti-MBP IgG were used. Panning experiments with panning buffers 
with physiological salt concentration (~140 mM) did not lead to the enrichment of peptides. For the 
binding of the NS3/4A substrates or for the binding of known peptide inhibitors ionic interactions are 
important. A high ionic strength in the buffer weakens these interactions, especially the P5 and P6 
interactions, which leads to an increase of the Km of the substrates or IC50 of inhibitors (Ingallinella et 
al., 1998). Therefore, the affinity enrichment was done in a buffer with a low ionic strength to 
strengthen the possible ionic interactions of peptides and protease. Interestingly only the panning in 
MTPs with low ionic strength buffer led to enrichment of peptides demonstrating the importance of 
both immobilisation method and panning condition for the outcome of the affinity enrichment. The 
reduction of the ionic strength led to the strong enrichment of two peptides, one with acidic elution 
(K5-66) and one with competitive elution (K6-10). 
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4.2.2 Inhibition of NS3/4A activity 
To test the inhibitory effect of these peptides in the in vitro NS3/4A activity assay the peptides were 
produced with an N-terminal MBP fusion and C-terminal His-Tag. Therefore the peptides had no free 
N- and C-terminus. The peptides could be produced in soluble form and in high amounts with the 
MBP fusion. The comparison with a chemically synthesised peptide showed that the N- and C-
terminal extensions had no influence on the inhibitory effect of the peptide. 
The peptides, K5-66 and K6-10, showed competitive binding with the NS3/4A inhibitor N-1725 
(Bachem) in a phage-ELISA experiment. This result gave a first hint that the peptides could bind at 
the same epitope of the NS3/4A protease as the inhibitor which binds at the subsites S1 – S6 of the 
protease (Ingallinella et al., 1998). Both peptides have a homology in their sequence. They have a 
similar quite hydrophobic 9 aa long motiv in the N-terminal part of the peptide that is interrupted by 
an aspartic acid: V-Y-L/V-L-D/G-G/D-P-G-Y. Later co-crystallisation of the N-terminal part of 
peptide K5-66 confirmed the assumption that this region is important for binding at the substrate 
binding region of the NS3/4A protease. Because of the homology in their sequence the peptides K5-
66 and K6-10 probably bind similar to the NS3/4A protease in this region. Both peptides have an 
inhibitory effect on protease activity. Peptide K5-66 has an IC50 value of about 21 nM and peptide 
K6-10 of about 26 nM. Also the N-terminal and C-terminal part of the peptides were tested separately 
in the activity assay. In both cases the N-terminal part of the peptides shows inhibition of the protease 
without the C-terminal part, but the inhibitory effect is reduced compared to that of the full length 
peptide. The C-terminal parts have no inhibitory effect at the tested concentrations. This finding is 
consistent with the results of the co-crystallisation studies. The crystal structure revealed that the N-
terminal part of K5-66 covers the active site of the protease. The C-terminal parts seem to work 
synergistically with the N-terminal parts increasing the inhibitory effect of the peptides presumably 
by additionally interactions with the protease surface and/or by stabilizing the peptide structure. 
 
4.2.3 Cosmix-plexing of inhibitory peptides K5-66 and K6-10 
To further improve the affinity of the peptides a recombination of the N-terminal and C-terminal parts 
was carried out with pre-selected populations using the cosmix-plexing technique (Collins et al., 
2001). Populations, containing about 20% of the clone K5-66 or K6-10, respectively, were chosen for 
recombination. It was intended to recombine the parts of the peptides with pre-selected peptides 
showing weak affinity to form novel ligands that exhibit stronger binding to the NS3/4A protease. It 
also automatically leads to identification of the region containing the most dominant motifs which 
contribute to the binding. 
The cosmix-plexing recombination yields N2 variants from the pre-selected population of N clones. 
The lowest number of eluted phages during the ‘low salt panning’ against MBP-NS3/4A protease in 
MTP was 2.06 x 104 phages for the acidic elution and 1.64 x 104 phages for the competitive elution 
after the 2nd panning round (PR). If it is assumed that these are all single clones and that at least two-
fold enrichment of binding clones over non-binders in each panning round occurred (Clackson and 
Lowman, 2004), the theoretical number of variants after recombination is about 1.6 x 107 for acidic 
elution 5th PR (clone K5-66) and 7.6 x 106 for competitive elution 6th PR (clone K6-10). After 
cosmix-plexing of the pre-selected population after the 5th panning round with acidic elution 
containing the peptide K5-66 (termed ‘peptides of K5-66’) and 6th panning round with competitive 
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elution containing the peptide K6-10 (termed ‘peptides of K6-10’) the number of single clones was 
8.9 x 107 and 9.6 x 107, respectively. This corresponds to 6 to 12-fold coverage of all possible variants 
after recombination. After cosmix-plexing several peptides with recognisable recombined sequences 
were found, but there were still a high proportion of ‘original’ or ‘parental’ peptides K5-66 and K6-
10. This could ensue where there is incomplete recombination or recombination between two 
identical clones.  
The recombined variants were submitted to further affinity selection under more stringent panning 
conditions with a panning buffer with a higher salt concentration to increase the stringency through 
weakening of ionic interactions and increased washing steps to identify peptides with higher affinity 
to the NS3/4A protease. Two separate pannings with the recombined peptides of K5-66 and K6-10, 
respectively, were performed. In both cases an enrichment of the N-terminal parts of the ‘original’ 
peptide with new C-terminal parts was seen. The enrichment shows that N-terminal parts of the 
peptides contribute the most to the binding to the protease and that the C-terminal parts could have a 
low affinity or act synergistically by stabilizing the peptide structure as noted above.  
From the panning with the peptides of K6-10 one peptide, CP6-4, with increased affinity to the 
NS3/4A protease could be identified. The peptide CP6-4 consists of the N-terminal part of peptide 
K5-66 and the C-terminal part of a peptide, CP6-11, that was first identified after recombination of 
the pre-selected population. The peptide CP6-11 and dominantly the C-terminal part of this peptide 
were enriched during panning. Therefore the C-terminal part could contribute the most to the binding 
of the peptide to the NS3/4A protease. The peptide CP6-11 showed the same affinity in the phage-
ELISA as the peptide K5-66 and has only a low inhibitory effect on the protease (~2.4 µM) under 
reducing conditions that prevented possible disulfide bond formation. The peptide K5-66 was not 
identified in panning with competitive elution before. The occurrence of the N-terminal part of this 
peptide in the panning with the peptides of K6-10 shows that the peptide was also enriched with the 
competitive elution method. The emergence of the N-terminal part could be due to high affinity of the 
peptide resulting in less efficient elution with the competitor. The acidic elution after recombination 
presumably led to a higher enrichment of this peptide. The recombination of the N-terminal part of 
peptide K5-66 and the C-terminal part of peptide CP6-11 resulted in the formation of a new inhibitor 
(CP6-4) with higher affinity to the NS3/4A protease. The peptide showed a ca. 4-fold increase of the 
phage-ELISA signal compared to the peptide K5-66 which corresponded to a decrease of the IC50 
value to 16 nM.  
Notably the peptide CP6-4 was also found in the elution of the panning of peptides of K5-66. This 
shows that the peptide CP6-11 was also enriched during panning with acidic elution and that the same 
recombined variant was enrichment. The low enrichment of the peptide CP6-4 could be due to the 
high amount of peptide K5-66 after recombination which favours the enrichment of the ‘original’ 
peptide. From the panning with the peptides of K5-66 also one additionally peptide, CP5-46, with 
increased affinity to the NS3/4A protease could be identified. The peptide consists of the N-terminal 
part of peptide K5-66 with new C-terminal part and showed an about 8-fold increase of the phage-
ELISA signal compared to the peptide K5-66 which corresponded to a decrease of the IC50 value to 
about 11 nM. Both peptides, CP5-46 and CP6-4, have the N-terminal part of peptide K5-66 and share 
sequence homology in their C-terminal part: namely S/T-R-G-G/(-)-S.  
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The identification of two peptides with recombined sequences of inhibitory peptides that have an 
increased inhibitory effect and affinity to the NS3/4A protease shows that the cosmix-plexing was an 
efficient method to form novel ligands that exhibit stronger binding to the NS3/4A protease. 
 
4.2.4 Co-crystallisation of NS3/4A with CP5-46 and CP5-46-A 
To further optimise the peptide with the highest inhibitory effect, namely CP5-46, crystallisation of 
the NS3/4A protease in complex with the peptide was attempted. Co-crystallisation experiments were 
done with the peptide CP5-46 and a truncated form CP5-46-A that comprises the N-terminal part of 
the peptide. Crystals for diffraction measurement could only be obtained for peptide CP5-46-A and 
not for the full length peptide CP5-46. The crystal packing of the peptide CP5-46-A and NS3/4A 
complex showed that the peptide is located at the outside of the hexagonal unit cell. The bound full-
length peptide could interfere with the stacking of the unit cells and preclude the crystal formation. It 
could also be possible that the C-terminal part of the peptide is not fully bound to the protease and the 
emerging conformational heterogeneity hinders crystal growth. 
The resolved structure of the peptide-protease complex revealed that the peptide CP5-46-A is 
coordinated over a large part of the protease surface covering the active site of NS3/4A. Electron 
density for the amino acids 4 – 20 of the peptide could be measured. The first three amino acids, 
which are part of the N-terminal constant region, are not bound to the protease and therefore no 
electron density could be observed.  
The C-terminal part of the peptide, Pro13 – His19, forms a ‘proline’-finger motive that binds to a 
pocket at the primed site of the protease. The shallow depression extends the S4` subsite of the 
protease and the bottom of the pocket is formed by the NS4A cofactor. The ‘proline’-finger motive 
fits nicely into the pocket, thus also interacting with the surface of the NS4A cofactor. It also forms 
several hydrogen bonds with NS3 residues and coordinated water molecules. His19 forms an 
intramolecular salt bridge with Asp11 stabilizing the structure of the ‘proline’-finger motive, 
however, removal of this interaction by deletion of Cys20 and His19 from peptide CP5-46-A had no 
influence on the inhibitory effect of the peptide. The intramolecular salt bridge could be important for 
the folding and structure of the full-length peptide. The ‘proline’-finger motive extends the binding of 
the peptide at the primed site of the protease to a region probably not occupied by the natural 
substrate and, therefore, displaying interactions with the protease differing from the substrate or 
product-based inhibitors. 
The N-terminal part of the peptide, Gly4 – Pro13, binds in the region of the protease with the 
designated subsites S6 – S4`, essentially mimicking the binding of a natural substrate and covering 
the active site of the NS3/4A protease. Arg5 – Val7 bind in the region of the subsites S5 – S3 forming 
an anti-parallel ß-strand with the backbone of the NS3/4A protease. The formation of an anti-parallel  
ß-sheet is conserved between all protease substrates (Romano et al., 2010). In the region of the ß-
strand, Gly4 – Leu6, the peptide is positioned similarly to the way the enzyme binds the natural 
substrates, but the peptide backbone is shifted away in the region of the subsites S3 – S1 compared to 
the binding of the substrates. Most of the product-based inhibitors are bound at the active site of the 
NS3/4A protease, spanning the S4 – S1` subsites and thus showing a similar binding pattern of the 
backbone compared to the natural substrates. It is emphasised here that the novel peptide inhibitors 
differ in this respect from product-based inhibitors developed to mimic the natural substrate. 
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Compared to product-based small molecules the peptide backbone of CP5-46-A that binds in the 
region of the subsites S1` to S4 has a similar geometric structure but is shifted away from the active 
side residues of the NS3/4A protease. Most interestingly the side chains of the peptide in this region 
have similar functional groups and they are positioned similarly compared to the functional groups of 
the small molecule inhibitors (see Figure 3-40 C and D). The peptide residues P1` – P4 show similar 
hydrophobic interactions with the protease surface and some side chains show the same occupation of 
the protease subsites compared to the functional groups of the small molecule inhibitors. This shows 
that using the phage display method an inhibitor could be found that revealed a similar optimised 
binding to the S1` – S4 subsites like the small molecule inhibitors but differing in exhibiting a 
different binding of the peptide backbone. This could be important in the case of resistance 
development as discussed further below.  
The shift of the peptide backbone away from the active side residues of the NS3/4A protease is 
important for preventing cleavage of the peptide. The peptide is coordinated at both sides of the 
catalytic triad of the protease but it was shown that it is not processed by the protease. Several 
parameters preclude the nucleophilic attack on the peptide backbone. The large side chain of Leu10 
that binds to the subsite S1` moves the peptide backbone away from the active site residues. Also two 
hydrogen bonds are formed that have an additive effect on the geometrically constraint. They are 
formed by the peptide residues that could be attacked by the hydroxyl group of the catalytic triad 
keeping the peptide backbone away from the active site residues. One hydrogen bond is formed with a 
backbone amide that is part of the oxyanion hole presumably diminishing the charge redistribution 
function of the oxyanion hole disturbing the stabilisation of the tetrahedral intermediate and therefore 
increasing the activation energy of the reaction. The prevention of peptide cleavage is a sum of 
geometrically constraints and inhibition of the function of the oxyanion hole. 
The co-crystallisation of peptide CP5-46-A showed that large peptides have the potential for additive 
binding interactions at different sites of the protease. The exact class of binding differs from the 
binding of the natural substrates and product based small molecule inhibitors. Therefore the newly 
developed inhibitory peptide defines new areas of binding which could open new channels of drug 
development or new derivatives.  
The C-terminal part of the peptide CP5-46 could have additionally interactions with the protease 
surface or it could stabilise the peptide structure by intramolecular interactions. The peptide could 
form a native-like secondary structure already in solution (Fersht, 1999) before binding that has a 
higher affinity for the protease, increasing the rate of association (ka).  
 
4.2.5 Structure-based optimisation of peptide CP5-46-A 
Examination of the crystal structure of the complex, allowed a prognosis for potential amino acid 
exchanges which might improve binding geometry and charge interaction between the peptide and the 
enzyme and could improve the inhibitory effect with respect to the peptide CP5-46-A. Exchanges for 
the amino acids were suggested that bind to the S1` and S4 subsites of the protease that could have a 
better potential interaction with residues of the NS3/4A protease. It was also attempted to mimic the 
electrostatic interactions of a natural substrate at positions P5 and P6.  
The amino acid exchanges proposed at the positions P1` and P4 did not enhance the inhibitory effect 
of the peptide; in fact quite to the contrary, the inhibition of the protease was totally abolished or 
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substantially decreased. The amino acid exchanges did not lead to a cleavage of the peptides 
suggesting that the binding of the peptide to the protease is perturbed. In contrast, an exchange at 
position P4 to Asp, which has a different functional group but a side chain of the same length as the 
‘original’ Leu, decreased the IC50 20-fold. The exchange to Glu, which has the same functional group 
but a longer side chain than Asp, abolished the inhibitory effect. This shows that the subsites could 
not accommodate the binding of a larger side chain and that a negative charge is not preferred for 
binding at these subsites.  
The change at amino acid positions 4 and 5 of peptide CP5-46-A to the negative charged amino acids 
Asp and Glu increased the potency of the peptide about 6-fold. To solve the question whether or not 
the proposed ionic interactions between the new peptide residues had in fact contributed to the 
observed increase of the inhibitory effect, the optimised peptide was co-crystallised with NS3/4A. 
The structure of the complex showed that the overall binding of the peptide to the protease is not 
influenced by these amino acid exchanges. Notably the position of the backbone and side chain of 
Glu5 is similar to the binding of the mimicked substrate. It was shown for short peptide inhibitors that 
a change of Glu5 to a positively charged amino acid resulted in a 3 to 10-fold decrease in the 
inhibitory effect (Ingallinella et al., 1998). The suggested ionic interactions between Asp4 of the 
peptide CP5-46-A-4D5E and Lys165 of the NS3/4A protease have apparently not formed. Therefore, 
it was concluded that the amino acid exchange at position P5 could be solely responsible for the 
increase in the inhibitory effect. However, it could also be possible that the high ionic strength during 
crystal formation (~1.1 M KCl) destabilised the ionic interactions between Asp4 and Lys165 and that 
the flexible N-terminal end led to a dislocation of the side chain. Peptides with only one amino acid 
exchange could be used to test if both changes have an influence on the increase of the inhibitory 
effect of the optimised peptide. 
The introduction of the amino acid exchanges Asp4 and Glu5 into the full length peptide CP5-46 
improved the inhibitory potency about 10-fold to a Ki of about 530 pM. This shows that it was 
possible to develop a potent long peptide inhibitor using various methods including phage-display, 
cosmix-plexing and structure based optimisation, leading finally to the identification of an inhibitor 
with a binding affinity in the picomolar range. 
 
4.2.6 NS3/4A protease resistance mutation A156V 
In 2011 two NS3/4A protease inhibitors received approval for clinical use (Klein and Struble, 2011; 
Poordad, 2011). Monotherapy with these protease inhibitors leads to the rapid selection of resistant 
variants. The newly developed drugs can therefore only be used in combination therapy with state of 
the art therapy regimes. Thus patients will be exposed to the same side effects as before (Sarrazin and 
Zeuzem, 2010; Gentile et al., 2010). Most of the new protease inhibitors are bound at the active site 
of the NS3/4A protease, spanning only the S4–S1` subsites and thus showing a similar binding pattern 
and resistance profile (Sarrazin and Zeuzem, 2010; He et al., 2008). It was suggested that resistance 
mutations occur at positions where the inhibitors have part of their structure extending outside the 
consensus volume modelled to be occupied by the normal substrates, the 'substrate envelope' thus the 
binding of the inhibitors is weakened without severe influence on substrate binding (Romano et al., 
2010). Notably the residues R155 and A156 interact with the inhibitors where they extend most 
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extensively beyond the 'substrate envelope'. Mutation at these positions confer high-level resistance 
against nearly all drugs reported in the literature (Romano et al., 2010; Lenz et al., 2010). 
It was thus of primary interest to investigate the effect of known resistant HCV NS3/4A mutations on 
the inhibitory effect of the optimised peptide CP5-46-4D5E. The primary intention in developing 
longer peptides as inhibitors was to have inhibitors which might provide an alternative binding 
mechanism to the small molecular weight inhibitors. These might be a priori binding at alternative 
sites and/or because of their larger interactive surface be less affected by HCV resistance mutations. 
Several amino acids of NS3 that are involved in resistance mutations against protease inhibitors are in 
the proximity of the bound peptide. Especially A156 is totally covered by the modelled surface of the 
peptide and is in direct contact with the surface of the peptide. Modelling showed that a mutation to 
Val could have the highest impact on the inhibitory potency of the peptide and therefore the NS3/4A 
protease with the point mutation A156V was produced in recombinant form and used for activity 
measurements. The peptide CP5-46-4D4E was tested with the NS3/4A protease with the resistance 
mutation A156V. The peptide shows negligible susceptibility to the A156V mutation (1.5-fold 
increase of IC50 value). This shows for one of the most important resistance mutations that the peptide 
inhibitor is far less affected than small molecule inhibitors. The resistance mutation A156V has the 
greatest impact on the activity of both alternative compound groups, namely the linear α-ketoamide 
inhibitors and the macrocyclic inhibitors (Lenz et al., 2010). Many other resistance mutations against 
NS3/4A inhibitors are known and it still remains to be tested with the peptide inhibitor to maintain the 
assumption that the peptide inhibitor has a higher barrier for resistance development. It is not unlikely 
that resistance mutation can also occur against the peptide inhibitors, however, because of the 
alternative binding mechanism and because of their larger interactive surface single HCV resistance 
mutations should be less effective. Such mutations could occur at yet unknown sites many likely 
remote from the binding site for the small molecule inhibitors. The larger interactive surface and more 
flexible binding of the peptide inhibitors should also allow binding even if one resistance mutation 
occurs, making it likely that more than one amino acid mutation would be needed to completely 
prevent binding of the inhibitor (McKeage et al., 2009; Ghany et al., 2009). 
Because of the heterogeneity between genotypes and subgenotypes, inhibitors will not have the same 
activity in all HCV variants. The new small molecule protease inhibitors show a varying activity in 
different genotypes. The optimised peptide inhibitor was developed with a HCV genotype 1b protease 
from one of the clinically most relevant subgroups. It remains to be tested if it shows such a strong 
inhibitory effect on proteases of the different genotypes. Because of the large interactive surface and 
more flexible binding of the peptide inhibitors they could also exhibit the same efficacy for NS3/4A 
proteases of other genotypes. Even if this were not the case the method demonstrated here for the 
development of peptide inhibitors could be rapidly utilised, initially using the immobilised protease 
from the desired resistant genotype as affinity target. 
 
4.3 Intracellular peptide delivery 
Sufficient bioavailability and in vivo distribution is a major requirement for new drug candidates in 
development. The pharmaceutical industry was challenged in the 1990s by high drug candidate 
attrition, at least partly due to adverse pharmacokinetics and bioavailability (Kola and Landis, 2004). 
A comparison of successful small molecule drugs with failed drug candidates led to the development 
Discussion 
 
104 
of the ‘rule of five’ to evaluate the drug-likeness of lead candidates (Lipinski et al., 2001). In 
summary this highly empirical rule postulates that drug candidates must be not highly lipophilic, 
should be low molecular weight molecules with no more than five hydrogen bond donors and no 
more than 10 hydrogen bond acceptors. These demands on the compound properties constrict the 
number of possible lead candidates for drug development. Also the ‘druggable genome study’ 
revealed for the human genome a much smaller number of possible targets than originally thought 
(Hopkins and Groom, 2002). Many biological targets are not ‘druggable’ because of the lack of 
suitable ('addressable') binding pockets. Peptides in contrast can have a larger surface area that is 
involved in binding and a synergistic binding effect of many interactions at various sites on the target 
protein. Therefore peptides have the potential to extend the number of ‘druggable’ targets (Groner, 
2009). On the other hand peptides have a low oral bioavailability because they are degraded by 
proteolytic enzymes and they cannot cross the membrane of the intestinal tract. Also peptide drugs 
that target intracellular proteins have to cross the plasma membrane. Because of the highly selective 
permeability of cell membranes to macromolecules, methods for cell delivery of peptides are 
necessary. 
The sufficient bioavailability of small molecule drugs is dearly purchased at the cost of diversity of 
compounds that are located within the available chemical space. Especially proteases have often 
similar catalytic mechanism requiring relatively large peptidic or peptidomimetic inhibitors to achieve 
selective inhibition (Drag and Salvesen, 2010). Decreasing the diversity of compounds reduces 
presumably the specificity of drug candidates. Also the number of ‘druggable’ targets is constricted 
because of the constraints of small molecule drugs. Biologic drugs, including peptides, in contrast, 
have the positive attributes of high activity, target specificity, low side-effects and lower potential 
toxicity but, on the negative side, low bioavailability (Sato et al., 2006). Therefore novel application 
and cell delivery methods would not only enhance the development of biological drugs but also 
expand the development possibilities of small molecule drugs.  
For the intracellular delivery of the inhibitory peptides against the NS3/4A protease two different 
delivery methods were explored: cell penetrating peptides (CPP) and pH sensitive polymersomes. 
CPPs are short peptides that can cross cellular membranes and thereby deliver a cargo into cells 
(Schwarze et al., 2000). Polymersomes are nanoparticles that consist of a pH-sensitive copolymer 
which self assembles and forms vesicles that disrupt after acidification in the endosomes releasing the 
cargo into the cytosol because of a massive osmotic shock (Massignani et al., 2009; Massignani et al., 
2010).  
 
4.3.1 Intracellular delivery of peptides using polymersomes 
The encapsulation of the inhibitory peptides into polymersomes seemed the most promising method 
for intracellular delivery because of the efficient endosomal escape that was described in literature 
(Massignani et al., 2010) and because of a protection of the peptide from peptidases inside the 
polymersomes. Also targeting of hepatocytes with specific ligands on the surface of the 
polymersomes could have been possible. Unfortunately the polymersomes with encapsulated 
inhibitory peptide showed no inhibition of viral replication in the cell culture replicon assay compared 
to the control. Interestingly an increase in viral replication was seen at increased polymersome 
concentration. This effect cannot be explained. Because of the preparation and testing of the 
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polymersomes in different laboratories the polymersomes containing the peptides were stored for over 
four weeks until usage. Degradation of the polymersomes or peptide could be possible. Also the 
encapsulation of peptide was not very efficient in the experiments and needs to be further optimised. 
Even though the intracellular delivery of inhibitory peptides with polymersomes was not very 
efficient in the first experiments it is still an interesting method for intracellular delivery of peptides 
and should be further explored. 
 
4.3.2 Intracellular delivery of peptides using cell penetrating peptides 
It has been shown that cell penetrating peptides (CPP) were able to deliver various biological cargos 
into cells and also some in vivo animal studies were done that demonstrated intracellular delivery 
using CPPs and demonstrating biological activity of the cargo (Sawant and Torchilin, 2010; Chen and 
Harrison, 2007). To test the intracellular delivery of the inhibitory peptides different CPPs were fused 
to the peptides and tested in the cell culture replicon assay. As controls the inhibitory peptide fused to 
a non-CPP peptide and a fusion of a CPP to a scramble peptide were used. The inhibitory peptide 
fused to a non-CPP peptide had neither influence on the viral replication nor on the cell viability even 
at high peptide concentrations. Interestingly the CPP fused to the scramble peptide showed a low 
inhibitory effect at 20 µM and started to become toxic for the cells at a peptide concentration of 100 
µM. This could be due to cell stress because of accumulation of peptide inside the cell that leads also 
to degradation of viral proteins. Only the fusion of the inhibitory peptide to the Antennapedia peptide 
showed an inhibitory effect in the replicon assay. The other peptide-CPP fusions tested showed no 
inhibitory effect at all or only a low inhibitory effect comparable to the control. This shows that the 
successful delivery using CPPs strongly depends on the delivered cargo, the concentration of the CPP 
and the cell type. No systematic pattern has been discerned to date, leaving only empirical trial and 
error (Richard et al., 2005; Duchardt et al., 2007; Patel et al., 2007; Van den Berg and Dowdy, 2011). 
The EC50 value of the Antp-K5-66-A peptide is about 3.4 µM which is a 27-fold increase compared to 
the IC50 value of the NS3/4A assay (125 nM). This increase could be due to low endosomal escape of 
the CPP-peptide fusion, which leads to degradation of the peptide in the lysosomes (Heitz et al., 2009; 
Patel et al., 2007). Another possibility could be degradation of the peptide by any of several cellular 
pathways for protein degradation leading to the apparent increase in the IC50 value. The N-terminal 
fusion of the Antp peptide to an inhibitory peptide had no influence on the inhibitory effect of the 
peptide (data not shown). In this case it appears that the decrease of the inhibitory effect is due to 
inefficient cell delivery and/or due to low stability of the peptide in cell culture. The fusion of the 
Antp peptide with the full length peptides CP5-46 and CP6-4, that have an higher potency in vitro 
than the peptide K5-66-A, showed a reduced inhibitory effect in the replicon cell culture model 
compared to the peptide K5-66-A. There maybe a negative correlation between the length of the 
fusion peptide fusion and uptake into the cell. Also the localisation of the peptide fusion in the cell 
could have been altered. Fluorescence labeled peptides could be used to see if there are differences in 
the cell localisation of the full-length peptide and N-terminal part (K5-66-A). 
The inhibition of the viral replication by the Antp-K5-66-A fusion in the replicon cell culture model is 
an encouraging initial indication of an in vivo effect of the peptide showing that it is possible to 
inhibit the HCV virus also with large inhibitors that are unable to cross the cell membrane on their 
own. Further studies have to be made to increase the efficacy of intracellular delivery but the 
feasibility of HCV inhibition by large peptide in cell culture has been shown.  
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4.4 Perspectives 
With the use of peptide phage display inhibitory peptides against both HCV proteases were isolated. 
For a clinical application these peptides need further development. 
Against the NS2-3 protease one peptide was found that presumably inhibits protease cleavage on 
dimer formation. This initial indication of a direct effect on NS2-3 cleavage needs further 
corroborative evidence. Besides the essential role in HCV polyprotein processing, the NS2 protein has 
other essential functions in the viral life cycle. A second peptide that showed specific affinity for the 
NS2-3 protease might therefore interfere with other NS2 functions without inhibiting the protease 
function. If the cell delivery efficacy is improved the cell-based infectious HCV assay could be used 
to evaluate the effect of both peptides on the NS2 protein. This would be a valuable extension to the 
in vitro enzyme assay performed to date. 
Affinity selection against the NS3/4A protease resulted in the identification of inhibitory peptides in 
the low nanomolar range. Recombination, using the cosmix-plexing technique, and structure based 
optimisation was shown to be applicable to improve the affinity of the peptide inhibitor to a Ki down 
to the pM range. To further improve the affinity additional amino acid exchanges could be tested. For 
instance an exchange of Glu5 of the optimised peptide to D-Glu5 could improve the inhibitory effect 
3-fold (Ingallinella et al., 1998). D-amino acid exchanges could also be used to increase the stability 
of the peptide for cell delivery to avoid degradation by cellular proteases. This would in all likelihood 
also reduce the immunogenicity of the peptides due to a limitation in MHC presentation which 
requires porteolytic trimming of the antigen before presentation in the MHC complex (Lien and 
Lowman, 2003; Sato et al., 2006). For the Antp peptide it has been shown that the D-amino acid 
enantiomer is internalised as efficiently as the L-amino acid form (Derossi et al., 1996) and could also 
increase the stability of the peptide fusion. 
Several CPP-conjugated drugs are in clinical development with promising results (Johnson et al., 
2011) and fusion to a CPP could serve for clinical application of the peptides. Nevertheless, for a 
therapeutic use the efficacy of the cell delivery must be increased.  
Another possibility for improvement lies in the area of cell-specific targeting, i.e. cell type specific 
delivery should be tried, e.g., by coupling hepatocyte specific ligands to nano particles, to boost the 
cell delivery. Should these issues remain unsolved in the immediate future the peptides can still serve 
as lead structures for the development of peptide mimetics, e.g., in a fashion following the 
development of the clinically relevant small molecules discussed above which were originally 
modelled on the normal substrate peptides. 
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5. Abstract 
At the outset it was planned to develop inhibitory peptides against the NS2-3 and NS3/4A proteases 
of the Hepatitis C Virus (HCV) as leads for drugs for HCV treatment. These proteases are essential 
for the viral life cycle and therefore present interesting targets for the development of new specific 
antiviral HCV drugs. Worldwide up to 170 million people are chronically infected with HCV (Yu and 
Chiang, 2010). HCV infections are the leading cause of chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma (Shepard, 2005). The standard of care achieves a sustained viral response in 
only about half of the patients treated and is associated with considerable severe side effects (Manns 
et al, 2001). 
In 2011, two new HCV drugs, NS3/4A protease inhibitors, were approved by the FDA (Klein and 
Struble, 2011; Poordad, 2011). Because of rapid resistance development the drugs can only be used in 
combination with the current treatment. Thus there remains an unmet need for HCV drugs for an 
effective treatment that can replace the standard of care with its severe side effects. 
Large peptides might provide an alternative binding mechanism to the small molecular weight 
inhibitors in development. These might be binding at alternative sites and/or because of their larger 
interactive surface peptides are less affected by HCV resistance mutations. In this work the 
combinatorial phage display peptide library CPL19YS-2 displaying large peptides was used for 
iterative affinity enrichment on these HCV proteases.  
The NS2-3 protease was produced in a form that exhibited 50% self-cleavage activity. Affinity 
enrichment against the NS2-3 protease led to the identification of two peptides that showed specific 
affinity for the NS2-3 protease. One peptide showed low inhibition of NS2-3 protease cleavage to 
about 70% at a concentration of 270 nM presumably due to inhibition of protease dimer formation. 
This is an initial indication of a direct effect on protease cleavage requiring further corroborative 
evidence. 
The NS3/4A protease was produced as a single chain construct connecting the NS3 protease domain 
with the NS4A co-factor (Dimasi et al., 1998). An MBP fusion increased the solubility of the protease 
considerably. Affinity enrichment against NS3/4A protease led to the identification of two peptides 
that inhibited the NS3/4A protease in the low nanomolar range. Recombination of the peptides with 
pre-selected populations led to the identification of peptides with increased affinity to the protease. 
One showing a two-fold increase in the Ki value to 5.2 nM. For optimisation of the inhibitory peptide 
X-ray crystallography and structural modelling were successfully implemented for the N-terminal 
region of the peptide. The co-crystallisation showed that the peptide covers the active site and that 
peptide cleavage is prevented by a sum of geometrical constraints and inhibition of the function of the 
oxyanion hole. Protein modelling was applied to make predictions for structural optimisation by 
mimicking ionic interactions of a natural substrate. One such designed variant increased affinity 10-
fold to a Ki value of about 530 pM. The optimised peptide showed a negligible susceptibility to the 
important A156V resistance mutation of the NS3/4A protease, which is highly resistant to the small 
molecular weight inhibitors. This gives an initial indication that large peptides are less affected by 
resistance mutations. Inhibition of viral replication in cell culture was demonstrated by fusion of an 
inhibitory peptide to the Antp cell penetrating peptide. The efficacy of the peptide was reduced about 
30-fold but it is an encouraging initial indication of intracellular inhibition of viral replication. 
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5.1 Zusammenfassung 
Ziel dieser Arbeit war die Entwicklung inhibitorischer Peptide gegen die NS2-3 und NS3/4A 
Proteasen des Hepatitis C Virus (HCV), die als Ausgangspunkt für die Entwicklung von 
Medikamenten dienen können. Die HCV Proteasen sind essentiell für den Lebenszyklus des Virus 
und daher interessante Ziele für die Entwicklung neuer spezifischer Medikamente. Weltweit sind bis 
170 Millionen Menschen chronisch mit HCV infiziert (Yu und Chiang, 2010). HCV Infektionen sind 
der Hauptgrund für chronische Hepatitis, Leberzirrhose und Leberzellkarzinom (Shepard, 2005). Die 
Standardbehandlung erreicht nur in ungefähr der Hälfte der behandelten Patienten eine dauerhafte 
Eliminierung des Virus und ist verbunden mit zahlreichen Nebenwirkungen(Manns et al, 2001). 
2011 wurden zwei NS3/4A Protease-Inhibitoren zur Behandlung von HCV zugelassen (Klein und 
Struble, 2011; Poordad, 2011). Da der Virus schnell Resistenzen gegen diese Inhibitoren entwickelt, 
ist nur eine Anwendung mit der ursprünglichen Therapie möglich, die starke Nebenwirkungen hat. 
Daher besteht noch immer ein großer Bedarf an neuen Medikamenten für eine Behandlung, die die 
Standardbehandlung ersetzen können. Große Peptide könnten alternative Bindungsmechanismen 
bieten, verglichen mit den Kleinmolekül-Inhibitoren in Entwicklung. Dies könnte Bindung an 
alternative Stellen sein und/oder Peptide werden möglicherweise wegen ihrer großen 
Bindungsoberfläche weniger stark von HCV Resistenzmutationen beeinträchtigt. In dieser Arbeit 
wurde die Phagen Display Peptid Bibliothek CPL19YS-2, die große Peptide präsentiert, für iterative 
Affinitätsanreicherungen verwendet.  
Die NS2-3 Protease konnte in einer Form produziert werden, die 50% Selbstspaltungs-Aktivität 
aufwies. Mittels Affinitätsanreicherung konnten zwei Peptide identifiziert werden, die spezifische 
Affinität für die NS2-3 Protease zeigen. Ein Peptid reduziert bei einer Konzentration von 270 nM die 
Aktivität der Protease auf 70%, wahrscheinlich durch Verhinderung der Dimer-Bildung. Dies ist ein 
erster Hinweis auf eine direkte Wirkung auf die Aktivität der Protease, die aber noch weitergehend 
untersucht werden muss.  
Die NS3/4A Protease wurde als Fusionsprotein produziert, bei dem die NS3 Protease Domäne mit 
dem NS4A Kofaktor verbunden wurde (Dimasi et al., 1998). Eine zusätzliche Fusion mit dem MBP 
Protein verbesserte die Löslichkeit der Protease erheblich. Mittels Affinitätsanreicherung konnten 
zwei Peptide identifiziert werden, die die NS3/4A Protease bei Konzentrationen im unteren 
nanomolaren Bereich inhibieren. Rekombination der Peptide mit pre-selektierten Peptiden führte zu 
Varianten mit verbesserter Affinität. Eine Variante zeigte eine zweifache Verbesserung des Ki Wertes 
auf 5,2 nM. Für die weitere Verbesserung des N-terminalen Bereichs des Peptids wurden 
Röntgenkristallographie und Strukturmodellierung erfolgreich eingesetzt. Die Ko-Kristallisation 
zeigte, dass das Peptid das aktive Zentrum der Protease verdeckt und das die Spaltung des Peptids 
durch geometrische Beschränkungen und Inhibierung des „oxyanion hole“ verhindert wird. Anhand 
des Modells vorgeschlagene ionische Interaktionen, die denen des natürlichen Substrats ähneln, 
konnten die Affinität des Peptids 10-fach auf einen Ki Wert von 530 pM verbessern. Das optimierte 
Peptid zeigte nur eine geringe Anfälligkeit für die A156V Resistenzmutation der NS3/4A Protease, 
die starke Resistenz gegen Kleinmolekül-Inhibitoren bewirkt. Dies ist ein erster Anhaltspunkt dafür, 
dass große Peptide weniger stark von Resistenzmutationen beeinträchtigt sind. Inhibition von viraler 
Replikation in Zellkultur konnte mittels Fusion an das zellpenetrierende Peptid Antp gezeigt werden. 
Die Wirksamkeit des Peptids war ca. 30-fach verringert, aber es ist ein erster viel versprechender 
Befund für eine intrazelluläre inhibitorische Wirkung. 
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7. Appendix 
7.1 Purification of Antennapedia-peptides 
	  
	  
Figure 7-1: Production and purification of Ant-K5-66 peptide. 10% Tricine PAGE gel, M: molecular weight marker, BI: 
before induction, I: 5h after induction, BB: before binding, AB: after binding; W: washing fractions, E1: elution fraction 1 
µl, E2: elution fraction 1.5 µl. 3µl of each other fraction were loaded onto the gel. 
7.2 Purification of MBP-peptides 
	  
Figure 7-2: Production and purification of MBP-K6-10 (A) and MBP-K5-66 (B) peptide. 12% SDS-gel, M: molecular 
weight marker, BI: before induction, I: 3 h after induction, BB: before binding, AB: after binding; W: washing fractions, E: 
elution fraction. 3 µl of each fraction were loaded onto the gel, except elution fraction: A: 2 µl, B: 2 µl. 
	  
Figure 7-3: Production and purification of MBP-CP5-46 (A) and MBP-CP6-4 (B) peptide. 12% SDS-gel, M: molecular 
weight marker, BI: before induction, I: 3 h after induction, BB: before binding, AB: after binding; W: washing fractions, E: 
elution fraction. 3 µl of each fraction were loaded onto the gel, except elution fraction: A: 1 µl, B: 2 µl 1:5 dilution. 
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7.3 NS3/4A activity assay 
7.3.1 Inhibition of NS3/4A activity 
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Figure 7-5: Determination of the IC50 of peptide K6-10-A (A), K5-66-A (B) K6-10-B (C), and K5-66-B (D) using the 
NS3/4A activity assay. Assay was done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 1 nM NS3/4A. All 
peptides chemically synthesised. Excitation filter: 360/40 nm, emission filter: 460/40 nm. Velocity of fluorescence increase 
over one hour was compared to that of a scrambled control peptide K5-66-R (E). Each measurement was done in duplicate, 
IC50 in nM. The curve was fitted with GraphPad Prism using a nonlinear regression model with variable slope : 
Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-X)*slope)). 
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Figure 7-4: Production and purification of MBP-NS2-E11 (A) and MBP-CP6-11 (B) peptide. 12% SDS-gel, M: 
molecular weight marker, BI: before induction, I: 3 h after induction, BB: before binding, AB: after binding; W: washing 
fractions, E: elution fraction. 3 µl of each fraction were loaded onto the gel, except elution fraction: A: 1 µl 1:5 dilution, B: 1 
µl 1:5 dilution. 
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7.3.2 Cosmix-plexing of inhibitory peptides K5-66 and K6-10 
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Figure 7-6: Determination of the IC50 of peptide CP5-46 (A) and CP6-11 (B) using the NS3/4A activity assay. Assay 
was done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 1 nM NS3/4A. Peptide CP5-46 was chemically 
synthesised. Peptide CP6-11 was produced as MBP fusion protein with His-Tag. Excitation filter: 360/40 nm, emission 
filter: 460/40 nm. Velocity of fluorescence increase over one hour was compared to that of a scrambled control peptide or 
the NS2-K11 control peptide. Each measurement was done in duplicate, IC50 in nM. The curve was fitted with GraphPad 
Prism using a (A) nonlinear regression model with variable slope and normalised response: Y=100/(1+10^((LogIC50-
X)*slope)) or a (B) nonlinear regression model with variable slope : Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-
X)*slope)). 
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Figure 7-7: Determination of the IC50 of peptide CP5-46-A (A), CP5-46-P1 (B), CP5-46-P3(C) and CP5-46-P4 (D) 
using the NS3/4A activity assay. Assay was done in buffer M2235 with 5 µM substrate M-2235 (Bachem) and 1 nM 
NS3/4A. All peptides chemically synthesised. Excitation filter: 360/40 nm, emission filter: 460/40 nm. Velocity of 
fluorescence increase over one hour was compared to that of a scrambled control peptide CP5-46-R. Each measurement was 
done in duplicate, IC50 in nM. The curve was fitted with GraphPad Prism using a nonlinear regression model with variable 
slope: Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-X)*slope)). 
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7.3.3 Structure-based optimisation of peptide CP5-46-A 
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Figure 7-8: Determination of the IC50 of peptide CP5-46-A-10Q (A), CP5-46-A-10E (B), CP5-46-A-6E (C) , CP5-46-A-
6Q (D) and CP5-46-A-6D (E) using the NS3/4A activity assay. Assay was done in buffer M2235 with 5 µM substrate M-
2235 (Bachem) and 1 nM NS3/4A. All peptides chemically synthesised. Excitation filter: 360/40 nm, emission filter: 460/40 
nm. Velocity of fluorescence increase over one hour was compared to that of a scrambled control peptide CP5-46-R (F). 
Each measurement was done in duplicate, IC50 in nM. The curve was fitted with GraphPad Prism using a nonlinear 
regression model with variable slope : Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-X)*slope)). 
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7.4 Co-crystallisation of NS3/4A with CP5-46 and CP5-46-A 
	  
	  
Figure 7-9: Refmac5 refinement data. 
	  
7.5 NS3/4A protease resistance mutation A156V 
	  
Figure 7-10: Production and purification of MBP-NS3/4A A156V. 14% SDS-gel, M: molecular weight marker, BI: 
before induction, I: 3 h after induction, BB: before binding, AB: after binding; W1-3: washing fractions, E: elution fraction. 
3 µl of each fraction were loaded onto the gel, except elution fraction: 1 µl 1:20 dilution.
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